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Abstract 
There is ample evidence of the crucial role of PI3K/Akt dependent signalling in 
cardiac function, cellular growth and cell apoptosis. The PI3K/Akt pathway mediates 
cardioprotective effects in experimental models of cardiovascular disease. For example, 
activation of this pathway ameliorates the sepsis-induced cardiac dysfunction, whereas 
its activation in myocardial ischaemia/reperfusion (I/R) limits cardiac injury.  
This thesis investigates the role of two drugs, which activate the PI3K/Akt-
pathway, namely the haematopoietic cytokine erythropoietin and the anti-malarial drug 
artesunate, in a mouse animal model of experimental sepsis-induced cardiac dysfunction 
and in a rat model of regional myocardial I/R injury, respectively.  
Using a clinically relevant model of caecal ligation and puncture in mice, I 
demonstrated that aged (8 months) C57BL/6 mice (receiving fluid resuscitation and 
antibiotic therapy) developed significant cardiac dysfunction (within 24 h), while younger 
mice (2 months) did not. Erythropoietin attenuated the impaired systolic contractility (in 
vivo and ex vivo) caused by endotoxaemia (lipopolysacchride 9 mg kg-1; young mice) 
and sepsis (aged mice). These beneficial effects were associated with activation of Akt 
and endothelial nitric oxide synthase survival pathways and inhibition of the glycogen 
synthase kinase 3β, nuclear factor-κB and interleukin 1β pro-inflammatory pathways, 
secondary to activation of the β-common receptor.  
A single bolus administration of artesunate at the start of reperfusion in a rat model 
of myocardial I/R significantly attenuated the infarct size. This effect was mediated via 
activation of pro-survival pathways (PI3K/Akt and ERK 1/2 and STAT-3) and inhibition 
of the glycogen synthase kinase 3β and nuclear factor-κB pro-inflammatory pathways. 
Thus, in this thesis I have demonstrated that pharmacological activation of the 
PI3K/Akt pathway by erythropoietin and artesunate in sepsis and myocardial I/R, 
respectively, plays a vital role in the amelioration of cardiac dysfunction and injury. 
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Chapter 1 
 
 
General Introduction 
 
 
 
 
 
 
 
 
 
1.1 Sepsis 
 
Sepsis is a severe, debilitating clinical condition that has gained momentum as 
becoming the leading cause of death in critically ill patients (Hotchkiss & Karl, 2003; 
Martin, 2012), predominantly as a consequence of multiple organ failure (MOF) (Rudiger 
& Singer, 2007). The increase in incidence of sepsis is affected by various patient-specific 
factors ranging from age to co-morbid medical conditions (Martin, 2012) to race and 
gender (Martin et al., 2003; Esper et al., 2006; Mayr et al., 2010). Sepsis 
disproportionately affects the elderly with an average age being in early to mid-60s with 
older age being an independent risk factor for death from sepsis (Martin et al., 2003). Co-
morbid conditions such as cancer and diabetes which alter the immune system result in a 
significantly elevated risk for developing sepsis and may also contribute to succumbing 
to contracting nosocomial sepsis due to their increased interaction with the healthcare 
systems (Danai et al., 2006). Likewise, the increased use of invasive procedures and 
immunosuppressive drugs also plays a part in the increased incidence, with a study 
showing that sepsis among patients immunosuppressed prior to the onset of sepsis were 
associated with higher mortality than in immunocompetent patients (Poutsiaka et al., 
2009). Additionally, other factors contributing to the increased incidence of sepsis include 
transplantation, and prosthetic implants and devices, as well as the increasing problem of 
antimicrobial resistance (LaRosa, 2010).  Despite technical developments in intensive 
care units (ICU) and advanced supportive treatment, sepsis still affects approximately 
700,000 people annually with a resulting death rate of 210,000 per year in the United 
States (Angus et al., 2001). A recent study explored the impact of evidence-based 
treatments for severe sepsis in critical care units across England, Wales and Northern 
Ireland between 1995 and 2005 and revealed not only a rise in admissions from 23.5 % 
to 28.7 %, but also an increase in the total number of deaths from 9,000 to 14,000 
(Harrison et al., 2006).  
Sepsis is defined as a systemic inflammatory response to known or suspected 
infection (i.e. by positive culture) manifested by two or more of the conditions of the 
systemic inflammatory response syndrome (SIRS) (Table 1.1). Severe sepsis refers to 
sepsis that is accompanied by evidence of hypoperfusion abnormalities (lactic acidosis, 
oliguria, and acute alterations in mental state) or dysfunction of at least one organ system. 
When severe sepsis is accompanied by hypotension (systolic arterial pressure < 90 
mmHg, mean arterial pressure < 60 mmHg or a reduction in systolic blood pressure of >  
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40 mmHg from baseline) or the need for vasopressors, despite adequate fluid 
resuscitation, the term ‘septic shock’ applies (Bone et al., 1992, Levy et al., 2003). The 
development of hypotension is mediated in part by the enhanced formation of NO by 
iNOS, which leads to excessive vasodilatation resulting in a reduced response of the 
vasculature to vasopressor therapy with catecholamines (vascular hyporeactivity) (Julou-
Schaeffer et al., 1990; Thiemermann & Vane, 1990; Szabo et al., 1993; Hollengberg et 
al., 2000) Progression of this continuum from sepsis to severe sepsis and septic shock is 
associated with increased morbidity and mortality, whereby mortality rates are seen to 
rise from 25-30% for severe sepsis up to 40-70% for septic shock (Lever & Mackenzie, 
2007). 
 
Table 1.1 Defining criteria of ACCP/SCCM named conditions  
 
Criterion Value 
SIRS Core body temperature >38 0C or < 36 0C; Heart rate >90 
beats per minute; Respiratory rate >20 breaths per minute 
or PaCO2 <32 mm Hg; White blood cell count >12 x 10
9 
cells/L or <4 x 109 cells/L, or 10 % immature bands 
Sepsis At least two SIRS criteria caused by known or suspected 
infection 
Severe sepsis Sepsis with acute organ dysfunction (including 
hypoperfusion and hypotension) caused by sepsis 
Septic shock Sepsis with persistent or refractory hypotension or tissue 
hypoperfusion despite adequate fluid resuscitation 
ACCP: American College of Chest Physicians; SCCM: Society of Critical Care Medicine 
(Bone et al., 1992). 
 
 
1.1.2. Pathophysiology  
There has recently been a shift in the spectrum of responsible microorganisms 
from predominantly Gram-negative bacteria in the late 1970s, to a higher incidence of 
Gram-positive bacteria at present, with the odd cases of sepsis caused by viruses, fungi, 
and to a lesser extent, parasites (Riedemann et al., 2003). A 2009 data review of more 
than 11,000 patients from 37 countries demonstrated i) the cause of the infections was  
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Gram-negative in 57 %, Gram-positive in 44 % and fungal in 11 %; ii) the primary source 
of infection was 47 % in the lung, 23 % in the abdomen or 8 % in the urinary tract and 
iii) a significant proportion of patients presented with co-morbidities including 24 % with 
diabetes and 14 % with congestive heart failure (Martin et al., 2009). Sepsis develops 
when what is otherwise an expected and appropriate inflammatory response to an 
infectious process becomes amplified and gradually dysregulated. A continuum exists 
from a low grade systemic inflammatory response associated with a self-limited infection 
to a marked systemic response with solitary or multi-organ dysfunction (Cinel & Opal, 
2009).  
Bacterial recognition and signalling are dynamically modulated during sepsis, 
serving as essential functions of cells of the innate immune system (Salomão et al., 2008).   
Several bacterial components such as lipopolysaccharide (LPS) of Gram-negative 
bacteria and peptidoglycan (PepG) primarily of Gram-positive bacteria induce septic 
shock in animals. The initiation of the host response during sepsis involves a family of 
pattern recognition receptors which, recognise unique cellular motifs found on pathogens, 
referred to as pathogen-associated molecular patterns (Janeway & Medzhitov, 1998).  
Host recognition of microbial components leading to the initiation of the septic 
response is highly dependent on the presence of LPS-binding protein (LBP) and the 
opsonic receptor cluster of differentiation 14 (CD14) (Wright et al., 1990). This receptor 
which can be found in two forms: a membrane bound form (mCD14) or one that is free 
in the circulation soluble CD14 (sCD14) not only is involved in the activation of 
monocytes by LPS and PepG (Pugin et al., 1994), but it also mediates macrophage 
apoptosis (Devitt et al., 1998) and is involved in the shuttling of LPS between serum 
proteins such as LBP (Yu et al., 1997). The importance of CD14 in sepsis is highlighted 
by two findings i) serum levels of CD14 rise in sepsis (Landmann et al., 1995) and ii) 
administration of an anti-CD14 antibody conferred protection in primates against lethal 
endotoxin shock (Leturcq et al, 1996). 
LPS is shed from the bacterial cell wall and binds to CD14 however, initiation of 
cellular activation cannot take place without the association of the LPS/CD14 complex 
with a family of transmembrane receptors known as toll-like receptors (TLR’s) (Cohen, 
2002). Thus, TLR4 is known to recognise LPS, whilst TLR2 is predominantly responsible 
for the recognition of Gram-positive cell-wall structure (Takeuchi et al., 1999). 
Intracellular signalling relies on binding of the intracellular TLR domain, TIR (Toll/IL-1  
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receptor homology domain), to IRAK (IL-1 receptor-associated kinase), a process 
facilitated by two adapter proteins, MyD88 (myeloid differentiation protein 88) and 
TIRAP (TIR domain-containing adapter protein) (Doyle & O’Neill, 2006). An effector 
response is achieved through one of two pathways; an MyD88-dependent pathway, which 
relies on the use of tumour necrosis factor (TNF)-α receptor associated factor (TRAF)-6, 
or an MyD88-independent pathway, which employs the use of the inducing interferon-
(TRIF) adaptor protein (Doyle & O’Neill, 2006). 
As a result of the host-microbial interaction, there is activation of the innate 
immune response with a purpose to orchestrate a defensive response incorporating both 
the humoral and cellular components of the immune system (Cohen, 2002). The 
transcriptional regulatory factor NF-κB is a central player in modulating the expression 
of various immunoregulatory mediators (e.g. IL-1β, TNF-α and nitric oxide synthase) that 
are involved in cellular responses to infection and participate in inflammatory reactions 
leading to organ dysfunction and death in patients with sepsis (Hiscott et al., 1993; 
Udalova et al., 1998; Abraham, 2000; Tak & Firestein, 2001; Abraham, 2003). Signalling 
pathways initiated by engagement of TLR’s by bacterial products or cytokine receptors 
lead to nuclear accumulation of NF-κB and enhanced transcription of the above genes 
(Tak & Firestein, 2001; Zhang & Ghosh, 2001; Senftleben et al., 2002). Cytokines such 
as IL-1 and TNF- α that are under the regulatory control of NF-κB can induce further 
activation of this transcriptional factor, leading to potentiation of inflammatory responses 
in the septic host (Abraham, 2003). Exposure of animals to LPS or bacteria results in the 
activation of NF- κB in various organs and cell populations (Blackwell et al., 2000; 
Carlsen et al., 2002). Similarly, NF- κB activation is enhanced in patients with sepsis 
(Böhrer et al., 1997; Arnalich et al., 2000) and sepsis-induced acute lung injury (Schwartz 
et al., 1996; Moine et al., 2000). Of note, the degree of activation of this transcriptional 
factor was a better predictor of outcome than physiological based scores in patients with 
sepsis (Böhrer et al., 1997) with a similar pattern reported for pulmonary and circulating 
levels of IL-1β and TNF-α showing persistent elevation correlating with a worse clinical 
outcome (Meduri et al., 1995). 
During the first 30-90 min post exposure to LPS, mononuclear cells release the 
prototypic inflammatory cytokines such as TNF-α and  interleukin 1β (IL-1β) which, 
mediate various immunopathological features of LPS (Dinarello, 1997 Consequently, a 
secondary level of inflammatory response is activated, involving many lipid mediators,  
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reactive oxygen species (ROS), cytokines, and up-regulation of cell adhesion molecules 
which, facilitate the migration of inflammatory cells, namely leukocytes (Cohen, 2002). 
The up-regulation of adhesion molecules both on neutrophils and endothelial cells sees 
extravasation of neutrophils into the surrounding tissue which, not only aides in the killing 
of microorganisms but also leads to injury of the endothelium by the release of mediators 
which increase vascular permeability with the eventual flow of protein-rich oedema fluid 
into tissues (Russell, 2006). In addition, the activation of endothelial cells results in the 
release of nitric oxide (NO), a potent vasodilator and key mediator of septic shock 
(Russell, 2006). Inducible nitric oxide (iNOS) a cytokine-induced enzyme involved in 
immune defence (Nathan & Hibbs, 1991), is found in macrophages (Stuehr et al., 1991), 
and various other cells (Scott-Burden et al., 1992; Charles et al., 1993) is known to 
produce large amounts of NO over a long period of time (Cho et al., 1992). This enzyme 
is normally not active under normal conditions but the activation of macrophages and 
various other cells with proinflammatory cytokines or endotoxin leads to expression of 
iNOS (Thiemermann, 1997).Induction of iNOS by endotoxin in vitro and in vivo is a 
secondary process to the release of pro-inflammatory cytokines such as IL-1 and TNF-α, 
which alone, in concert with other cytokines, or with platelet-activating factor activate 
cells to express iNOS protein and activity (Thiemermann, 1997). The enhanced formation 
of NO by iNOS in the vasculature has been implicated in the pathophysiology of septic 
shock, as evidenced by the fact serum levels of NO oxidative products are elevated in 
animals (Cunha et al., 1994) and humans (Barthlen et al., 1994; Goode et al., 1995) 
undergoing septic shock. Circulatory shock is associated with an enhanced formation of 
NO because of the early activation of eNOS and the delayed induction of iNOS activity 
in various cell types such as macrophages and cardiac myocytes (Szabo et al., 1993). 
Studies demonstrating inhibition of NO synthesis reduces the hypotension induced by 
LPS (Thiemermann & Vane, 1990), whilst mice lacking iNOS are resistant to endotoxin-
induced mortality (Wei et al., 1995) and impairment of vascular contraction (Gunnett et 
al., 1998). Likewise, in large animal models, selective iNOS inhibitors attenuated the 
organ dysfunction resulting from endotoxaemia (Matejovic et al., 2001) or bacterial 
sepsis (Matejovic et al., 2004; Enkhbaatar et al., 2006; Matejovic et al., 2007). 
Furthermore, the adaptive immune system becomes activated involving the activation of 
B-cells. Invading microorganisms become opsonised and are presented to natural killer 
(NK cells). If the infection is cleared a resolution phase ensues. However, if the infection  
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persists, amplification of the inflammatory response can be detrimental to the host often 
leading to organ dysfunction (Russell, 2006). 
 
Figure 1.1.1 The orchestration of the inflammatory response to sepsis. Binding of 
LPS to TLR4 and PepG to TLR2 activate intracellular signal-transduction pathways 
which leads to the activation and translocation of cytosolic NF-κB to the nucleus resulting 
in the initiation of gene transcription of various pro-inflammatory cytokines such as 
(TNF-α and IL-1β) and anti-inflammatory cytokines such as (IL-10). Release of 
proteases, oxidants and prostaglandins secondary to activation of neutrophils, 
macrophages and monocytes injure the endothelium resulting in increased permeability 
and vasodilation. Activation of endothelial cells by the action of cytokines induces the 
production of NO, a potent vasodilator, by inducible nitric oxide synthase (Russell, 2006).   
 
1.1.3. MOF 
MOF is defined as ‘the presence of altered organ functions in an acutely ill patient 
such that homeostasis cannot be maintained without intervention (Bone et al., 1992). 
Septic shock is the main cause of MOF in the ICU, and the severity of MOF is correlated 
directly to mortality (Blanco et al., 2008). It has been shown to be the main cause of death  
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in patients with severe sepsis, accounting 43.1% of patients (Vincent et al., 2011). 
Patients that survive the initial septic insult may ultimately succumb to widespread organ 
dysfunction that can either be acute, due to hyper-inflammatory response, or more 
prolonged due to immune dysfunction and infection (Sauaia et al., 1996: Baue, 2006). 
The pathogenesis of organ dysfunction is multifactorial, comprising of endothelial 
dysfunction, tissue hypoperfusion, and/or mitochondrial dysfunction and excessive 
inflammation. It is evident that the persistent microvascular alteration in sepsis is 
associated with the development of organ dysfunction and death (Chierego et al., 2006), 
with the endothelium recognised as central in the pathogenesis of microvascular 
dysfunction and sepsis physiopathology (Aird, 2003). The association between 
endothelial cell signalling activation and the subsequent severity of organ dysfunction 
was highlighted by a recent study demonstrating a strong correlation between circulating 
levels of biomarkers of endothelial activation [e.g. soluble E-selectin,  soluble fms-like 
tyrosine kinase-1 (sFlt-1)] and sepsis severity (Shapiro et al., 2010). sFlt-1 which, 
contributes to endothelial cell activation and correlates with inflammatory cascade 
activation (Shapiro et al., 2008), exhibited the strongest association in patients with the 
Sequential Organ Failure Assessment (SOFA) score, a measure of quantifying the 
severity of patient illness based on the degree of organ dysfunction (Vincent et al., 1996). 
In addition, lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), an 
endothelial cell membrane protein that recognises endotoxin and pathogenic 
microorganisms (Chen et al., 2002), mediates endothelial dysfunction, induces 
superoxide production and increases endothelial adhesiveness to leukocytes and 
chemokine production. Inhibition of LOX-1 reduced leukocyte adherence in intestinal 
submucosal venules of endotoxaemic rats (Landsberger et al., 2010). 
Furthermore, tissue hypo-perfusion and hypoxia are thought to be central factors 
to the pathogenesis of organ dysfunction (Cohen, 2002). There is however, an ongoing 
debate as to the relative contributions of microvascular dysfunction and bioenergetic 
derangements leading to the development of MOF.  The mechanisms which are thought 
to impair blood flow and, thus, result in hypo-perfusion include: i) widespread fibrin 
deposition as a result of an IL-6-induced up-regulation of tissue factor in conjunction with 
a TNF-α-induced suppression of natural anticoagulants, leading to microvascular 
occlusion, ii) development of tissue exudates compromising adequate oxygenation, and  
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iii) disorders of microvascular homeostasis resulting from elaboration of vasoactive 
substances such as histamine and prostanoids (Cohen, 2002).  
In addition to hypoxia, cells may be dysoxic in that they are unable to properly 
utilise available oxygen. Whilst Ince and Sinaasappel suggest the sepsis-associated 
microcirculatory distress leading to tissue hypoxia is associated with microvascular flow 
redistribution (Ince & Sinaasappel, 1999), others have shown increased tissue oxygen 
tension in organs of animals (Rosser et al., 1995) and patients (Boekstegers et al., 1991), 
suggesting that maybe the defect in sepsis lies in the cellular oxygen uptake (tissue 
dysoxia) rather than in oxygen delivery. Indeed, recently Brealey and Colleagues 
demonstrated an association between NO overproduction, antioxidant depletion, 
mitochondrial dysfunction and reduced concentrations of adenosine 5’ triphosphate, 
correlate with organ failure and eventual outcome. In addition, to tissue hypo-
perfusion/microvascular flow redistribution, this observation highlights that 
bioenergetics failure could be a central mechanism underlying multi-organ dysfunction 
(Brealey et al., 2002).  
 Indeed microvascular shunting can result in regional areas of tissue hypoxia and 
thus reduced generation of adenosine triphosphate (Spronk et al., 2004), whilst reduction 
in mitochondrial respiration can be attributable to a variety of factors such as i) decreased 
expression of mitochondrial proteins and ii) direct inhibition/damage from reactive 
nitrogen and oxygen species, despite adequate oxygenation (cellular dysoxia) (Singer et 
al., 2004). Increased venous oxygen saturations seen in resuscitated sepsis could be 
explained by a combined effect of shunting and reduced mitochondrial utilisation, whilst 
a maintained/elevated tissue oxygen tension that have been demonstrated in various organ 
beds (Rosser et al., 1995; VanderMeer et al., 1995) may be a result of a reduction in 
metabolic activity to match/exceed the reduction in energy supply related to a decreased 
oxygen delivery or mitochondrial dysfunction (Abraham & Singer, 2007). 
 
1.1.4. Cardiac Dysfunction 
Myocardial dysfunction is a recognized manifestation of sepsis and septic shock, 
with myocardial depression occurring in almost 40 % - 50 % of patients (Fernandes & 
Assuncao, 2012; Rudiger & Singer, 2007). Patients with myocardial dysfunction have 
significantly higher mortality (70%) compared to 20 % in septic patients without  
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cardiovascular impairment (Parillo & Parker, 1990). Contractile dysfunction is 
characterised by a reversible reduction in ejection fraction, biventricular dilatation, 
blunted blood pressure response to intravenous fluids, and a diminished ability to 
augment cardiac output despite increased levels of circulating catecholamines (Hoesel et 
al., 2007).   Cardiovascular dysfunction has over the years gained platform to becoming 
a prevalent problem in the management of critically ill patients, associated with MOF 
morbidity and mortality (Muller-Werdan et al., 2006). 
What are the characteristics of septic myocardial dysfunction? Clinically, before 
the introduction of the pulmonary arterial catheter, two distinct clinical profiles of septic 
shock were described (MacLean et al., 1967), one characterised by warm, dry skin and a 
bounding pulse despite hypotension (‘warm’ shock) and the other associated with 
hypotension, clammy skin and low volume pulse (‘cold’ shock) (Rabuel & Mebazaa, 
2006). Subsequently, it was concluded that patients in septic shock went through an initial 
early hyperdynamic phase following onset of illness and ultimately either recovered or 
deteriorated in heart failure or myocardial depression related to sepsis, leading to 
hypodynamic shock and death (Clowes et al., 1966). The latter phase was further 
confirmed by animals studies demonstrating septic shock characterised by reduced 
cardiac output (CO) and high systemic vascular resistance (SVR), resulting in animal 
death (Weil et al., 1956; Postel & Schloerb, 1977). However, a later study by Wilson and 
colleagues were the first to provide a description of septic shock in humans as associated 
primarily with normal or elevated CO (with elevated SVR) and very rarely with low CO 
(Packman & Rackow 1983). With the recognition of inadequate volume resuscitation of 
patients with septic shock, subsequent studies employing the use of pulmonary artery 
catheter consistently demonstrated that adequately volume-resuscitated patients typically 
exhibit a hyperdynamic circulatory state associated with a high CO, reduced SVR, normal 
stroke volume and high heart rate (Wilson et al., 1965; Weisel et al., 1977; Winslow et 
al., 1973; Krausz et al., 1977; Parker et al., 1987; Ahmed et al., 1991), which also 
consistent with non-survivors (Parker et al., 1987). 
Evidence of myocardial depression in septic shock was demonstrated by Calvin 
and colleagues who were first to show myocardial dysfunction in septic patients 
adequately resuscitated, characterised by a decreased ejection fraction (EF) and an 
increased end diastolic volume index (Calvin et al., 1981). Extending this observation, 
Parker and colleagues demonstrated that i) septic survivors showed an increased end- 
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diastolic volume index with reduced EF, which was not seen in non-survivors as they 
exhibited normal cardiac volumes, and ii) the acute changes in end-diastolic volume index 
and EF were reversible even after persisting for several days (Parker et al., 1984). Since 
then, a number of studies have confirmed the development of cardiac dysfunction, 
ranging from isolated cardiomyocytes (Ren et al., 2002), to isolated hearts (McDonough 
et al., 1998; Merx et al., 2004), to in vivo animal models (Natanson et al., 1986; Stahl et 
al., 1990; Merx et al., 2005), and in human subjects (Jafri et al., 1990; et al., 1998; 
Poelaert et al., 1997). All of these studies support the view that decreased contractility 
and impaired myocardial compliance are causative factors in sepsis-induced myocardial 
dysfunction.  
Furthermore, myocardial depression has also been explored with respect to its 
prognostic value. Parker and colleagues upon reviewing septic patients on initial 
presentation and at 24 h, found that a heart rate (HR) of < 106 beats per min (bpm) 
predicted a favourable outcome (Parker et al., 1987).  Presenting at 24 h with a systemic 
vascular resistance index of > 1529 dyne. s-1. cm-5. m-2, a HR of < 95 bpm, and a cardiac 
index of > 0.5 L. min-1. m-2 was also associated with survival. In addition, common 
biomarkers of cardiovascular disease, troponin I and T have also been evaluated as 
prognostic markers of sepsis: Troponin levels correlate positively with left ventricular 
dysfunction (Fernandes et al., 1999; ver Elst et al., 2000; Mehta et al. 2004), with 
intensity of vasopressor therapy (Turner et al., 1999), duration of hypotension (Arlati et 
al., 2000) and severity of sepsis, all predicting a poor short-term outcome (Amman et al., 
2001; Mehta et al., 2004). More recently, Rudiger and colleagues investigated using a 
long-term rat model of faecal peritonitis, whether depressed myocardial function could 
be detected early in sepsis. They demonstrated i)  significant differences in stroke volume 
and heart rate assessed 6 h after insult could predict a 3-day mortality with positive and 
negative predictive values of  93 % and 80 %, respectively and ii) presence of intrinsic 
myocardial depression with poor-prognosis animals tolerating less fluid compared to 
good-prognosis or sham animals (Rudiger et al., 2013). The predicted mortality was 
found to be associated with significant differences in transcripts of genes expressing 
proteins related to TLR2/MyD88 and JAK/STAT inflammatory pathways. 
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1.1.4.1 Aetiology of cardiac dysfunction 
 A number of mediators have been implicated in myocardial depression in sepsis 
(Figure 1.1.2). These include mitochondrial dysfunction, inflammatory signalling, and 
alterations in cellular homeostasis. One of the early notions based on animal studies of 
cardiac depression was that myocardial dysfunction resulted from ischaemia, a result of 
an inadequate coronary blood supply. However, this was later disputed by two studies 
evaluating coronary haemodynamics in patients with septic shock. Patients were found to 
have similar or greater coronary flow when compared to control subjects (Cunnion et al., 
1986; Dhainaut et al., 1987).  These findings disregarded ischaemia as a key factor in 
sepsis-induced cardiac dysfunction. 
Various sepsis studies have highlighted the importance of mitochondrial 
dysfunction (Gallerich et al., 2002; Crouser, 2004), linking it to severity and outcome 
(Brealey et al., 2002). Mitochondria comprise approximately 30 % of the myocardial 
volume (Kayar et al., 1987). Cardiomyocyte mitochondrial ultrastructural damage has 
been shown in both animal (Schumer et al., 1971; Watts et al., 2004; Suliman et al., 2004) 
and clinical studies of sepsis (Cowley et al., 1979; Soriano et al., 2006). Disturbed 
mitochondrial respiratory function characterised by reduced oxygen consumption is often 
seen in the late stages of sepsis (Schumer et al., 1971). Reduced activities of 
mitochondrial electron transport chain enzyme complexes are reported in septic hearts in 
vivo, resulting in part, from inhibitory effects of reactive oxygen and nitrogen species on 
the ATP production and oxidative phosphorylation (Trumbeckaite et al., 2001; Levy et 
al., 2004; Suliman et al., 2004). Furthermore, the mitochondrial permeability transition 
pore (mPTP) has been shown to play a role in the development of mitochondrial 
dysfunction since its inhibition has been shown to improve cardiac function ex vivo and 
reduce mortality in septic mice (Larche et al., 2006). 
 The existence of a myocardial depressant factor (MDF) dates back as early as 
1947, as seen in an experimental model of haemorrhagic shock (Wiggers et al., 1947) to 
1970’s, using blood of dogs subjected to endotoxic shock (Lefer & Martin, 1970) and 
lastly to 1979 modelled using coronary ostia of dogs infused with plasma of septic 
patients (McConn et al., 1979). Many substances have been proposed as the MDF, 
including TNF-α and IL-1β. Indeed, these cytokines constitute key mediators of 
myocardial depression in sepsis (Fernandes Jr & Cesar de Assuncao, 2012). Recently,  
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TNF-α was demonstrated to trigger cardiac apoptosis in an LPS model of endotoxaemia, 
where TNF-α-dependent caspase activation was induced thereby, contributing to the 
development of cardiac dysfunction (Carleson et al., 2005).   Caspase activation is a 
crucial step which leads to apoptotic cell death, a process which has been implicated in 
the pathophysiology of human cardiovascular diseases such as ischaemic heart disease 
(reviewed in Haunstetter & Izumo, 1998). Likewise various investigators have shown the 
part played by caspase in role of apoptosis in the cardiac dysfunction in sepsis, whereby 
inhibition of caspase with the broad spectrum benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone (z-VAD.fmk) ameliorated the endotoxin-induced cardiac apoptosis 
and contractile dysfunction (Fauvel et al., 2001; Nevière et al., 2001; Carelson et al., 
2005). Furthermore, not only do TNF-α and IL-1β individually exert cardio depressant 
effects, but they can also synergistically depress contractile function, an effect which 
could be reversed by inhibition of NO synthase (Cain et al., 1999). Additionally, further 
evidence of the involvement of NO in the TNF-α-mediated myocardial depression effects 
were seen whereby TNF-α inhibited contraction of isolated hamster papillary muscles, 
which was reversed following the addition of L-NG-monomethyl-L-arginine, a non-
selective inhibitor of NO synthase (Finkel et al., 1992). These data strongly implicate 
myocardial NO synthase in the negative inotropic effects of cytokines such as TNF-α and 
IL-1β.    
Moreover, over the last 15 years, the effect of NO as a potential mediator of 
myocardial depression in sepsis is becoming increasingly established. The impact of NO 
on cardiac function is multifaceted, as it has an effect on systemic vascular tone, thus 
impacting preload, afterload, and coronary vascular tone (Fernandes & Assuncao, 2012). 
In septic shock, the increased production in NO via the action of inducible NO synthase 
(iNOS) is an important contributor to circulatory collapse and possibly organ/dysfunction 
and host defence (Thiemermann & Vane, 1990). Ullrich and colleagues demonstrated that 
iNOS (NOS2) is required for the development of systolic and diastolic dysfunction in 
mice challenged with endotoxin (Ullrich et al., 2000). Infusion of methylene blue, a non-
specific NOS inhibitor, to septic patients prevented the stroke volume, left ventricular 
stroke work from falling and reduced the need for inotropic support (Kirov et al., 2001). 
However, these effects did not lead to improvements in patient outcome. Other studies in 
animals (Meyer et al., 1994) and human subjects (Hussein et al., 1999; Bakker et al., 
2004; Watson et al., 2004) have explored reversing the hypotension associated with septic  
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shock using analogues of L-arginine such as monomethylarginine and nitroarginine 
methyl ester as inhibitors of NOS. Although these studies demonstrate an increase in 
arterial pressure following NOS inhibition, some animal studies have indicated increased 
mortality (Young, 2004). Following the phase II clinical studies (Bakker et al., 2004; 
Watson et al., 2004) testing the safety and efficacy of 546C88 (NGmethyl- L-arginine 
hydrochloride; NOS inhibitor) in patients with septic shock, a phase III study was 
undertaken to extend the study of safety and efficacy of this inhibitor, with the primary 
efficacy objective being survival at 28 days (Lopez et al., 2004).  However, this trial was 
stopped due to an increase in mortality observed in the treatment group. Increases in 
pulmonary hypertension, cardiac failure, and reduced cardiac output was seen in these 
patients (Lopez et al., 2004). A possible reason for the disparity between the above studies 
was attributed to the use of a higher dose of 546C88, whilst a post-hoc analysis suggested 
that low doses of this drug (i.e. ≤ 5 mg kg-1 hr-1)may have provided an overall survival 
benefit (Lopez et al., 2004).  This could be explained in part by the fact that widespread 
blockade of NO synthesis could lead to excessive vasoconstriction and a fall in cardiac 
output due to the inhibition of not only excessive NO production (from iNOS) but also 
basal production from endothelial or neuronal NOS  (constitutive NOS) (Young, 2004).  
Therefore, a more targeted approach to inhibition of nitric oxide synthesis may be 
warranted in the future. 
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 Figure 1.1.2. Illustration showing how some of the potential underlying mechanisms 
contribute to myocardial dysfunction and also effect on one another. Cytokines such 
as tumour necrosis factor α (TNF- α) an early mediator of endotoxin-induced shock is 
derived from various cells including cardiac myocytes in response to sepsis. It leads to 
release of interleukin 1 β (IL-1β), which depresses cardiac contractility via stimulation of 
nitric oxide synthase (NOS). High levels of nitric oxide (NO) contributes to cardiac 
dysfunction through reactive oxygen species (ROS) generation. Circulating myocardial 
depressant substances (MDF) such as IL-1β found in increased concentrations in sepsis 
also exerts cardiodepressive effects. Furthermore, mitochondria produce increased levels 
of NO and ROS, which lead to inhibition of oxidative phosphorylation and decreased 
production of adenosine triphosphate (ATP), a process leading to ‘cytopathic hypoxia’. 
Endothelial cells undergo structural as well as functional changes ‘activation’, which 
result in increased up-regulation and thus expression of cell adhesion molecules such as 
selectins, immunoglobulins (vascular cell adhesion molecule 1; VCAM-1). This 
subsequently leads to leukocyte adhesion, followed by traversing of endothelium and 
finally migration extravascularly. VLA-4 alpha4beta1 integrin (very late antigen-4). 
Picture redrawn from Merx, 2007. 
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1.1.5. Current treatments 
Over the years there has been considerable progress of our understanding of both 
pathophysiology of sepsis and of the fundamental principles governing pathogen-host 
interactions. Indeed, many studies have reported novel interventions, which appear to 
improve outcome in animal models of sepsis. These findings fuelled the hope that these 
discoveries may ultimately result in a reduction in mortality in septic patients. Over the 
past three decades, the general consensus regarding the current management of sepsis has 
mainly focused on supportive measures, consisting of the administration of broad-
spectrum antibiotics, haemodynamic resuscitation and appropriate support of organ 
function (Osuchowski et al., 2009). 
Early goal directed therapy (EGDT) with targeted fluid resuscitation in 
conjunction with measures of oxygen delivery has been shown to improve survival in 
patients presenting with septic shock in a randomised, controlled, single-centre study 
(Rivers et al., 2001). This protocol was shown to be effective when it was initiated during 
the first 6 h in the emergency department, an effect seen to reduce 28-day mortality rate 
(Rivers et al., 2001). 
In addition, if the patient demonstrates lack of response to resuscitation or if there 
is evidence of volume overload, the stimulation of the depressed cardiovascular system 
can be achieved by means of vasopressor therapy. The recommended first choice agent 
for septic shock is norepinephrine, which results in potent peripheral arterial 
vasoconstriction without significant increases in heart rate or cardiac output (Dellinger et 
al., 2008; Dellinger et al., 2013). Clinical trials have shown that when compared with 
dopamine, norepinephrine was associated with improvement in in-hospital and 28-day 
mortality in septic patients (Vasu et al., 2011) and a decreased risk of death and lower 
incidence of arrhythmic events (De Backer et al., 2012). However, it is suggested that 
dopamine should be used only in highly selected patients, such as when there is low risk 
of tachyarryhthmias or bradycardia (Dellinger et al., 2013). Furthermore, second-line 
agents for patients who have persistent hypotension despite maximal doses of 
norepinephrine/dopamine include epinephrine and vasopressin (Dellinger et al., 2013). 
Vasopressin has been proposed for use in septic shock due to it being an endogenous 
peptide with potent vasoactive effects in addition to its depressed circulating levels in 
septic shock (Landry et al., 1997). Low doses of vasopressin may be effective in raising 
blood pressure in patients, refractory to other vasopressors and may exhibit other potential  
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physiologic benefits such as improvement in renal function (Holmes et al., 2001; Patel et 
al., 2002; Lauzier et al., 2006). However, according to the 2012 Surviving Sepsis 
Campaign guidelines, since high doses of vasopressin have been associated with cardiac, 
digital, and splanchnic ischaemia, it should not be the single initial vasopressor but should 
be reserved for salvage therapy, when failure to achieve an adequate MAP with other 
vasopressors is not possible (Dünser et al., 2003; Dellinger et al., 2013). Following first-
line treatment, 0.03 U/min of vasopressin may be added to norepinephrine with an 
anticipated effect equivalent to that of norepinephrine alone (Dellinger et al., 2008; 
Dellinger et al., 2013).The Vasopressin and Septic Shock Trial (VASST) demonstrated 
that although vasopressin administration reduced the requirement for norepinephrine, 
mortality rates were not significantly lower in patients receiving vasopressin in addition 
to norepinephrine when compared to patients receiving norepinephrine alone (Russell et 
al., 2008). 
Moreover, in the case of inotropic support for septic patients, dobutamine has been 
recommended as the first choice inotrope for patients with measured or suspected reduced 
cardiac output, in the presence of adequate left ventricular filling pressure (or clinical 
assessment of sufficient fluid resuscitation) and adequate MAP (Dellinger et al., 2013). 
A dose of up to 20 µg kg-1 min-1 is recommended by the 2012 Surviving Sepsis Campaign, 
in the presence of myocardial dysfunction or persistent hypoperfusion despite adequate 
fluid resuscitation and adequate MAP (Dellinger et al., 2013). In addition, in patients who 
continue to be hypotensive following fluid resuscitation who may exhibit low, normal or 
increased cardiac outputs, treatment with a combined inotrope/vasopressor such as 
norepinephrine is suggested (Dellinger et al., 2013). Inotropic therapy is not 
recommended for increasing cardiac index to supranormal levels (Dellinger et al., 2008; 
Dellinger et al., 2013), since a study showed increased mortality rates in patients with 
sepsis who were maintained on high levels of oxygen delivery (Hayes et al., 1994). 
The use of corticosteroids in patients with sepsis is controversial: Many studies 
have demonstrated that high-dose corticosteroid therapy is not effective in patients with 
severe sepsis or septic shock (Sprung et al., 1984; Bone et al., 1987; Cronin et al., 1995), 
while others suggest that corticosteroid therapy is associated  improvement in the shock 
state and a survival benefit in patients with vasopressor-unresponsive septic shock 
(Bollaert et al., 1998; Briegel et al., 1999; Annane et al., 2002). It should be noted, that a  
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benefit with corticosteroid therapy was associated with a greater risk of nosocomial 
infection and recurrent sepsis (Sprung et al., 2008). 
Furthermore, many studies have focused on targeting inflammatory and 
coagulation pathways, which have shown promising results in animal studies, but have 
either failed to be translated into a clinical setting or were associated with significant 
adverse effects. For instance, recombinant human activated protein C (APC), which plays 
a role in regulating blood clotting and inflammation, was shown to reduce absolute 
mortality by 6.1 % and relative mortality by 19.4 % in a randomized study of 1690 
patients (Ely et al., 2003). In contrast, a later analysis of six randomised clinical trials 
including 6307 adults and 474 paediatric patients with either high or low risk of death 
found no evidence that APC reduced the risk of death in adults or children with severe 
sepsis or septic shock, and instead was associated with increased risk of bleeding (Marti-
Cavajal et al., 2012). The more recent PROWESS-SHOCK trial evaluated the effects of 
dotrecogin alfa (Xigris) in 1697 septic shock patients and showed no beneficial effect on 
the 28-day mortality, which resulted in the subsequent removal of this product from the 
market (Ranieri et al., 2012).  
Thus, there is still an unmet clinical need for the discovery of specific therapeutic 
interventions for septic shock. 
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1.2.   Myocardial Infarction 
 
Despite major advances in prevention and treatment, ischaemic heart disease 
remains the leading cause of morbidity and mortality in the Western world, and is rapidly 
gaining its leading position in the developing world (Bolli et al., 2004). Restoration of 
early blood flow to the ischaemic myocardium with thrombolytic therapy is presently the 
most effective therapy to limit infarct size and, thus, preserve cardiac function and 
geometry following myocardial infarction (MI) (Fibrinolytic therapy trialists, 1994; 
Cannon et al., 1994). However, reperfusion alone is inadequate to salvage the damaged 
myocardium, as complications resulting from loss of viable myocardium are still common 
post MI. For instance, reperfusion of previously ischaemic tissue may result in 
‘myocardial ischemia/reperfusion (I/R) injury’, whereby reperfusion itself leads to 
additional cell death and increase in infarct size (Braunwald & Kloner, 1985). Various 
interventions aimed at reducing myocardial I/R injury, although proven successful in 
experimental studies, have failed to translate into clinical settings (Yellon & Hausenloy, 
2007). One reason for this is translational failure is that many of these interventions are 
given prior to or during the ischaemic insult in animals, while this strategy cannot be 
applied clinically (Bolli et al., 2004; Arslan et al., 2008). One other reason is that animal 
studies are carried out in young, healthy male animals without common underlying 
diseases that so often are found in patients with MI (Byrne et al., 2012). Thus, there 
continues to be a growing need to uncover novel translatable interventions that could 
lessen the global impact of this disease on society. 
 
1.2.1.   Ischaemic Injury 
 
Myocardial ischaemic injury results from severe impairment of the coronary 
artery blood supply that is inadequate to meet the myocardial oxygen requirements, 
usually as a result of thrombosis or other acute alterations of coronary atherosclerotic 
plaques. (Buja et al., 2005). During the early stages of ischaemic injury, the loss of 
oxygen leads to the cessation of mitochondrial oxidative phosphorylation and, thus, 
depletion in adenosine triphosphate (ATP) production for energy metabolism. To 
compensate there is an increase in anaerobic glycolysis for ATP production which, results 
in the accumulation of hydrogen ions (H+) and lactate, and consequently intracellular 
acidosis and inhibition of glycolysis as well as mitochondrial fatty acid and residual  
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energy metabolism. Alterations in ion transport in the sarcolemma and organelle 
membranes contribute to the impaired contraction despite the persistent electrical activity 
resulting in ventricular arrhythmias (Buja et al., 2005).  
Progression to an advanced stage of cardiomyocyte injury is characterised by an 
altered metabolic milieu and constant increase in cytosolic calcium ion (Ca2+) which, 
results in phospholipase activation and phospholipid degradation with release of 
lysophospholipids and free fatty acids, all of which, culminate in impairment of cell 
membrane function (Buja et al., 2005). Furthermore, changes including i) generation of 
toxic oxygen species and free radicals-induced peroxidative damage to fatty acids of 
membrane phospholipids by ischaemic myocytes as well as ischaemic endothelial cells 
and activated leukocytes and ii) cleavage of cytoskeletal filaments by activated proteases, 
collectively lead to progressive increase in membrane permeability, severe derangements 
of intracellular electrolytes and ATP exhaustion (Buja et al., 2005).  
 
1.2.2.   Reperfusion Injury 
 
Whilst clinically early and successful myocardial reperfusion is the most effective 
strategy for reducing the size of a myocardial infarct and thus improving clinical outcome, 
the process of restoring blood flow to the ischaemic myocardium can itself induce injury 
(Yellon & Hausenloy, 2007), with some animal studies demonstrating its accounts up to 
50 % of the final size of an MI (Simonis et al., 2012). This paradox termed myocardial 
reperfusion injury, which was first postulated in 1960 by Jennings and colleagues 
paradoxically reduces the beneficial effects of myocardial reperfusion (Jennings et al., 
1960).  
The injury to the myocardium during reperfusion can be characterised by four 
types of cardiac dysfunction: i) ‘myocardial stunning’ which describes the mechanical 
dysfunction persisting after the reperfusion despite the absence of irreversible damage 
and restoration of normal or near normal coronary flow (Braunwald & Kloner, 1982), ii) 
‘no-reflow phenomenon’, is defined as the inability to reperfuse a previously ischaemic 
region (Krug et al., 1966) due to impedance encountered by the microvascular blood flow 
(Ito et al., 2006), iii)  ‘reperfusion arrythmias’ which, although can be potentially harmful, 
can be controlled with effective interventions (Manning et al., 1984) and iv) ’lethal 
reperfusion injury’, is thought to be an independent mediator of cardiomyocyte death, 
distinct from ischemic injury (Yellon & Hausenloy, 2007).  
     Chapter 1: General Introduction 
Lethal reperfusion injury as a separate entity has been a matter of debate. Some 
investigators suggest that reperfusion can exacerbate the necrotic component of cell death 
following a fixed period of ischaemia, as evidenced by an extension in infarct size 
(Matsumura et al., 1998; Zhao et al., 2000a). Other investigators on the other hand, 
demonstrate that the sudden metabolic changes and the existence of oxidative stress 
accompanying reperfusion can itself initiate injury irrespective of ischaemia (Hearse, 
1977; Vanden Hoek et al., 1996). Nevertheless, a means of validating the existence of 
lethal reperfusion injury has been demonstrated by the ability to modify myocyte death 
by interventions administered at the time of reperfusion.  
The reperfusion phase sees the ischaemic myocardium become subjected to 
various rapid biochemical and metabolic changes, which augment the changes generated 
during the ischaemic period. These changes include the generation of ROS, rapid 
restoration of physiological pH and intracellular Ca2+ overload and immune activation, 
all of which, converge to mediate cardiomyocyte death through the opening of the mPTP. 
ROS generation through xanthine oxidase and the reduced nicotinamide adenine 
dinucleotide/nicotinamide adenine dinucleotide phosphate oxidase system, mediates 
myocardial injury by damaging the cell membrane by lipid peroxidation, acting as a 
neutrophil chemoattractant and mediating dysfunction of the sarcoplasmic reticulum, 
contributing to intracellular Ca2+ overload (Yellon & Hausenloy, 2007). 
Disruption in the normal mechanism regulating Ca2+ in the cardiomyocyte sees an 
abrupt increase in intracellular Ca2+ which, is secondary to sarcolemmal-membrane 
damage and oxidative stress-induced dysfunction of the sarcoplasmic reticulum, a 
phenomenon termed the calcium paradox (Piper et al., 1998). Restoration of perfusion 
results in the transport of H+ in exchange with Na+, to normalize the pH. Increased 
intracellular levels of Na+ activates the sarcolemmal Na+/Ca2+ exchanger which, leads to 
Ca2+ overload in the cell with subsequent hypercontracture of cardiomyocyte and 
mitochondrial permeability transition pore opening, eventually resulting in death (Yellon 
& Hausenloy, 2007).  
 Furthermore, several hours into reperfusion sees the influx of neutrophils into the 
infarcted myocardium in response to the release of chemoattractants. Subsequently, up-
regulation of cell adhesion molecules such as integrin beta-2 and intracellular adhesion 
molecule 1 facilitates the migration of neutrophils into myocardial tissue where they  
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cause vascular plugging, release of degradative enzymes and generation of ROS, leading 
to cardiomyocyte death (Vinten-Johansen, 2004). 
 
1.2.3.    Cardiac Cell Death 
It is a recognised fact that cell death following I/R occurs via both necrosis and 
apoptosis (Kajstura et al., 1996; Gill et al., 2002; Chiong et al., 2011). Necrosis is a 
degenerative process, characterised by loss in cellular integrity and release of cytosolic 
contents which provokes an inflammatory response (Hamacher-Brady et al., 2006). It is 
found to predominate within the ischaemic myocardium (Hamacher-Brady et al., 2006) 
and is fundamental to I/R injury and oxidative damage (Vaseva et al., 2012). In contrast, 
the energy-dependent mechanism, apoptosis, (Gill et al., 2002) is characterised by a 
pattern of nuclear pyknosis, cytoplasmic condensation and cell shrinkage, without 
provoking an inflammatory response (Buja et al., 1993), and is known to dominate in the 
ischaemic border and non-ischaemic regions (Hamacher-Brady et al., 2006).   
Although studies performed on both animal models and tissue from human 
subjects implicate both apoptosis and necrosis in myocardial I/R (Gottlieb et al., 1994; 
Kajstura et al., 1996; Zhao et al., 2000b; Freude et al., 2000), the exact contribution of 
these two forms of cell death in the setting of I/R injury is unclear, as are the factors that 
determine which death pathway is initiated (Hausenloy & Yellon, 2004). However, taking 
all experimental evidence into account (Gottlieb et al., 1994; Freude et al., 2000; Zhao et 
al., 2000b) and the fact that ATP the main driver of apoptosis is depleted during 
ischaemia, one can conclude that the reperfusion phase either triggers or accelerates the 
apoptotic component of cell death. Furthermore, the relationship between apoptosis and 
necrosis is also unclear, with some suggestions that there may be overlap in terms of early 
signalling events between the two pathways, as shown by various investigators 
(Hausenloy & Yellon, 2004). A study by Zhao and colleagues demonstrate that both 
necrosis and apoptosis occur simultaneously during reperfusion, with necrotic cell death 
peaking after 24 h post-reperfusion and apoptotic cell death increasing up to 72 h of 
reperfusion (2001).Others have shown that pharmacological inhibition of apoptotic 
signalling during reperfusion can attenuate both the apoptotic and necrotic components 
of cell death (Yaoita et al., 1998; Holly et al., 1999; Mocanu et al., 2000; Zhao et al., 
2003), which suggest that the apoptotic process can evolve into necrotic cell death. 
suggest that targeting the reperfusion-induced apoptotic component of cell death can 
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impact on both process of cell death leading to not only a reduction in infarct size but also 
an improvement in contractile function (Zhao et al., 2003) 
 
1.2.3.1.   Mitochondrial Mediated Apoptosis 
Apoptosis is mediated by two pathways; the intrinsic pathway, primarily mediated 
by the mitochondria, and the extrinsic pathway which involves activation of death 
receptors (Whelan et al., 2010). The intrinsic pathway begins with the permeabilisation 
of the mitochondrial outer membrane which is thought to either be, mPTP dependent, or 
independent (Green & Kroemer, 2004).  
Signals transmitted to the mitochondria lead to the release of pro-apoptotic 
proteins such as cytochrome c from its intermembrane space to the cytosol which in 
conjunction with other proteins forms a complex known as an apoptosome (Rodriguez & 
Lazebnik, 1999). This complex promotes the activation of caspase 9, which in turn 
activates effector caspases that collectively orchestrate the execution of apoptosis.  In 
contrast, the pore independent pathway is regulated by the B-cell lymphoma (Bcl)-2 
family which is sub-categorised into anti-apoptotic members such as Bcl-2 and B-cell 
lymphoma-extra-large and pro-apoptotic components (Green & Kroemer, 2004). The 
actions of the pro-apoptotic components activate apoptosis via two ways; i) disruption of 
function of anti-apoptotic Bcl-2 family members (Letai et al., 2005), or ii) formation of 
channels in the outer mitochondrial membrane to aide in the release of apoptogenic 
proteins from the intermembranal space (Korsmeyer et al., 2000).  
 
1.2.3.2.   Death Receptor Pathway of Apoptosis 
The receptor-mediated pathway is initiated by the binding of a death ligand 
(CD95/Fas ligand or TNF-α) to its cognate cell surface death receptor (CD95/Fas or 
TNFα receptor 1) (Ashkenazi et al., 1998). Subsequently, death adapter molecules such 
as Fas-associated death domain (FADD) and TNF receptor-associated death domain form 
homotrimers which become recruited to the cytoplasmic tail of the death receptor, through 
interactions between death domains found present in both proteins (Thorburn et al., 
2004). Consequently, procaspase 8 is recruited by FADD to form the death inducing 
signalling complex. Once activated, caspase 8 precipitates the apoptotic cascade via  
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processing of downstream effector caspases such as caspase 3 (Hamacher-Brady et al., 
2006), leading to the death of the cell.  
Studies of experimental models of myocardial infarction have demonstrated an 
enhanced expression of Fas ligand (Kajstura et al., 1996) possibly due to an increased 
sensitivity of myocytes to Fas-mediated death following I/R injury (Rasper et al., 1998). 
Indeed, under normal conditions Fas is tightly regulated by its inhibitors namely cFLIP 
which, interacts with FADD to antagonise apoptosis (Irmler et al., 1997). However, this 
inhibitory protein otherwise abundantly expressed in the heart, is downgraded 
dramatically following I/R injury (Rasper et al., 1998), rendering cardiomyocytes 
susceptible to death via the Fas-pathway (Gill et al., 2002).  
 
1.2.4. Pro-survival Signalling Pathways 
Pharmacological activation of endogenous pro-survival kinase cascades, during 
the first few minutes of reperfusion, following a lethal ischaemic insult, has been 
hypothesized to attenuate reperfusion-induced cell death (Yellon & Baxter, 1999). Since 
it has been identified that apoptosis contributes to myocyte death following reperfusion 
injury (Gottlieb et al., 1994; Freude et al., 2000), and that activation of pro-survival 
kinases protects against apoptotic injury, the ability to manipulate/up-regulate the 
reperfusion injury salvage kinase (RISK) and survivor activating factor enhancement 
(SAFE) pathways, during early reperfusion may provide a potential approach to limiting 
reperfusion-induced cell death.  
 
1.2.4.1. The Reperfusion Injury Salvage Kinase Pathway 
The RISK pathway refers to a group of protein kinases namely PI3K-Akt and 
p42/p44 extra-cellular signal regulated kinases (ERK 1/2) that, when specifically 
activated during the early stages of reperfusion, confer cardioprotection by preventing 
lethal reperfusion injury (Hausenloy & Yellon, 2004). 
A conserved family of signal transduction enzymes, the PI3Ks and their 
downstream target Akt are known to regulate inflammatory response, cellular 
proliferation and survival (Cantley, 2002). Akt, exerts its effect via activation of two 
subsets of downstream substrates: i) the anti-apoptotic substrates such as eNOS (Bell & 
Yellon, 2003), which, when phosphorylated, are activated stimulating cellular processes  
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essential for increased survival and ii) the pro-apoptotic substrates such as GSK-3β 
(Nishihara et al., 2006), which, when phosphorylated, become inactive (Franke et al., 
2003). Additionally, a member of the mitogen-activated protein kinases (MAPKs), ERK 
1/2 (p42/p44) is associated with regulation of cell proliferation, differentiation and 
survival (Widmann et al., 1999). Activation of ERK 1/2 has been shown to mediate 
cellular protection in settings myocardial I/R (Shimizu et al., 1998; Yue et al., 2000). 
There is extensive preclinical evidence that activation of the RISK pathway by 
various pharmacological agents such as hydrogen sulphide ex vivo (Hu et al., 2008), and 
insulin-like growth factor-1 in vitro (Matsui et al., 1999) and in vivo (Fujio et al., 2000) 
as well as by mechanical interventions such as pre (Li et al., 2011) -and post-conditioning 
(Zhu et al., 2006) reduces the myocardial infarct size by up to 50 %. This protection has 
been demonstrated to be in part due to inhibition of the mPTP (Davidson et al., 2006), 
improved uptake of Ca2+ into the sarcoplasmic reticulum (Abdallah et al., 2006), and the 
recruitment of anti-apoptotic pathways (Yellon & Baxter, 1999). 
 The pharmacological activation of the RISK pathway has been demonstrated to 
induce cardioprotection through the phosphorylation of a variety of downstream effectors 
such as Bcl-2-associated promoter (BAD) (Jonassen et al., 2001), eNOS (Bell & Yellon, 
2003) and GSK-3β (Gross et al., 2004). Many of these protective downstream signalling 
pathways appear to converge on the mitochondria, acting in concert to inhibit the mPTP: 
i) phosphorylation and inactivation of pro-apoptotic factors such as BAD which otherwise 
exert their apoptotic effects via opening of the mPTP, ii) phosphorylation and activation 
of eNOS is expected to inhibit mPTP opening via the release of NO (Brookes et al., 2000) 
and iii) phosphorylation and inhibition of GSK-3β is shown to mediate inhibition of 
mPTP (Juhaszova et al., 2004). Additionally, activation of the ERK 1/2 component of the 
RISK pathway is shown to form complexes with mitochondrial PKCε (Baines et al 2002) 
which confers cardioprotection through inhibition of mPTP opening (Baines et al., 2003). 
  
1.2.4.2. The Survivor Activating Factor Enhancement Pathway 
Over the years TNF-α has been recognised to play a vital role in the innate 
immune system’s response to various forms of stress, such as infection (Huang et al., 
2009; Roman-Campos et al., 2009; Lula et al., 2009; Ba et al., 2010), trauma and I/R 
(Thielmann et al., 2002; Reil et al., 2007; Skychally et al., 2007; Heusch et al., 2007). 
However, emerging evidence paradoxically support the notion that i) exogenous TNF-α  
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could confer cardioprotection against an I/R insult in a time- and dose-dependent manner 
(Lecour et al., 2002; Lecour et al., 2005), and ii) activation of this multifunctional 
cytokine contributes to myocardial adaptation (Valeur et al., 2009) and is required for 
protection by ischaemic pre-(Deuchar et al.,  2007) and post-conditioning (Lacerda et al., 
2009).   
Therefore, how does TNF-α exhibit these differing roles? TNF-α levels in blood 
and tissue are increased in acute MI with it being implicated as a mediator of adverse 
remodelling in heart failure (HF) (Mann, 2003).  Indeed, mice lacking TNF-α are 
protected against myocardial I/R injury (Maekewa et al., 2002), whilst addition of TNF-
α antibodies results in a reduced infarct size in both rats (Gurevitch et al., 1997) and 
rabbits (Belosjorow et al., 2003). However, attempts to neutralise TNF-α in patients with 
HF has led to a worsening effect (Mann, 2002). Likewise, Kurrelmeyer showed mice 
deficient in both TNF-α receptors developed larger myocardial infarcts, compared with 
their littermate controls following acute MI (2000). These apparent contradictory findings 
can depend on which receptor is activated, both of which are found in human and rat 
cardiac myocytes (Krown et al., 1995; Torre-Amione et al., 1995). In fact, myocardial 
TNF-α and TNF receptor activation can be said to exhibit an ambivalent role in 
myocardial I/R injury and protection from it (Figure 1.2.1).  Where excessive expression 
of TNF-α and subsequent cardiomyocyte TNF receptor type 1 (TNFR1) activation 
induces contractile dysfunction, hypertrophy, fibrosis and cell death and mediates pro-
inflammatory responses. Whilst, a lower TNF-α concentration and subsequent 
cardiomyocyte TNF receptor 2 (TNFR2) activation mediates signals that promote tissue 
repair and angiogenesis and confers protection (Luo et al., 2006; reviewed in 
Kleinbongard et al., 2011). Additionally, besides TNF-α concentration (Lecour et al., 
2002; Deuchar et al., 2007) and receptor subtype activation, the duration of its exposure 
and localisation also contributes to the myocardial action of TNF-α (Kleinbongard et al., 
2011).  
Now it has become clear that TNF-α initiates the activation of an alternative and 
‘RISK free’ pathway termed SAFE (Lecour, 2009) which, involves the activation of Janus 
kinase (JAK) and signal transducer and activator of transcription 3 (STAT-3) (Lecour et 
al., 2005a) (Figure 1.2.2). Briefly, following activation of the membrane receptor 
(TNFR2) by a ligand (e.g.TNF-α) two adjacent juxtaposed JAK’s are 
transphosphorylated activating STAT proteins (Boengler et al., 2008). The subsequent  
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phosphorylation of STAT proteins results in its dissociation from its receptor and 
translocation into the nucleus, whereby it binds to specific DNA sequences, regulating 
the expression of target genes involved in various processes such as inflammation and 
apoptosis (Boengler et al., 2008). Considering STAT-3 is a transcription factor, its 
cardioprotective effects do not seem to ensue at a transcriptional level, since the 
timeframe between its activation and its action is too short. Therefore, it is possible that 
STAT-3 elicits additional effects via direct phosphorylation of different components 
(Lecour, 2009).  Several targets of STAT-3 implicated in conferring its cardioprotective 
effects have been identified; i) phosphorylation and inactivation of pro-apoptotic factor 
Bad (Lecour et al., 2005b), ii) phosphorylation and subsequent inactivation of GSK-3β 
(Gross et al., 2006) and iii) induction of mitochondrial ROS (Lacerda et al., 2006). Within 
the cardiomyocyte, the mitochondria represent the most relevant site for ROS formation 
(Dröge, 2002; Turrens, 2003; Balaban et al., 2005; Murphy, 2009), where generation of 
free radicals is perceived to be essential to achieve protection by TNF- α (Lecour 2005). 
It is also perceived to act as a trigger to ischaemic preconditioning (Baines et al., 1997; 
Tritto et al., 1997) through the activation of protein kinase C (PKC) (Baines et al., 1997). 
The study by Lacerda demonstrates that TNF- α initiates sequential mitochondrial 
perturbations mediated by the production of ROS which originates mainly from the 
mitochondria, in C2C12 murine skeletal muscle cells. Free radical scavengers inhibited the 
protective effect of TNF-α on cell viability, their respiratory parameters and their inner 
mitochondrial membrane potential (2006).  
It could be said that like TNF-α, ROS exhibits paradoxical effects, which is more 
dependent its variable concentration. Mitochondrial DNA is highly susceptible to 
increased oxidative stress damage, whereby excess oxidative stress besides contributing 
to irreversible myocardial injury also contributes to reversible contractile dysfunction 
(‘stunning’) and further inducing long-lasting mPTP opening, resulting in cellular 
dysfunction and cell death (Bolli, 1990; Guth et al., 1993; reviewed in Perrelli et al., 
2011).On the other hand, low levels of ROS is perceived to play a role in modulating 
cardioprotective signalling pathways such as PKC through redox signalling and also as 
secondary messengers (reviewed in Perrelli et al., 2011; Penna et al., 2006; Philipp et al., 
2006; Zatta et al., 2006; Cohen et al., 2008). In fact, ROS formation is seen to result 
following activation of mitochondrial adenosine triphosphate-dependent potassium 
(KATP) channel activation, secondary to activation of PKC (Lecour et al., 2002; Lecour et  
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al., 2005). Furthermore, limited ROS production not only inhibits mPTP opening but a 
transient or short duration opening of mPTP has been suggested to induce a slight 
transient formation of ROS and various investigators have demonstrated to be relevant 
for cardioprotection (Bernardi & Petronilli, 1996, Ichas et al., 1997; Petronilli et al., 1999; 
Di Lisa & Ziegler, 2001; Petronilli et al., 2001; Lim et al., 2007; Hausenloy et al., 2009). 
In addition, the involvement of redox signalling by transient/reduced formation of ROS 
could also be another mechanism by which ROS is involved in cardioprotection in this 
setting of SAFE pathway activation. Studies show that ROS scavengers such as N-
acetylcysteine prevents the protective effects of ischaemia or pharmacological post 
conditioning (Penna et al., 2006; Penna et al., 2007; Tsutsumi et al., 2007; Penna et al., 
2009; Yao et al., 2010). Likewise, the IPC-induced cardioprotective effects are 
completely abolished when the heart is pre-perfused with N-acetyl cysteine to scavenge 
ROS, which suggests that redox signalling plays a crucial role in generating survival 
during myocardial adaptation to ischaemia (reviewed in Das & Maulik, 
2003).Furthermore, activation of the RISK or SAFE pathways do not necessarily occur 
independent of one another, as some studies demonstrate that in fact they can occur 
concomitantly, in settings of ischaemic preconditioning (Suleman et al., 2008), insulin, 
and opioid-induced cardioprotection (Fuglesteg et al., 2008; Gross et al., 2008). Such 
interactions have been attributed to i) p58 regulatory subunit of PI3K may control serine 
phosphorylation of STAT-3 (Pfeffer et al., 1997) and ii) JAK can enhance the 
phosphorylation of Akt subsequent to binding to the p58 regulatory subunit of PI3K 
(Zhang et al., 2005). 
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Figure 1.2.1. The protective vs. damaging effects of TNF-α in myocardial ischaemia 
reperfusion (I/R).  Depiction of the differential concentrations of tumour necrosis factor 
α (TNF-α) along with the subsequently activation of receptor subtype (TNFR1 and 
TNFR2). Activation of TNFR2 initiates various signalling cascades, which eventually 
lead to inhibition of mitochondrial permeability transition pore (mPTP) opening. The 
expression of the anti-apoptotic B-cell CLL/lymphoma 2 (Bcl-2) is increased, similarly, 
the phosphorylation and thus inactivation of the pro-apoptotic factor Bcl-2-associated 
death promoter (Bad) is increased by TNF-α. Additionally, some of these signalling 
cascades is also shared with TNFR1, which can induce increased activation of anti-
apoptotic proteins via nuclear factor kappa B (NF-κB). Dotted lines depict protein 
translations. COX2 cyclooxygenase 2, ERK extracellular signal-regulated kinase, GSK-
3β glycogen kinase synthase 3 β, iNOS inducible nitric oxide synthase, JAK Janus kinase, 
KATP adenosine triphosphate-dependent potassium channels, PKC protein kinase C, ROS 
reactive oxygen species, STAT3 signal transducer and activator of transcription. Redrawn 
from Kleinbongard et al., 2011. 
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1.2.5. Mitochondrial Permeability Transition Pore 
 Under physiological conditions, the mitochondria provide ATP through oxidative 
phosphorylation, with its inner membrane acting as a selective barrier to metabolites and 
ions (Halestrap et al., 2004). The mitochondria possess an innate mechanism, that is 
mediated by a non-specific pore, namely the mPTP which upon activation i.e. under 
cellular stress opens (Crompton et al., 1999), converting the mitochondria from an 
organelle that supports the life of the cell to that which actively induces both necrotic and 
apoptotic cell death (Halestrap et al., 2004). 
It comes as no surprise that since the mitochondrion plays a fundamental role in 
the apoptotic death machinery of the cell (Kroemer, 1998) that many of the anti-apoptotic 
pathways which are activated by pro-survival kinase cascades converge here. It is the role 
of the mPTP, a non-specific large conductance pore, of the inner mitochondrial membrane 
that is suggested to be a critical determinant of lethal reperfusion injury (Hunter & 
Hayworth, 1979; Heusch et al., 2010). During ischaemia, the mPTP remains closed, only 
to open during the first few minutes of reperfusion (Griffiths & Halestrap, 1995), in 
response to oxidative stress, mitochondrial Ca2+ overload and restoration of physiological 
pH (Griffiths & Halestrap, 1995; Kim et al., 2006). Furthermore, the extent of 
mitochondrial permeability determines the fate of the cell, thus either i) the cell recovers 
if the mitochondrial permeability is minimal, ii) moderate effect leads to activation of 
programmed cell death, apoptosis, and iii) if severe, due to the inadequate energy 
production, die via necrosis (Honda & Ping, 2006). As the mPTP is known to be a critical 
determinant of lethal reperfusion injury (Crompton et al., 1999) , many investigators have 
demonstrated its pharmacological inhibition at the time of reperfusionto be 
cardioprotective (Griffiths & Halestrap, 1993; Hausenloy et al., 2002; Clarke et al., 
2002). Indeed, it’s been shown that inhibition of mPTP via activation of pro-survival 
pathways (as mentioned above) is through modulation of several kinases which converge 
on the mitochondria (Davidson et al., 2006).  
 
1.2.6. Ischaemic Preconditioning 
A means of protecting the myocardium before occurrence of an acute coronary 
artery occlusion, is to precondition the myocardium with brief periods of ischaemia. This 
cardioprotective phenomenon, termed ischaemic preconditioning (IPC), was first 
discovered by Murry and colleagues by which, brief non-lethal ischaemic episodes (5 to  
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10 min), followed by periods of reperfusion, confers protection against a subsequent 
prolonged period of myocardial ischemia (index ischaemia) (Murry et al., 1986). IPC 
offers two windows of protection in time; ‘early’ and ‘late’ preconditioning (Kuzuya et 
al., 1993). Early protection also known as ‘classical IPC’ lasts for approximately 1 to 2 h 
following the initial preconditioning (Baxter & Yellon, 1994) and is shown to reduce the 
infarct size by 75 % (Murry et al., 1986). Late protection also termed ‘delayed IPC’ 
reappears from approximately 24 to 72 h after the initial preconditioning stimulus (Yellon 
& Baxter, 1995) and is thought not to be as powerful as the early preconditioning effect, 
reducing the infarct size by approximately 50 % (Kuzuya et al., 1993).  
The amount and duration of the ischaemic phase during IPC influences not only 
the amount of protection conferred on the myocardium but also the signalling pathways 
involved, as too many repetitive stimuli might abolish preconditioning (Barbosa et al, 
1996; Liem et al., 2001). Indeed, the duration of the ischaemic phase during IPC as well 
as the period of reperfusion demonstrate rigid time frames within which protection of the 
myocardium is seen (Riksen et al., 2004). Thus, for periods of ischaemia one cycle of 
1.25 min (Barbosa et al, 1996) to five 5-min ischaemia/5-min reperfusion cycles confers 
protection to the myocardium (Piot et al., 1997). On the other hand, for the duration of 
reperfusion, the minimum amount to confer protection is usually around 30 sec and 1 min 
(Alkhulaifi et al., 1993), whilst anything more than 1 to 2 h abolishes the infarct-limiting 
effect (Li et al., 1992; Burckhartt et al., 1995).  
During the brief preconditioning periods of ischaemia and reperfusion, trigger 
substances are released such as bradykinin, adenosine and opioids (Riksen et al., 2004), 
which in turn activate specific membrane-bound receptors. As a consequence, several 
complex intracellular signalling cascades notably isoforms of protein kinase C (PKC) 
(Ping et al., 1997 Liu et al., 2001; Meldrum et al., 1997) and tyrosine kinases (Ping et al., 
1999a) are activated, which converge on mitochondrial end-effectors, including the ATP 
sensitive potassium channel and the mPTP (Riksen et al., 2004). Indeed, the RISK 
pathway has been identified to be an important target for cardioprotection during IPC 
(Tong et al., 2000; Oldenberg et al., 2004). Studies have shown PKC activation is 
achieved via activation of PI3K, which in turn activates the serine/threonine kinase Akt. 
The resulting effect is inactivation of the pro-apoptotic GSK-3β (Riksen et al., 2004).  
As for ERK 1/2, its involvement in the setting of IPC is still unclear, with some 
studies showing ERK1/2 phosphorylation following an IPC stimulus (Fryer et al 2001;  
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Mocanu et al 2002), and in one instance showing this phosphorylation leading to 
protection (Fryer et al 2001). Furthermore, activation of ERK 1/2 mediates early 
preconditioning in parallel (Vahlhaus et al., 1998) or downstream of PKC (Ping et al., 
1999b).  It is interesting to note that the same kinase cascades are involved in mediating 
cardioprotection at the time of reperfusion and following an IPC trigger. Strong evidence 
suggests that the various upstream signalling pathways converge on mitochondrial 
proteins aimed at limiting in particular the reperfusion injury (Riksen et al., 2004). It is 
possible that the kinase cascades may constitute a common pathway of cardioprotection 
for both instances. Evidence suggests this might in actual fact be the case; i) agents that 
possess preconditioning effects such as bradykinin (Strickler et al., 1996; Baxter & 
Ebrahim, 2002) also exert protection when given upon reperfusion (Budde et al., 2000; 
Bell & Yellon, 2003) and ii) agents such as insulin that are cardioprotective when given 
upon reperfusion have also been demonstrated to precondition the myocardium (Baines 
et al., 1999; Gordon et al., 2003). 
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 Fig 1.2.2. Activation of survival pathways.  Ischaemic preconditioning or 
administration of pharmacological agents at reperfusion can activate either the RISK 
pathway (1) or the SAFE pathway (2), to confer protection. Modified from Lacerda et al., 
2009 
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1.3. Erythropoietin 
Erythropoietin (EPO) is an acidic glycoprotein of approximately 34 kDa, that is 
primarily produced by the peritubular fibroblasts in the renal cortex (Wen et al., 1994). 
EPO’s role is to regulate hematocrit, by acting directly on red blood cell progenitors and 
precursors in the bone marrow, in order to control their proliferation, differentiation and 
maturation. As a hormone, EPO circulates at concentrations in the low picomolar range 
(1-7 pmol L-1), where plasma concentrations are maintained by a negative feedback loop 
in response to hypoxia, via stabilisation of hypoxia-inducible factor-1-alpha. This 
subsequently leads to the production and release of EPO into the circulation by the kidney 
(Jelkmann, 2007). Once EPO is in the circulation, it targets the hematopietic stem cells 
in the bone marrow to stimulate differentiation along the erythroid lineage by acting as a 
survival factor for erythroid progenitor cells.  
EPO binds to a preformed homodimeric EPO receptor (EPOR), which is 
approximately a 60 kDa transmembrane polypeptide (Jelkmann, 2011). The affinity of 
this receptor for EPO is approximately 100-200 pmol L-1, and is seen to exhibit peak 
expression at the colony forming unit-erythroid/proerythroblastic stage followed by an 
undetectable level at the reticulocytes (Ng et al., 2003). Binding of EPO to EPOR results 
in the homodimerisation of the receptor, followed by the activation of several signal 
transduction pathways, namely janus activated kinase (JAK2) and G-protein Ras. 
Subsequently, phospho-JAK-2 activates mutliple intacelullar pathways such as signal 
transducer and activator of transcription and PI3K/Akt (Figure 1.3.1). This ultimately 
results in the production of anti-apoptotic proteins and erythrocyte precursor survival 
(Jelkmann et al., 2008).  
Recombinant human EPO (RHuEPO) has not only revolutionised the treatment 
of patients with anaemia of chronic renal failure (CRF), but has also been demonstrated 
to be effective in correcting anaemia associated with a variety of non-uraemic conditions. 
Patients with CRF have a deficiency in endogenous erythropoietin production. Clinical 
studies demonstrated that treatment with EPO corrects the anaemia of CRF, avoids blood 
transfusion and improves quality of life (Eschbach, 1994). In addition, anaemia is a 
compliaction commonly encountered in malignancy, especially those of haematological 
origin, either at presentation or during the course of treatment (Ng et al., 2003), as more 
than half of cancer patients exhibit low serum level of EPO (Miller et al., 1990). Anaemia  
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identified at diagnosis is a poor prognostic factor and may affect the outcome of 
radiotherapy treatment (Ng et al., 2003). Although blood tranfusion remains the mainstay 
of treatment for symptomatic anaemia, it comes with its own side effect (Hamasaki & 
Yamamoto, 2000; van Bommel et al., 2001; Fernandes et al., 2001).  Therefore, treatment 
with RHuEPO for the correction of anaemia either as a supportive (post-cehmotherapy), 
preventive (pre-treatment), or maintenance (optimisation of haemaglobin  while not on 
treatment) therapy, has been used for various types of cancers (Cazzola et al., 1995; Rai 
et al., 1995; Dammaco et al., 1998; Demetri et al., 1998; Antonadou et al., 2001; 
Crawford et al., 2002) and has proven to have an excellent safety profile (Ng et al., 2003). 
Approximately two thirds of HIV patients have anaemia, especially those that are on 
treatment with Zidovudine (Ng et al., 2003). Studies have shown that treatment with 
RHuEPO not only corrects the anaemia but also improves the patient’s quality of life and 
survival (Henry et al., 1992; Phair et al., 1993; Moore et al., 1998). Furthermore, patients 
in intensive care regularly require blood transfusion since they present with very low 
endogenous serum EPO (van Iperen et al., 2000). The efficacy of EPO treatment with this 
subgroup of people has produced conflicting results, with an initial clinical trials 
demonstrating a reduction in the requirement of blood transfusions and an increase in the 
haemogblobin concentration  (Corwin et al., 1999; Corwin et al., 2002). This was later 
challenged when the same group found that trauma patients treated with epoietin alfa 
showed a lack of reducing the incidence of red-cell transfusion, which is an unexpected 
finding. It is presumed that this is due to the change in transfusion practice between the 
studies (Corwin et al., 2007). However, a decrease in mortality in the trauma patients who 
received epoietin alfa was observed, an effect that they speculate may be attributable to 
actions of EPO that are distinct to haematopoiesis.   
Moreover, the detection of EPOR mRNA, EPO binding, and EPOR signalling in 
various non-haemtaopoietic tissues such as the heart led to various investigators utilising 
adminstration of exogenous EPO to confer tissue protection (Sasaki et al., 2000; Li et al., 
2004; Jelkmann & Wagner, 2004) . Specifically, treatment with EPO has been shown to 
reduce mycardial infarct size, protect against ischaemia reperfusion and promote 
ventricular remodelling  as well as suppress the systemic inflammatory response in 
experimental animals subjected to coronary ligation and exert anti-apoptotic effects on 
myocytes and fibroblasts in the heart (Parsa et al., 2003; Moon et al., 2003; Narmoneva 
et al., 2004; Parsa et al., 2004; Nishiya et al., 2006; Shen et al., 2010). This alongside  
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knowing that i) EPO activates the PI3K/Akt pathway to confer tissue protection  
(Condorelli, et al., 2002; Calvillo et al., 2003; Kim et al., 2008) and ii) EPO reduced 
organ damage and improved survival in a model of endotoxic shock (Aoshiba et al., 
2009), make it a very appealing agent in investigating its potential role in protecting 
against the sepsis-induced cardiac dysfunction. 
 
 
Figure 1.3.1. Simplified view of the main signal transduction pathways activated by 
the erythropoietin haematopoietic receptor (EPOR). Binding of erythropoietin to its 
receptor (EPOR) induces dimerisation. Janus activated kinase (JAKs) bound via their 
SH2 domains undergo trans-phosphorylation and subsequently phosphorylate signal 
transducers and activators of transcription (STATs). Activated STATs translocate to the 
nucleus whereby they can activate/repress target gene promoters that control proliferation 
and apoptosis such as the Bcl-2 gene family. In addition, additional signal transduction 
pathways such as PI3K/Akt and Ras/Raf can also become activated following JAK2 
trans-phosphorylation which play a part in apoptosis and cellular growth, respectively. 
Dotted lines depicts phosphorylation process. Modified from Ng et al., 2003 
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1.3.1 Arestunate 
Artesunate (ARS) is a semi-synthetic derivative of artemisinin (qinghaosu), the 
principle active component of the medicinal plant qinghao (Artemisia annua) which, has 
been used as a remedy for fevers and chills over two millennia in China (Krishna et al., 
2004). Its anti-malarial potential was first demonstrated in 1971 when it was shown to be 
successful in killing Plasmodium berghei in mice (Qinghaosu Antimalaria Coordinating 
Research Group, 1979; Hien & White, 1993). However, to improve the poor solubility 
seen with artemisinin in oil and water, many derivatives were introduced which, today 
comprise a very important class of antimalarials (Figure 1.4) (Krishna et al., 2004). These 
include the water soluble ARS, considered the most clinically useful of the artemisinin 
class which, is metabolised to dihydroartemisinin (DHA) the active component 
responsible for exerting antimalarial effects due to its longer elimination half-time (~ 1 
h) (Krishna et al., 2004).  
Although the relatively short half-time for elimination exhibited by DHA confers 
an advantage that selection for drug-resistant parasites is less likely to occur, this may 
lead to a higher risk of recrudescence when the artemisinin class of drugs are used as 
monotherapy (Krishna et al., 2004). Thus, quite often this class of drugs is given as 
combination therapy which consists of two drugs often co-formulated with one 
artemisinin derivative and another antimalarial drug from a different class such as 
quinine, to treat uncomplicated falciparum malaria (FM). This being said, in endemic 
areas parenteral administration of ARS has been shown to be superior in antiparasitic 
efficacy and in lowering mortality due to severe malaria compared to quinine, showing 
beneficial effects especially in patients with high parasite levels (Dondorp et al., 2005; 
Dondorp et al., 2010; Sinclair et al., 2012). Likewise, a retrospective evaluation from a 
UK centre highlighted the superior efficacy of ARS over quinine for the treatment of 
severe FM (Eder et al., 2012), with recent studies advocating ARS as the preferred choice 
of first-line treatment in any geographical area (Askling et al., 2012; Sinclair et al., 2012).  
Artemisinins act more rapidly and via mechanisms that are distinct from other 
anti-malarial drugs, whilst exhibiting a wider range of parasite killing, from tiniest rings 
to more mature stages of parasites (ter Kuile et al., 1993; Angus et al., 1997). The 
peroxide bridge within the pharmacophore of this class of drugs is an essential component  
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for their anti-malarial activity since compounds lacking a peroxidic oxygen atom are 
devoid of activity (Krishna et al., 2004). Various targets have been implicated in the 
action of artemisinins, with independent lines of evidence from a range of experimental 
techniques propose that sarcoendoplasmic reticulum Ca2+-ATPase (SERCA) of P. 
falciparum (PfATP6) might be the primary target of artemisinins (Eckstein-Ludwig et al., 
2003; Jung et al., 2005; Uhlemann et al., 2005). Additionally, the involvement of the 
mitochondria in the mechanism of action of this class of drugs is recognised, with studies 
implicating the electron transport chain of P. falciparum as a potential target for 
artemisinins (Li et al., 2005), and effects on the mitochondrial inner membrane potential 
seen in neuronal cell cultures (Schmuck et al., 2002) as well as in parasites (Krungkrai et 
al., 1999). 
 
Figure 1.3.2. Chemical structures of members of the artemisnin family (A) 
Artemisinin and derivatives (B) artesunate (ARS), and (C) dihydroartemisinin (DHA). 
Artemisinins that lack the endoperoxide bridge such as 1-Carba-10-deoxoartemisinin (D) 
is devoid of anti-malarial activity due to the replacement of one of the peroxide oxygen 
atoms with carbon.  Redrawn from Krishna et al., 2004 
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 Besides its antimalarial effects, ARS has been shown to possess antiviral (Kaptein 
et al., 2006) and anti-inflammatory (Mirshafiey et al., 2006; Xu et al., 2007; Cheng et al., 
2011) to name a few. Of importance however in the context of the potential effects of 
ARS on the cardiovascular system, one recent study by Sun and colleagues investigating 
the effect of ARS in a model of I/R of the isolated rat myocardium, demonstrated for the 
first time that ARS alleviates the myocardial I/R injury in rats possibly via its anti-
oxidising effects and scavenging of free radicals (2007). This alongside the recent 
discovery that ARS has been found to associate with the PI3/Akt pathway (Xu et al., 
2007; Hou et al., 2008; Cheng et al., 2011), makes it a promising agent to be investigated 
further for its cardioprotective effects in a model of myocardial I/R in vivo. 
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1.3.  Aims 
Activation of cell signalling pathways confer tissue protection and/or inhibit 
inflammation in various settings of cardiovascular disease. Indeed, the involvement of 
the PI3K/Akt pathway in different settings of cardiac pathologies is well established. 
Activation of this pathway has been shown to ameliorate cardiac dysfunction and 
mortality during sepsis/septic shock. Likewise, activation of PI3K/Akt-dependent 
signalling protects cardiac myocytes against apoptosis and confers protection on the 
myocardium from I/R injury.   
Therefore, the purpose of this thesis is to investigate whether erythropoietin and 
artesunate, known activators of the PI3K/Akt pathway are cardioprotective in models of 
cardiac injury (sepsis-induced cardiac dysfunction) and dysfunction (myocardial I/R 
injury), respectively. In order to answer these questions, the investigation was divided 
into three main studies: 
 
Study 1: Development of a Model of Polymicrobial Sepsis (Chapter 2) 
As sepsis most frequently occurs in aging patients and the model of caecal ligation 
and puncture (CLP) mimics various aspects of clinical sepsis, I will set up a model of 
CLP focusing specifically on the development of cardiac dysfunction. In order to do this 
I will investigate the effects of sex, strain, severity of the model (altering needle size), 
fluid resuscitation and antibiotic therapy,  and age on the susceptibility to develop 
consistent organ dysfunction specifically cardiac dysfunction. 
 
Study 2: Sepsis-Induced Cardiac Dysfunction (Chapter 3) 
Our understanding of the actions of erythropoietin (EPO), a haematopoietic 
cytokine has shifted from a belief that the hormone acts exclusively on erythroid 
progenitor cells to the knowledge that this protein exerts significant protection in various 
tissues.  The beneficial effects of EPO are allegedly mediated by a putative ‘tissue-
protective receptor’ that is distinct from the ‘classical’ EPO receptor (EpoR) known to 
mediate erythropoiesis. Protection conferred by EPO in models of doxorubicin-induced 
cardiotoxicity and myocardial infarction have implicated activation of the PI3K/Akt  
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pathway. Thus, once I develop a CLP model of cardiac dysfunction, I will investigate the 
effect of erythropoietin on sepsis induced cardiac dysfunction, specifically: 
- the effect EPO has on the impairment of systolic contractility (measured in 
vivo by echocardiography or ex vivo in the isolated Langendorff-perfused 
heart) associated with endotoxaemia and polymicrobial sepsis using wild-type 
(WT) C57BL/6 mice 
- whether the effect of EPO is mediated through the proposed tissue protective 
receptor, with the use of βcR knock-out (KO) mice 
- the mechanisms underlying the observed beneficial effects of EPO including 
the phosphorylation of Akt on Ser473, phosphorylation of glycogen synthase 
kinase-3β (GSK-3β) on Ser9, phosphorylation of endothelial nitric oxide 
synthase (eNOS) on Ser1177, activation of nuclear factor (NF)-κB (measured 
as nuclear translocation of p65) and expression of interleukin-1beta (IL-1β). 
 
Study 3: Myocardial Ischaemia/Reperfusion Injury (Chapter 4) 
The demand to discover novel therapies for treating myocardial infarction can be 
said to correlate with its ever increasing mortality and morbidity rates. Artesunate (ARS), 
an anti-malarial drug has over the past few years shown to affect various cellular 
biochemical processes such as cellular apoptosis and oxidative stress. Additionally, 
various studies have demonstrated ARS to modulate inflammatory and survival 
pathways. 
In a model of regional I/R in the rat, I will investigate whether: 
- ARS attenuates the injury associated with myocardial I/R by measuring infarct 
size as an end point. 
- The mechanism underlying the observed beneficial effect, focusing on the 
activation of well-known survival pathways; i) RISK pathway 
(pharmacological inhibition of PI3K and ERK 1/2 signalling, phosphorylation 
of Akt on Ser473), ii) SAFE pathway (phosphorylation of STAT3 on Tyr705), 
and the downstream mediators of these pathway (eNOS; GSK-3β; NF-κB). 
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Chapter 2 
 
 
 
Modification of a Model of Polymicrobial Sepsis 
– Caecal Ligation and Puncture 
 
 
 
 
 
2.1.  Introduction  
Sepsis is a heterogeneous condition, which consists of a dysregulated host 
response to an infection, subsequently ensuing in haemodynamic, cardiovascular, 
metabolic, inflammatory, and innate and adaptive immune alterations (Levy et al., 2003; 
Namas et al., 2012). The increasing prevalence, mortality rates and lack of effective 
therapy underscore the need for further research and highlights the importance for 
understanding the fundamental pathophysiological processes involved, to aide in 
recognizing new therapeutic targets.  
The development of experimental sepsis models to elucidate the progression and 
pathophysiology of clinical sepsis go back as far as the 1930’s, where studies focused 
primarily in exploiting models of intra-abdominal sepsis with the administration of 
endotoxin and intravenous or peritoneal infusion of live organisms. The 1960’s saw a 
shift in focus from models of endotoxaemia to models of bacteraemia (Deitch et al., 
2005). These included injection of live bacteria, inoculation of faeces, and the 
intramuscular, intraperitoneal or subdermal implantation of faeces-containing capsules. 
The path of discovery led to various models involving ischaemia and bowel perforation 
like the most frequently used sepsis model caused by CLP (reviewed in Mai et al., 2012). 
The CLP model of intra-abdominal sepsis was developed by Wichterman and 
colleagues is today regarded as the gold standard for modelling polymicrobial sepsis 
(Wichterman et al., 1980), as it closely resembles the development and features of human 
sepsis (Dejager et al., 2011). Multiple aspects of the CLP procedure address the 
complicated clinical course of sepsis: these include tissue trauma as a result of a 
laparotomy, necrosis instigated by ligation o;f the cecum, and infection as a consequence 
of the leakage of peritoneal microbial flora into the peritoneum. The latter process 
eventually leads to septic shock via activation of the inflammatory response, secondary 
to translocation of enteric bacteria into the bloodstream (Dejager et al., 2011). 
Accordingly, polymicrobial sepsis is characterised by an early hyperdynamic phase, 
subsequently followed by a late hypodynamic phase (Rittirsch et al., 2009). Animals 
subjected to CLP appear healthy in the initial stages post procedure, but at 12 h after the 
procedure, they begin to demonstrate the clinical signs of sepsis including malaise, fever,  
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chills, pilorection, generalised weakness and dampened gross motor activity, with 
lethality ensuing at about 18-24 h post CLP (Rittirsch et al., 2009). 
Despite its clinical relevance and widespread utilisation in sepsis research, one of 
the major concerns of the CLP model is controlling the magnitude of the septic challenge 
across different laboratories (Dejager et al., 2011). On the basis of the characteristics of 
the model, the outcome post CLP is strongly influenced by various factors during the 
procedure: i) the percentage of cecum ligated (Singleton & Wischmeyer, 2003) and, 
hence, the amount of necrosis that is induced; ii) the microbial amount entering the 
peritoneum, which, is dependent on the number and size of puncture and pressure exerted 
on the caecal end; iii) sex, age and strain of the animals; and iv) supportive treatment such 
as fluid resuscitation and antibiotic regimen (Dejager et al., 2011). Nevertheless, the 
variability of this procedure confers on it an advantage by which the model can be tailored 
to induce sepsis with a range in severity, and allows to investigate acute as well as chronic 
sepsis (Dejager et al., 2011).  
Therefore, I sought to establish a model of CLP, which results in a consistent 
cardiac dysfunction as assessed in vivo by echocardiography. Specifically, I investigated 
the effect of i) gender differences; ii) differing strains (inbred C57BL/6 and outbred CD-
1) in a time course-dependent manner; iii) alterations in fluid resuscitation and antibiotic 
therapy; iv) needle size; and v) age of C57BL/6 mice, on the development of cardiac 
dysfunction. The preference to utilise mice over rats was because the long term aim was 
to be able to potentially test a compound in a clinical model of CLP (Chapter 3). As most 
genetically manipulated knockout mice are on a C57BL/6 background, this mouse strain 
was the preferred choice. 
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2.2  Methods 
The animal protocols followed in this study were approved by the local Animal 
Use and Care Committee in accordance with the derivatives of both the Home Office 
guidance on the Operation of Animals (Scientific Procedures Act 1986) published by Her 
Majesty’s Stationary Office and the Guide for the Care and Use of Laboratory Animals 
of the National Research Council (PPL: 70/6525). 
 
Animals and Quantification of Organ Dysfunction 
This study was performed on a total of 60 C57BL/6 inbred mice [12 female, 19.38 
± 0.28 g;46 male (2 months, 26.68 ± 0.51 g; 5 months, 32.78 ± 1.10 g; 8 months, 32.15 ± 
1.74 g)  Harlan Laboratories, Wyton, UK], and a total of 43 CD-1 outbred mice (23 
female, 28.46 ± 0.50 g; 20 male, 38.27 ±  2.15 g, Harlan Laboratories, Wyton, UK), , 
receiving a standard diet and water ad libitum.  
At the end of each experiment, mice were anaesthetised with a 1.5 ml kg-1 of 
ketamine (100 mg ml-1) and xylazine (20 mg ml-1) mixture (2:1; 1.5 ml kg-1 i.p.) before 
being sacrificed. Approximately 1 ml of blood was collected via cardiac puncture into 
serum gel S/1.3 tubes (Starstedt, Nümbrecht, Germany). Blood was centrifuged for 3 min 
at 9000 g at room temperature, to separate serum. Serum samples were transferred to plain 
eppendorfs and immediately packaged and sent off at room temperature to a contract 
laboratory for veterinary clinical chemistry (IDEXX Laboratories, Wetherby, UK) and 
analysed within 24 h of collection. The following marker enzymes were evaluated as 
biochemical indicators of multiple organ injury/dysfunction, using a kinetic ultraviolet 
test on a Beckman Coulter analyser (Beckman Coulter Ltd, High Wycombe, UK): 
 Renal function was evaluated by measuring the rise in serum levels of urea 
(indicator of impaired excretory function of the kidney and/or increased protein 
and amino acid catabolism) and creatinine (indicator of reduced glomerular 
filtration rate, and hence, renal dysfunction (Thiemermann et al., 1995).  
 Hepatic injury was assessed by measuring the rise in serum levels of alanine 
aminotransferase (ALT, a specific marker for hepatic parenchymal injury), and 
aspartate aminotransferase (AST, a non-specific marker for hepatocellular injury) 
(Thiemermann et al., 1995). 
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Caecal Ligation and Puncture 
I followed the original CLP protocol introduced by Wichterman and colleagues 
(1980) with slight modifications including analgesia (buprenorphine; 0.5 mg kg-1) and 
antibiotic therapy (Imipenem/Cilastatin; 20 mg kg-1). This specific combination of 
imipenem and cilastatin was chosen due to the fact it is a broad spectrum beta-lactam 
antibiotic, known for its role in inhibiting bacterial cell wall biosynthesis (Birnbaum et 
al., 1985). Additionally, it appears to be a preferred choice of antibiotics, employed by 
various other laboratories in the mouse CLP model (Wang et al., 1998; Ulloa et al., 2002) 
and has been associated with increased survival when compared with triple antibiotic 
therapy (Newcomb et al., 1998).  A 20-gauge (G) needle was used with the double 
puncture technique for the studies involving the different strains, sex and altered 
antibiotics therapy, which in some cases went for a maximum period of 5 days. For the 
experiments of increased severity which were carried in aged C57BL/6 mice, an 18-G 
(i.e. larger size and hence, a more severe insult) needle was used with a double puncture 
technique, in order to generate cardiac dysfunction during the early phase of sepsis (24 
h).  
Briefly, anaesthesia was achieved with a ketamine (100 mg ml-1)/ xylazine (20 mg 
ml-1) mixture (2:1; 1.5 ml kg-1) injected i.p. Buprenorphine was administered additionally 
to provide adequate analgesia. A temperature of 37 0C was maintained by placing the 
animals on a homeothermic blanket and performing surgery in a temperature-controlled 
room. Surgery was performed under sterile conditions (i.e. use of sterile drapes, sterilised 
equipment) and began with the opening of the peritoneum via a 1.5 cm midline incision 
in order to exteriorise the caecum. The caecum was ligated just below the ileocaecal valve 
and punctured at both opposite ends. After a small amount of faecal matter was extruded 
from both ends to ensure patency, the caecum was placed back in its anatomical position. 
The peritoneum was sutured; 1 ml of Ringer’s lactate solution was given for resuscitation 
subcutaneously and the mice were placed back in their cages. Analgaesia was 
administered i.p. and fluid resuscitation and antibiotics therapy were administered 
subcutaneously 6 h after surgery and every 12 h after that for a maximum  
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of 3 days, unless otherwise stated. Sham-operated animals underwent the same surgical 
procedures (i.e. laparotomy and fluid resuscitation and antibiotic therapy), the caecum 
was exteriorised and then replaced but was neither ligated nor punctured. 
 
Experimental Design 
Animals were randomised into 4 study groups, subjected to CLP surgery, received 
relevant fluid resuscitation and antibiotics therapy, and assessed for cardiac function via 
echocardiography. A summary of the 4 study protocols is given in Table 2.2.1 with a 
detailed description treatments of animals given in Figure 2.2.1.  
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Table 2.2.1 Experimental groups of C57BL/6 and CD-1 male and female mice. 
 
Study Strain/ 
Sex 
Age 
(Months) 
Group Protocol 
(h) 
Needle n 
1 Male 
C57BL/6 
2  Sham  N/A N/A 5 
  2 CLP24 24 20-G 4 
  2 CLP48 48 20-G 3 
  2 CLP72  72 20-G 3 
 Female 
C57BL/6 
2 Sham N/A N/A 4 
  2 CLP24 24 20-G 3 
  2 CLP48 48 20-G 5 
2 Male  
CD-1 
2 Sham N/A N/A 4 
  2 CLP24 24 20-G 4 
  2 CLP48 48 20-G 3 
  2 CLP72 72 20-G 2 
  2 CLP96 96 20-G 4 
  2 CLP120 120 20-G 3 
 Female 
CD-1 
2 Sham  N/A N/A 3 
  2 CLP24 24 20-G 4 
  2 CLP48 48 20-G 4 
  2 CLP72 72 20-G 3 
  2 CLP120 120 20-G 3 
3 Male 
C57BL/6 
2 CLP24 + no  FRAT 24 20-G 4 
  2 CLP24 + 6 h FRAT 
 
24 20-G 14 
  2 CLP24 + 18 h FRAT 24 20-G 3 
 Female 
CD-1 
2 CLP24 + 6 h FRAT 24 20-G 2 
  2 CLP72 + 6 h FRAT 72 20-G 2 
4 Male 
C57BL/6 
2 CLP 2 months 24  18-G 5 
  5 CLP 5 months 24  18-G 5 
  8 CLP 8 months 24  18-G 9 
 
FRAT, fluid resuscitation and antibiotic therapy; N/A, not applicable; G, gauge 
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Figure 2.2.1. Experimental procedure and animal treatment. FRAT, fluid 
resuscitation and antibiotic therapy   
 
 
Assessment of Cardiac Function in vivo  
Left ventricular (LV) function was assessed in mice by echocardiography in vivo 
as reported previously (Khan et al., 2013). At 24 h subsequent to CLP surgery, mice were 
anesthetized with 3 % isoflurane and placed in a supine position, atop a heating pad 
embedded with ECG leads, to maintain body temperature and measure heart rate. Fur was 
removed with hair removal cream from the neckline to mid chest level, pre-heated 
ultrasound gel was applied to the chest and a steady state sedation level was maintained 
thereafter with 0.5 – 0.7 % isoflurane for the duration of the procedure. Mice were 
allowed to stabilize for approximately 10 mins after which, the heart was imaged using a 
Vevo-770 imaging system (VisualSonics, Toronto, Canada). Percent fractional area 
change (FAC) was assessed with a two-dimensional (B-mode) view along the parasternal 
short axis mid-ventricular papillary muscle level. Subsequently, measurements of LV 
dimensions and contractility such as ejection fraction (EF) and fractional shortening (FS) 
were obtained using an M-mode tracing.  
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Figure 2.2.2. Echocardiographic assessment showing (a) parasternal short-axis view 
producing a transverse cut of the left ventricle (LV) at the papillary muscle (PM) level at 
which the fractional area change (FAC) can be determined, (b) M-mode tracing used to 
display LV cavity and dimensions is used to determine ejection fraction (EF) and 
fractional shortening (FS). LVEDD, left ventricular end-diastolic diameter; LVESD, left 
ventricular end-systolic diameter. 
 
Materials 
Unless otherwise stated, all compounds in this study were purchased from Sigma-
Aldrich Company Ltd (Poole, Dorset, UK).  
 
Statistical Analyses 
All values described in the text and figures are presented as mean ± standard error 
of the mean (SEM) of n observations, where n represents the number of animals studied. 
Statistical analysis was performed using GraphPad Prism 5.0d (GraphPad Software, San 
Diego, California, USA). Data without repeated measurements were assessed by a one-
way ANOVA followed by a Dunnet’s post-hoc test.  
 
 
 
(a) (b) 
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2.3  Results 
 
Heart rate measurements in C57BL/6 and CD-1 mice following caecal ligation and 
puncture 
 Study 1- Heart rates of male and female C57BL/6 mice that have underwent 
CLP surgery, when compared to sham operated animals treated with vehicle (Sham), 
male C57BL/6 mice subjected to CLP surgery demonstrated no significant changes in 
heat rate (HR) (P > 0.05, Table 2.3.1), at 24, 48 and 72 h post-surgery. In contrast, when 
compared to sham operated animals treated with vehicle (Sham), female C57BL/6 mice 
subjected to CLP surgery demonstrated a significant change in HR at 24 (608.20 ± 15.74 
vs. 418.00 ± 43.47; P < 0.05, Table 2.3.1) and 48 hr (608.20 ± 15.74 vs. 440.00 ± 
31.54; P < 0.05, Table 2.3.1) post-surgery. 
 Study 2- Heart rates of male and female CD-1 mice that underwent CLP 
surgery, when compared to sham operated animals treated with vehicle (Sham), male 
CD-1 mice subjected to CLP surgery demonstrated no significant change in HR (P > 0.05, 
Table 2.3.1),  up to 120 h post-surgery. Similarly, when compared to sham operated 
animals treated with vehicle (Sham), female CD-1 mice subjected to CLP demonstrated 
no significant change in HR at 24, 48, 72 and 120 h (P > 0.05, Table 2.3.1) post-surgery. 
 Study 3- Heart rates of mal C57BL/6 and female CD-1 mice that underwent 
CLP surgery with subsequent alteration in fluid resuscitation and antibiotic 
therapy, when compared to sham operated animals treated with vehicle (Sham), male 
C57BL/6 mice subjected to CLP surgery for 24 h and administered no fluid resuscitation 
and antibiotic therapy (FRAT) demonstrated a significant change in HR (608.20 ± 15.74 
vs. 451.25 ± 44.39; P < 0.05, Table 2.3.1). Whereas, animals subjected to CLP surgery 
for 24 h and administered either fluid resuscitation and antibiotic therapy only at 6 h or 
18 h post-surgery demonstrated no significant changes in HR (P > 0.05, Table 2.3.1) when 
compared to Sham animals. 
 Moreover, when compared to sham operated animals treated with vehicle (Sham), 
female CD-1 mice subjected to CLP surgery and administered fluid resuscitation and 
antibiotic therapy only at 6 h 24 h or 72 h post-surgery demonstrated no significant 
changes in HR (P > 0.05, Table 2.3.1).  
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Study 4- Heart rates of aging male C57BL/6 mice that underwent CLP 
surgery, when compared to sham operated animals treated with vehicle (Sham), 2, 5 and 
8 months-old male C57BL/6 mice subjected to CLP surgery demonstrated significant 
changes in HR (2 months, 608.20 ± 15.74 vs. 497.40 ± 46.09; P < 0.05, Table 2.3.1; 5 
months, 608.20 ± 15.74 vs. 476.40 ± 25.18; P < 0.05, Table 2.3.1; 8 months 608.20 ± 
15.74 vs. 469.00 ± 12.81; P < 0.05, Table 2.3.1). 
  
Table 2.3.1.  Heart rate of C57BL/6 and CD-1 male and female mice  
 
Study Strain/ 
Sex 
Age 
(Months) 
Group Protocol 
(h) 
n Needle  Heart rate (bpm) 
1 Male C57BL/6 2  Sham  N/A 5 N/A 608.20 ± 15.74 
  2 CLP24 24 4 20-G 474.50 ± 56.74 
  2 CLP48 48 3 20-G 475.33 ± 57.74 
  2 CLP72  72 3 20-G 447.33±38.74 
 Female 
C57BL/6 
2 Sham N/A 4 N/A 575.75 ± 15.11 
  2 CLP24 24 3 20-G 418.00 ± 43.47  
  2 CLP48 48 5 20-G 440.00 ± 31.54  
2 Male  CD-1 2 Sham N/A 4 N/A 524.25 ± 25.16 
  2 CLP24 24 4 20-G 450.50 ± 42.27 
  2 CLP48 48 3 20-G 610.67 ± 61.91 
  2 CLP72 72 2 20-G 485.00 ± 12.00 
  2 CLP96 96 4 20-G 552.75 ± 29.66 
  2 CLP120 120 3 20-G 459.33 ± 45.73 
 Female CD-1 2 Sham  N/A 3 N/A 506.00 ±69.30 
  2 CLP24 24 3 20-G 519.00 ± 21.94 
  2 CLP48 48 4 20-G 580.50 ± 59.89 
  2 CLP72 72 3 20-G 515.67 ± 31.52 
   2 CLP120 120 3 20-G 478.67 ± 45.50 
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Table 2.3.1.  Heart rate of C57BL/6 and CD-1 male and female mice continued 
 
Study Strain/ 
Sex 
Age 
(Months) 
Group Protocol 
(h) 
n Needle  Heart rate (bpm) 
3 Male C57BL/6 2 CLP24 + 
no FRAT 
24 4 20-G 451.25 ± 44.39 # 
  2 CLP24 +  
6 h FRAT 
24 14 20-G 495.57 ±22.32 
  2 CLP24 + 
18 h FRAT 
24 3 20-G 526.00 ± 73.75 
 Female CD-1 2 CLP24 + 6 
h FRAT 
24 2 20-G 588.00 ± 37.00 
  2 CLP72 + 6 
h FRAT 
72 2 20-G 522.50 ± 75.50 
4 Male C57BL/6 2 CLP 2 
months 
24  5 18-G 497.40 ± 46.09 # 
  5 CLP 5 
months 
24  5 18-G 476.40 ± 25.18 # 
  8 CLP 8 
months 
24  9 18-G 469.00 ± 12.81 # 
 
FRAT, fluid resuscitation and antibiotic therapy; N/A, not applicable; G, gauge 
 
Heart rate measurements in C57BL/6 and CD-1 mice. Data are expressed as means ± 
SEM. for n number of observations.   P < 0.05 vs. Female C57BL/6 Sham; # P < 0.05 
vs. Male C57BL/6 Sham, (one-way ANOVA followed by a Dunnett’s post-hoc test). 
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Study 1 - Assessment of cardiac function in male and female C57BL/6 mice that were 
subjected to CLP over time 
The first step in establishing a model of CLP was to investigate the effects of sex 
on the response of mice to a septic insult and, thus, the susceptibility to develop cardiac 
dysfunction. Figure 2.3.1A shows representative M-mode echocardiograms of Sham, 
CLP24, CLP48 and CLP72 in male C57BL/6 mice. When compared to Sham mice, mice 
subjected to CLP surgery demonstrated no significant alterations in EF, FS, and FAC at 
24, 48, nor 72 h post-surgery (P > 0.05, Figures 2.3.1B-D). 
 
Figure 2.3.2A shows representative M-mode echocardiograms of sham, CLP24 
and CLP48 in C57BL/6 female mice. When compared to sham mice, mice subjected to 
CLP surgery demonstrated no significant alterations in EF, FS, and FAC 24 or 48 h post-
surgery (P > 0.05, Figures 2.3.2B-D). 
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Figure 2.3.1. Cardiac function in male C57BL/6 mice that underwent CLP. 
Representative M-mode echocardiograms (A), percentage ejection fraction (B), 
fractional shortening (C) and fractional area change (D) in mice randomised to 
undergo either: sham operation (Sham, n = 5), or CLP surgery with double puncture 
technique, and left for either 24 h (CLP24, n = 4), 48 h (CLP48, n = 3) or  72 h (CLP72, 
n = 3). Data are expressed as means ± SEM. for n number of observations. 
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Figure 2.3.2. Cardiac function in female C57BL/6 mice that underwent CLP. 
Representative M-mode echocardiograms (A), percentage ejection fraction (B), 
fractional shortening (C) and fractional area of change (D) in mice randomised to 
undergo either: sham operation (Sham, n = 4), or CLP surgery with double puncture 
technique, and left for either 24 h (CLP24, n = 3), or 48 h (CLP48, n = 5). Data are 
expressed as means ± SEM. for n number of observations. 
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Study 2 - Assessment of cardiac function in male CD-1 mice subjected to CLP over 
time 
As CLP survival and the physiologic response to sepsis are greatly affected by 
genetic background (Godshall et al., 2002, in addition to investigating the response of 
inbred C57BL/6 mice to a septic insult, I sought to investigate the susceptibility of outbred 
CD-1 mice to develop cardiac dysfunction. Figure 2.3.3A shows representative M-mode 
echocardiograms of sham, CLP24, CLP48, CLP72, CLP96, and CLP120 in CD-1 male 
mice. When compared to sham mice, mice subjected to CLP surgery demonstrated no 
significant alterations in EF, FS, and FAC over a 5-day period (P > 0.05, Figures 2.3.3B-
D). 
 
 
 
 
 
 
 
 
 
Figure 2.3.3. Cardiac function in male CD-1 mice that underwent CLP. 
Representative M-mode echocardiograms (A), percentage ejection fraction (B), 
fractional shortening (C) and fractional area of change (D) in mice randomised to 
undergo either: sham operation (Sham, n = 4), or CLP surgery with double puncture 
technique, and left for either 24 h (CLP24, n = 4), 48 h (CLP48, n = 3), 72 h (CLP72, 
n = 2), 96 h (CLP96, n = 4), or 120 h (CLP120, n = 3). Data are expressed as means 
± SEM. for n number of observations. 
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Assessment of cardiac function in female CD-1 mice subjected to CLP over time 
Figure 2.3.4A shows representative M-mode echocardiograms of sham, CLP24, 
CLP48, CLP72, and CLP120 in female CD-1 mice. When compared to sham mice, mice 
subjected to CLP surgery demonstrated no significant alterations in EF, FS, and FAC at 
24, 48, 72 and 120 h post-surgery (P > 0.05, Figures 2.3.4B-D). 
 
 
 
 
 
 
 
 
 
Figure 2.3.4. Cardiac function in female CD-1 mice that underwent CLP. 
Representative M-mode echocardiograms (A), percentage ejection fraction (B), 
fractional shortening (C) and fractional area of change (D) in mice randomised to 
undergo either: sham operation (Sham, n = 3), or CLP surgery with double puncture 
technique for either 24 h (CLP24, n = 4), 48 h (CLP48, n = 4), 72 h (CLP72, n = 3), 
or 120 h (CLP120, n = 3). Data are expressed as means ± SEM. for n number of 
observations. 
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Study 3- Assessment of cardiac function in male C57BL/6 and female CD-1 mice 
subjected to CLP with subsequent alterations in fluid resuscitation and antibiotic 
therapy 
Although animal models which do not receive supportive care (i.e. fluid 
resuscitation and antibiotic therapy) are not representative of the clinical situation and are 
likely to demonstrate high mortality rates, I wanted to alter the fluid resuscitation and 
antibiotic therapy (FRAT) frequency to determine whether this might alter the 
susceptibility of C57BL/6 and CD-1 mice to succumbing to develop cardiac dysfunction. 
Figure 2.3.5A shows representative M-mode echocardiograms of sham, CLP24, CLP24 
+ No FRAT, CLP24 + 6 h FRAT, and CLP24 + 18 h FRAT in C57Bl/6 male mice. When 
compared to sham mice, mice subjected to CLP surgery demonstrated no significant 
alterations in EF, FS, and FAC (P > 0.05, Figures 2.3.5B-D) 24 h post-surgery. In 
addition, alterations in fluid resuscitation and antibiotic therapy which, included 
administering no FRAT following CLP surgery, giving FRAT only at 6 h post CLP 
surgery, or giving FRAT only at 18 h post-surgery resulted in no significant alterations 
in EF, FS, and FAC (P > 0.05, Figures 2.3.5B-D). 
Figure 2.3.6A shows representative M-mode echocardiograms of sham, CLP24, 
CLP24 + 6 h FRAT, and CLP72, and CLP72 + 6 h FRAT in CD-1 female mice. When 
compared to sham mice, mice subjected to CLP surgery demonstrated no significant 
alterations in EF, FS, and FAC (P > 0.05, Figures 2.3.6B-D) 24 h post-surgery. Altering 
the frequency of dosing of fluid resuscitation and antibiotic therapy by administering only 
one dose of FRAT at 6 h post CLP surgery resulted in no significant alterations in EF, 
FS, and FAC (P > 0.05, Figures 2.3.6B-D) 24 h post-surgery. 
In addition, when compared to sham mice, mice subjected to CLP surgery 
demonstrated no significant alterations in EF, FS, and FAC (P > 0.05, Figures 2.3.6B-D) 
72 h post-surgery. Altering the fluid resuscitation and antibiotic therapy by administering 
only one dose of FRAT at 6 h post CLP surgery resulted in no significant alterations in 
EF, FS, and FAC (P > 0.05, Figures 2.3.6B-D) 72 h post-surgery. 
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Figure 2.3.5. Cardiac function in male C57BL/6 mice that underwent CLP with 
subsequent alterations to fluid resuscitation and antibiotic therapy (FRAT). 
Representative M-mode echocardiograms (A), percentage ejection fraction (B), 
fractional shortening (C) and fractional area of change (D) in mice randomised to 
undergo either: sham operation (Sham, n = 5), or CLP surgery with double puncture 
technique and given either a normal FRAT therapy (CLP24, n = 4), no FRAT (CLP24 
+ o FRAT, n = 4),  FRAT only at 6 h (CLP24 + 6 h FRAT, n = 14) or FRAT only at 
18 h (CLP24 + 18 h FRAT, n = 3) 24 h post-surgery. Data are expressed as means ± 
SEM. for n number of observations. 
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Figure 2.3.6. Cardiac function in female CD-1 mice that underwent CLP with 
subsequent alterations to fluid resuscitation and antibiotics therapy (FRAT). 
Representative M-mode echocardiograms (A), percentage ejection fraction (B), 
fractional shortening (C) and fractional area of change (D) in mice randomised to 
undergo either: sham operation (Sham, n = 4), or CLP surgery with double puncture 
technique  and given either normal FRAT (CLP24, n = 4) or FRAT only at 6 h post-
surgery (CLP24 + 6 h FRAT, n = 2) 24 h post-surgery, or  CLP surgery with double 
puncture technique  and given either normal FRAT therapy (CLP72, n = 3) or FRAT 
at only 6 h post-surgery (CLP72 + 6 h FRAT, n = 2) 72 h post-surgery. Data are 
expressed as means ± SEM. for n number of observations.  
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Study 4 - The development of cardiac dysfunction in aging male C57BL/6 mice 
subjected to CLP 
Although sepsis is more frequently observed in aging patients (Destarac & Ely, 
2002; Girard et al., 2005), the majority of preclinical studies utilise young mice as their 
model system. I sought to determine the effect that age has on the susceptibility of 
C57BL/6 mice to develop cardiac dysfunction. For this study I used a larger needle size, 
and thus a more severe model of polymicrobial sepsis and assessed cardiac function 24 h 
following CLP surgery.  Figure 2.3.7A shows representative M-mode echocardiograms 
of Sham 2 months, CLP 2 months, CLP 5 months, and CLP 8 months, in C57BL/6 male 
mice. When compared to sham operated animals treated with vehicle (Sham), 2, 5, and 8 
months old mice subjected to CLP surgery developed an age-dependent decrease in 
systolic contractility, characterized by a significant decrease in EF (P < 0.05, Figure 
2.3.7B), FS (P < 0.05, Figure 2.3.7C), and FAC (P < 0.05, Figure 2.3.7D) 24 h post-
surgery. 
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Figure 2.3.7. Cardiac function in aging male C57BL/6 mice that underwent 
CLP.  Representative M-mode echocardiograms (A), percentage ejection fraction 
(B), fractional shortening (C) and fractional area of change (D), in mice randomised 
to undergo either: sham operation (Sham, n = 5), or CLP surgery with double 
puncture technique  in mice of at ages 2 months (n = 5), 5 months (n = 5), 8 months 
( n = 9) 24 h post-surgery. Data are expressed as means ± SEM. for n number of 
observations.  P < 0.05 vs. Sham 2 months, (one-way analysis of variance with 
Dunnett’s post-hoc test) 
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Serum levels of markers of organ injury/dysfunction in C57BL/6 and CD-1 mice 
following caecal ligation and puncture 
  
Study 1- Assessment of liver injury and renal function in male and female 
C57BL/6 mice that have underwent CLP surgery, when compared to sham operated 
animals treated with vehicle (sham), male C57BL/6 mice subjected to CLP surgery 
demonstrated no change in serum levels of urea (P > 0.05, Table 2.3.1) and creatinine (P 
> 0.05, Table 2.3.1) or AST (P > 0.05, Table 2.3.1) and ALT (P > 0.05, Table 2.3.1), 72 
h post-surgery. However, due to the low n number in this group, a firm conclusion cannot 
be made and thus requires further confirmation. In contrast, when compared to sham 
operated animals treated with vehicle (sham), female C57BL/6 mice subjected to CLP 
surgery demonstrated significant increases in serum levels of urea (P < 0.05, Table 2.3.1), 
indicating possible renal dysfunction at 24 h post-surgery and AST and ALT, indicative 
of hepatic injury (P < 0.05, Table 2.3.1) at 24 and 48 h post-surgery. 
 Study 2- Assessment of liver and renal function in male and female CD-1 
mice that underwent CLP surgery when compared to sham operated animals treated 
with vehicle (sham), male CD-1 mice subjected to CLP surgery demonstrated no 
significant increases in serum levels of urea (P > 0.05, Table 2.3.1), creatinine (P > 0.05, 
Table 2.3.1), or ALT (P > 0.05, Table 2.3.1), at 24, 48, 72, 96, or 120 h period post-
surgery. However, a significant increase in serum level of AST (P < 0.05, Table 2.3.1) , 
indicating possible liver injury was observed at 24 and 48 h post-surgery.  
Whereas, when compared to sham operated animals treated with vehicle (sham), 
female CD-1 mice subjected to CLP surgery demonstrated no significant increases in 
serum levels of urea (P > 0.05, Table 2.3.1) or creatinine (P > 0.05, Table 2.3.1) at 24, 
48, 72, or 120 h post-surgery, but exhibited significant increases in serum levels of AST 
(P < 0.05, Table 2.3.1) and ALT (P < 0.05, Table 2.3.1) , indicative of hepatic injury (P 
< 0.05, Table 2.3.1) at 24 and 48 h post-surgery. 
 Study 3- Assessment of liver and renal function in male C57BL/6 and female 
CD-1 mice that underwent CLP surgery with subsequent alteration to fluid 
resuscitation and antibiotic therapy when compared to sham operated animals treated 
with vehicle (sham), male C57BL/6 mice subjected to CLP for 24 h and administered 
either no fluid resuscitation and antibiotic therapy (FRAT) or given only at 6 h or 18 h 
post-surgery demonstrated no change in serum levels of urea (P > 0.05, Table 2.3.1) or  
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creatinine (P > 0.05, Table 2.3.1) at 24 h post-surgery. Animals that were either 
administered no  fluid resuscitation and antibiotic therapy or given only at 6 h post-
surgery demonstrated significant increases in serum levels of AST (P < 0.05, Table 2.3.1) 
and ALT, indicative of hepatic injury (P < 0.05, Table 2.3.1) at 24 h post-surgery. In 
addition, animals that were given fluid resuscitation and antibiotic therapy as late as 18 h 
post-surgery demonstrated a significant increase in serum level of ALT, indicative of 
hepatic injury (P < 0.05, Table 2.3.1) at 24 h post-surgery.  
Moreover, when compared to sham operated animals treated with vehicle (sham), 
female CD-1 mice subjected to CLP surgery and administered fluid resuscitation and 
antibiotic therapy only at 6 h post-surgery demonstrated no change in serum levels of urea 
(P > 0.05, Table 2.3.1), creatinine (P > 0.05, Table 2.3.1) or AST (P > 0.05, Table 2.3.1) 
but demonstrated an increased trend in serum levels of ALT at 24 h post-surgery which, 
could indicate possible hepatic injury. However due to the low n number in this group a 
firm conclusion cannot be made and thus requires further confirmation at 24 h post-
surgery. In contrast, animals that were subjected to CLP surgery and administered fluid 
resuscitation and antibiotic therapy only at 6 h post-surgery demonstrated no significant 
change in serum levels of urea (P > 0.05, Table 2.3.1) and creatinine (P > 0.05, Table 
2.3.1) at 72 h post-surgery, but demonstrated an increased trend in serum levels of ALT 
and AST at 72 h post-surgery which, could indicate possible hepatic injury..  However, 
due to the low n number in these groups, a firm conclusion cannot be made and thus 
requires further confirmation 
Study 4- Assessment of renal and liver function in aging male C57BL/6 mice 
that underwent CLP surgery when compared to sham operated animals treated with 
vehicle (sham), 2 months-old male C57BL/6 mice subjected to CLP surgery demonstrated 
significant increases in serum level of urea (P < 0.05, Table 2.3.1), indicating possible 
renal dysfunction, and AST and ALT, indicative of hepatic injury (P < 0.05, Table 2.3.1) 
at 24 h post-surgery. In addition, 5 months-old male C57BL/6 mice subjected to CLP 
surgery demonstrated significant increases in serum levels of urea (P < 0.05, Table 2.3.1) 
indicating possible renal dysfunction, and AST and ALT, indicative of hepatic injury (P 
< 0.05, Table 2.3.1) at 24 h post-surgery. Furthermore, 8 months-old male C57BL/6 mice 
subjected to CLP surgery demonstrated significant increases in serum levels of urea (P < 
0.05, Table 2.3.1) and creatinine, indicative of renal dysfunction (P < 0.05, Table 2.3.1),  
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and AST (P < 0.05, Table 2.3.1) and ALT, indicative of hepatic injury (P < 0.05, Table 
2.3.1) at 24 h post-surgery. 
 
Table 2.3.2. Serum levels of markers of organ injury/dysfunction in C57BL/6 and 
CD-1 male and female mice 
Strain/ 
Sex 
Group Age 
(Months) 
 
Needle 
Size 
Average 
Urea 
(mmol/l) 
Average 
Creatinine 
(µmol/l) 
Average 
AST 
(iµ/l) 
Average 
ALT 
(iµ/l) 
Male 
C57BL/6 
Sham 
(n = 5) 
2 N/A 6.5 ± 
0.4 
27.3 ± 
0.8 
146.1 ± 
22.4 
52.1 ± 
12.3 
 CLP24 
(n = 4) 
2 
 
20-G ND ND ND ND 
 CLP48 
(n = 3) 
2 
 
20-G ND ND ND ND 
 CLP72 
(n = 2) 
2 
 
20-G 10.4 ± 0.9 27.1 ± 
2.0 
387.6 ± 
45.8 
93.8 ± 
11.5 
Female 
C57BL/6 
Sham 
(n = 4) 
2 N/A 7.3 ± 
0.58 
30.28 ± 
0.73 
159.65 ± 
18.51 
40.40 ± 
10.26 
 CLP24 
(n = 3) 
2 
 
20-G 18.7 ± 
2.1§ 
30.1 ± 
0.59 
858.8 ± 
77.7 § 
359.2 ± 
22.7 § 
 CLP48 
(n = 5) 
2 20-G 10.0 ± 
0.4 
27.4 ± 
1.5 
828.5 ± 
60.8 § 
249.6 ± 
25.6 § 
Male 
CD-1 
Sham  
(n = 4) 
2 N/A 6.65 ± 
0.36 
27.78 ± 
1.15 
123.70 ± 
29.30 
110.15 ± 
74.95 
 CLP24 
(n = 4) 
2 
 
20-G 9.6 ± 
1.3  
30.2 ± 
1.8 
681.0 ± 
58.8 # 
161.2 ± 
25.7  
 CLP48 
(n = 3) 
2 
 
20-G 5.6 ± 
1.2 
25.6 ± 
1.7 
284.9 ± 
11.0 # 
107.7 ± 
29.6  
 CLP72 
(n = 2) 
2 
 
20-G 4.7 ± 
0.6 
23.6 ± 
0.7 
189.2 ± 
7.50 
43.2 ± 
12.6 
 CLP96 
(n = 4) 
2 
 
20-G 5.3 ± 
0.1 
25.8 ± 
0.6 
138.0 ± 
10.0 
23.1 ± 
3.20 
 CLP 
120 
(n = 3) 
2 
 
20-G 6.6 ± 
1.3 
27.8 ± 
0.9 
141.0 ± 
14.5 
24.4 ± 
2.6 
Female 
CD-1 
Sham 
(n = 3) 
2 N/A 4.93 ± 
0.3 
27.1 ± 
1.1 
128.2 ± 
22.7 
23.0 ± 
3.6 
 CLP24 
(n = 4) 
2 
 
20-G 13.3 ± 
4.6 
30.2 ± 
1.0 
611.0 ± 
56.7 $ 
235.5 ± 
17.4 $ 
 CLP48 
(n = 4) 
2 
 
20-G 6.0 ± 
0.6 
27.20 ± 
1.1 
405.4 ± 
108.2 $ 
109.2 ± 
40.0 $ 
 
FRAT = fluid resuscitation and antibiotic therapy; N/A = Not applicable;  
ND = Not done; G = Gauge 
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Table 2.3.1. Serum levels of markers of organ injury/dysfunction in C57BL/6 and 
CD-1 male and female mice continued  
Strain/ 
Sex 
Group Age 
(Months) 
 
Needle 
Size 
Average 
Urea 
(mmol/l) 
Average 
Creatinine 
(µmol/l) 
Average 
AST 
(iµ/l) 
Average 
ALT 
(iµ/l) 
 CLP72 
(n = 4) 
2 20-G 4.7 ± 
0.4 
25.8 ± 
1.3 
171.3 ± 
29.1 
31.0 ± 
5.2 
 CLP 
120 
(n = 4) 
2 
 
20-G 5.4 ± 
0.1 
27.2 ± 
1.3 
145.7 ± 
17.5 
20.8 ± 
2.1 
Male 
C57BL/
6 
CLP24 + No 
FRAT 
(n = 4) 
2 
 
20-G 23.9 ± 
6.78 
53.4 ± 
15.3 
572.9 ± 
109.1  
403.1 ± 
67.2  
 CLP24 + 6h 
FRAT 
(n = 14) 
2 
 
20-G 20.9 ± 
3.5 
53.0 ± 
7.9 
522.1 ± 
49.9  
289.6 ± 
30.4  
 CLP24 + 18h 
FRAT 
(n = 3) 
2 
 
20-G 15.5 ± 
2.9 
44.3 ± 
3.5 
466.6 ± 
119.1 
296.4 ± 
95.3  
Female 
CD-1 
CLP24 + 6h 
FRAT 
(n = 2) 
2 20-G 4.4 ± 
1.2 
25.4 ± 
1.8 
370.5 ± 
100.8 
147.2 ± 
34.6  
 CLP72 + 6h 
FRAT 
(n = 2) 
2 
 
20-G 5.6 ± 
0.1 
29.9 ± 
0.3 
485.5 ± 
132.5 9 
74.2 ± 
20.4  
Male 
C57BL/
6 
CLP 2 
months 
(n = 5) 
2 
 
18-G 19.8 ± 
4.8  
40.9 ± 
7.0 
446.8 ± 
71.5  
287.7 ± 
64.9  
 CLP 5 
months 
(n = 5) 
5 
 
18-G 25.6 ± 
5.98  
38.1 ± 
6.20 
603.7 ± 
110.0  
310.9 ± 
53.8  
 CLP 8 
months 
(n = 10) 
8 
 
18-G 36.8 ± 
1.4  
76.3 ± 
8.0  
673.5 ± 
54.2  
356.6 ± 
35.2  
 
FRAT = fluid resuscitation and antibiotic therapy; N/A = Not applicable;  
ND = Not done; G = Gauge 
 
Serum levels of (A) urea, (B) creatinine (C) aspartate aminotransferase (AST) and (D) 
alanine aminotransferase (ALT) in C57BL/6 and CD-1 male and female mice. Data are 
expressed as means ± SEM. for n number of observations.  P < 0.05 vs. Male C57BL/6 
Sham; § P < 0.05 vs. Female C57BL/6; $ P < 0.05 vs. Female CD-1 Sham; # P < 0.05 vs. 
Male CD-1 Sham, (one-way analysis of variance with Dunnett’s post-hoc test). 
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2.4.  Discussion 
The reality that promising new modalities that otherwise prove successful in 
treating sepsis in an experimental model fail to translate successfully into a clinical 
setting, highlights the importance for utilising animal models that more closely reproduce 
the pathophysiological changes associated with human sepsis. Animal models of sepsis 
can be classified into three strategies: i) administration of bacterial wall fragments such 
as lipopolysaccharide or PepG (see chapter I, section 1.1.2); ii) administration of life 
bacteria or viruses (or injection of faeces); and iii) alteration of the endogenous protective 
barrier of the animal, such as the model of CLP (Djager et al., 2011). Furthermore, many 
of the therapeutic failures can be attributed to initiating clinical trials on the basis of 
results obtained in animal models that do not take into consideration the multiple factors, 
which have a bearing on the clinical outcome of patients. These factors include i) animals 
housed in specific pathogen-free facilities, ii) usage of inbred strains, iii) animals being 
of the same age, weight and gender. The reality is that patients are far more heterogenous 
with respect to gender, age, nutritional status, and supportive care than any animals used 
in preclinical studies (Djager et al., 2011).  
I sought to refine an existing model of CLP (Wichterman et al., 1980) and develop 
a more clinically relevant model of CLP-induced cardiac dysfunction, by altering factors 
such as strain, sex, age, insult (bacterial load - needle size) and alterations in fluid 
resuscitation and antibiotic therapy, factors, which are thought to play a significant role 
in the development of organ dysfunction in animal models of CLP. In my study changes 
in gender as well as alterations in fluid resuscitation and antibiotic therapy did not appear 
to have an effect on the susceptibility of young inbred C57BL/6 and outbred CD-1 mice 
to develop cardiac dysfunction. In contrast, having seen the difficulty in obtaining 
reproducible cardiac dysfunction in young mice, I have set-up a modified model of sepsis-
induced cardiac dysfunction in inbred C57BL/6 mice, based upon the standard 
polymicrobial CLP model with two distinctive features: i) use of aged mice, and ii) the 
use of appropriate fluid resuscitation and antibiotic therapy.  
Various preclinical and clinical studies have demonstrated a gender dimorphism 
of the immune and organ responsiveness in susceptibility to and morbidity from shock, 
trauma, and sepsis (Angele et al., 2000). Females exhibit a form of protection in terms of 
their cardiovascular (Mizushima et al., 2000) and immunologic (Angele et al., 1997) 
responses during infectious challenge, while male patients demonstrate a higher incidence 
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of severe sepsis (Aube et al., 1992; Wichmann et al., 2000) and of infections in general 
(McGowan et al., 1975; Holmes et al., 1998; Offner et al 1999). The difference in the 
gender-mediated response to injury has been predominantly attributed to the differing 
hormonal milieu of each sex (De Maio et al., 2005). Various investigators that have 
demonstrated i) during the proestrus phase, oestrogen has effects on immune function and 
confers protection in sepsis models (Diodato et al., 2001; Merkel et al., 2001; Knoferl et 
al., 2002; Kher et al., 2005), ii) a decrease in testosterone levels by either castration or 
pharmacological blockade has shown to be beneficial following haemorrhagic shock 
(Remmers et al., 1997; Remmers et al., 1998), and iii) females in the proestrus phase are 
able to maintain splenic immune functions and, thus, tolerate sepsis better compared to 
their male littermates (Zellweger et al., 1997). I report here that young (2 month old) 
female C57BL/6 and CD-1 mice failed to develop significant cardiac dysfunction 24 h 
subsequent to undergoing CLP surgery. This finding was associated with an overall 
resistance to develop significant renal dysfunction and liver injury, two organs, which are 
known to fail early on in the septic syndrome (Abraham & Singer, 2007). I failed to see 
a gender difference in the response to CLP, as also male C57BL/6 and CD-1 mice 
demonstrated a similar trend, possibly as a result of the CLP procedure not being severe 
enough to result in organ dysfunction. 
In addition, the implications of a genetic variance for the immune response to 
sepsis has been an area of great research, with previous investigators demonstrating that 
the response to endotoxaemia (De Maio et al., 1998; O’Malley et al., 1998) and 
polymicrobial sepsis (Stewart et al., 2002) amongst inbred mice is strain-dependent, a 
factor leading to increased susceptibility amongst the C57BL/6 strain. Of note, the CLP 
protocol implemented by Stewart and colleagues, comprises of a single puncture 
technique with a 25 G needle size. Additionally, animals were only given 1 ml of saline 
post-operatively with no mention of administration of fluid resuscitation or antibiotics. It 
could be that this group wished to assess the mortality between the two strains they 
investigated using a model of severe sepsis but because the purpose of the study was to 
determine the influence of genetic variation in the response to sepsis, one would think to 
use a model that was more representative of the clinical setting. Therefore, I think the 
lack of fluid resuscitation and antibiotic administration in this case may have been a huge 
contributor to the increased mortality they observed in their C57BL/6 strain of mice. I 
failed to see a significant effect of the strain difference in mice on the susceptibility to 
succumb to cardiac dysfunction between the inbred and outbred mice. A possible 
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explanation for not seeing an increase in C57BL/6 susceptibility to organ 
injury/dysfunction which has been shown by other studies could due to the difference in 
model severity i.e. needle size and whether or not fluid resuscitation and antibiotic therapy 
was initiated as part of the protocol. 
 Currently, the therapeutic approach of patients with sepsis is centred on early 
administration goal-directed haemodynamic resuscitation and appropriate antibiotics 
(Hollenberg et al., 2004; Kumar et al., 2006). Clinically intravenous antibiotic therapy 
should be initiated immediately following obtaining positive blood culture. A 
retrospective cohort study of 14 intensive care units (ICU) found that each hour delay in 
antimicrobial administration correlates with decreased survival (Kumar et al., 2006). 
Other studies show that failure to initiate adequate antimicrobial therapy correlates with 
increased morbidity and mortality in septic patients admitted to the ICU (Ibrahim et al., 
2000; Garnacho-Montero et al., 2003; Harbarth et al., 2003). Likewise, adequate fluid 
resuscitation serves as one of the keystones in the management of shock, with the purpose 
of counteracting the effects of the sepsis-induced hypovolaemia, by preserving 
intravascular fluid volume, restore effective tissue perfusion and re-establish and 
maintain a balance between tissue oxygen demand and supply (Vincent & Gerlach, 2004).  
Although patients with septic shock can be successfully resuscitated with crystalloids (i.e. 
Ringer’s solution) and colloids (i.e. Hydroxyethyl starch), the choice of fluids in this 
setting remains controversial. Titration with either colloids or crystalloids to the same 
level of filling pressure restores tissue perfusion to the same degree (Rackow et al., 1983). 
However, colloids are evidently the preferred choice in various countries despite the 
possible risks and higher costs compared to crystalloids (Finfer et al., 2010). A choice 
seen to be due data suggesting that they improve cardiac performance more effectively in 
patients with hypovolaemia (Rackow et al., 1983; Trof et al, 2010) and the lower 
resuscitation volumes required (Lamke et al., 1976; Rackow et al., 1983), although the 
latter is put into question following a more recent study (Bayer et al., 2012). 
This being said, the utilisation of sufficient antibiotic therapy and fluid 
resuscitation is still variable in animal models of sepsis. The importance of these 
supportive treatments in the severity of the sepsis response has been illustrated by using 
different resuscitation strategies and by the use of antibiotic in CLP. The importance of 
antibiotic in animal studies is highlighted in the study of Romero and colleagues, whereby 
they observed increased resistance of IFN-γ knockout mice to CLP-induced mortality 
(Romero et al., 2010). This was in contrast to the study of Echtenacher and colleagues in 
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which no antibiotic treatment was applied (Echtenacher et al., 2001). Furthermore, a 
study by Vianna and colleagues in a CLP model, demonstrated that animals treated with 
imipenem exhibited higher survival rates with significant infection control, effects 
explained by i) reduced levels of plasma TNF-α and plasma and peritoneal fluid levels of 
IL-6 and ii) higher endotoxin plasma concentrations, possibly as a result from rapid 
killing of bacteria in the peritoneum (Vianna et al., 2004). There was no difference in 
mortality nor in the susceptibility to develop organ dysfunction between the mice that had 
the normal fluid resuscitation and antibiotic therapy (Imipenem/Cilastatin with those that 
had an altered fluid resuscitation and antibiotic therapy. Although the purpose of altering 
the fluid resuscitation antibiotic therapy either by giving this late or not at all, was to try 
and induce significant cardiac dysfunction, it does not serve as a clinically relevant model 
for this particular study. Patients presenting or suspected to have sepsis are resuscitated 
with the preferred colloid solution and are put on a course of antibiotic therapy straight 
away to fight off the course of infection. Therefore, since the aim of setting up a CLP 
model of cardiac dysfunction is to be able to test a potential translatable drug (Chapter 3), 
it was important to mimic the clinical situation as much as possible. Thus a regime 
comprising of antibiotic therapy commencing at 6 h post-surgery to simulate a short 
window of undiagnosed sepsis, and continued 12 h after that, was applied in my final 24 
h aged model which, successfully developed significant organ dysfunction. In retrospect, 
having used a crystalloid as the preferred choice of resuscitation fluid in this study, it 
would be interesting to see if there is any difference in the model response to the CLP 
insult when using a colloid such as hydroxyethyl starch, since a recent study showed 
improved short-term survival and acid-base balance when using a colloid compared with 
a crystalloid, in a model of endotoxin-induced septic shock (Kellum, 2002).   
Sepsis is predominantly a disease affecting the elderly with recent epidemiologic 
studies demonstrating mean ages of approximately 65 years in United States and 
European intensive care units (Angus et al., 2001; Padkin et al., 2003). An observational 
study analysing approximately 500 geographically separated acute care hospitals in the 
United States during 1979 to 2002, showed that the incidence of sepsis is 
disproportionately increased in elderly adults, with age being an independent predictor of 
mortality (Martin et al., 2006). Additionally, there is very good evidence from a multitude 
of studies documenting a relationship between age and increased mortality in CLP 
(Turnbull et al., 2009). Compared to young mice, aged mice subjected to CLP 
demonstrate increased systemic levels of inflammatory cytokines (Turnbull et al., 2003; 
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Saito et al., 2003) in addition to increased splenic apoptosis (Turnbull et al., 2004), and 
both of these two factors are associated with increased mortality in sepsis in humans 
(Hotchkiss et al., 1999; Bozza et al., 2007) and animal studies (Remick et al., 2002; 
Chang et al., 2007). I demonstrate that unlike young mice, 8-months old C57BL/6 male 
mice developed multi-organ failure (despite adequate fluid resuscitation and antibiotics 
therapy) including kidney dysfunction, hepatic injury, and most notably cardiac 
dysfunction at 24 h. The increased susceptibility of 8-months old mice to develop both 
renal dysfunction and hepatic injury is consistent with a prior study whereby Miyagi and 
colleagues demonstrated that inbred C57BL/6 only develop acute kidney injury at an age 
of 42-44 weeks (Miyagi et al., 2003).  
 
Limitations 
 As with all animal studies, this study has certain limitations. Performing 
experiments in a temperature-controlled room on a heat mat does not necessarily equate 
to maintaining adequate body temperature. It is known that administration of anaesthetics 
leads to significant loss of body temperature (Gardner et al., 1995; Sessler & Akca, 2002) 
and that due to the nature of the surgical procedure in CLP, post-operative hypothermia 
becomes a factor that modulates outcome (Nemzek et al., 2008), as studies demonstrate 
that correction of perioperative hypothermia has been shown to decrease the incidence of 
wound infections (Kurz et al., 1996; Xiao & Remick, 2005). Therefore, more stringent 
measurement and thus control of individual animal body temperature should be adhered 
to for future experiments. In addition, some groups in this study were made up of low n 
numbers, a result of not only financial constraints but also insufficient experimental 
planning. Therefore, for these particular groups any organ-specific effects seen should be 
confirmed by doing more n numbers. It is not expected that cardiac parameters for naïve 
animals would be any different from sham animals (Takuma et al., 2001; Roth et al., 
2002). Since the shams in this study exhibit normal cardiac parameters which are 
expected for such animals under the influence of anaesthesia, one could assume that they 
are not exerting any effect on the parameters measured. Nevertheless, the inclusion of 
naïve animals serves as part of good experimental practice and will exclude the possibility 
of shams having any effect on the parameters measured. Furthermore, inclusion of age-
specific sham controls should be made not only to ensure that there is no age-dependent 
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effects on any parameters measured for the sham groups, but also to allow the correct 
comparison of age-specific CLP treated animals to their respective shams.  
 
Conclusion 
 I demonstrate that young inbred and outbred mice show resistance to develop 
cardiac dysfunction following CLP. Having utilised 8-months old mice, I managed to 
establish a model of renal dysfunction, hepatic injury, and most notably consistent cardiac 
dysfunction, whilst employing a clinically relevant fluid resuscitation and therapy. 
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Chapter 3 
 
 
Erythropoietin Attenuates Cardiac Dysfunction 
in Experimental Sepsis via Activation of the β-
Common Receptor 
 
 
 
 
3.1.    Introduction 
 
The haematopoietic growth factor erythropoietin (EPO) has long been known to 
function in maintaining optimal tissue oxygenation through the regulation of 
erythrocytes, via a negative feedback control system, which enables cross-talk between 
the kidney and the bone marrow (Sharples & Yaqoob, 2006). Recombinant human EPO 
(rhEPO) is widely recognised clinically for the management of anaemia associated with 
end-stage renal disease (Eschbach et al., 1987) and non-myeloid malignancies (Gabrilove 
et al., 2001). However, during the past two decades, our understanding of the actions of 
EPO has shifted from a belief that the hormone acts exclusively on haematopoietic 
progenitor cells to the knowledge that this agent possesses much broader salutary effects, 
like those seen in preclinical models of, haemorrhagic shock (Abdelrahman et al., 2004), 
and endotoxic shock (Aoshiba et al., 2009).   
The beneficial non-erythropoietic effects of EPO have been reported to be 
mediated by a putative ‘tissue-protective receptor’ that is distinct from the ‘classical’ EPO 
receptor (EpoR) known to mediate erythropoiesis (Leist et al., 2004). This receptor has 
been proposed to be a heteromer between the EPO receptor and the β-common receptor 
(βcR, also called CD131), present also in the myocardium (Brines et al., 2004). The βcR 
is also the signal-transducing component common to IL-3, IL-5, and granulocyte-
macrophage colony stimulating factor receptors (D’Andrea & Gonda, 2000).  In addition, 
the ‘tissue-protective receptor’ is thought to specifically bind to EPO with a lower affinity 
than the classical EPOR (Masuda et al., 1993).  
The discovery of a functional EPO receptor in the cardiovascular system, 
particularly in endothelial cells (Anagnostou et al., 1994) and cardiomyocyes (Wright et 
al., 2004), as well as the finding of a cellular co-localization of EPO, βcR and EPOR in 
cardiomyocytes (Brines et al., 2004) points towards a role of EPO in modulating cardiac 
function. Evidence from animal models support the notion that EPO (Cai et al., 2003; 
Calvillo et al., 2003) as well as non-haematopoietic tissue-protective EPO-analogues such 
as carbamylated EPO (Moon et al., 2006; Ueba et al., 2010) exert cardioprotective effects 
in a variety of disease models.  These effects are primarily through the inhibition of 
myocardial apoptosis (Calvillo et al., 2003), the reduction in inflammation (Rui et al., 
2005), and the induction of angiogenesis (Carlini et al., 1995), to name but a few. 
Therefore, I sought to investigate the effects of EPO and, specifically, the role of 
the βcR in the cardiac dysfunction associated with endotoxaemia (caused by LPS) and 
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polymicrobial sepsis (caused by CLP). Specifically, I have investigated i) the effect EPO 
has on the impairment of systolic contractility (measured in vivo by echocardiography or 
ex vivo in the isolated Langendorff-perfused heart) associated with endotoxaemia and 
polymicrobial sepsis using WT C57BL/6 mice; ii) whether the effect of EPO is mediated 
through the proposed tissue protective receptor, with the use of βcR KO mice; iii) the 
mechanisms underlying the observed beneficial effects of EPO including the 
phosphorylation of Akt on Ser473, phosphorylation of GSK-3β on Ser9, phosphorylation 
of eNOS on Ser1177, activation of NF-κB (measured as nuclear translocation of p65) and 
expression of IL-1β. Because sepsis most frequently occurs in aging patients (Girard et 
al., 2005), I subsequently investigated the effects of EPO and the role of the βcR in aging 
animals with sepsis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: EPO attenuates sepsis-induced cardiac dysfunction 
3.2.  Methods 
The animal protocols followed in this study were approved by the local Animal 
Use and Care Committee in accordance with the derivatives of both the Home Office 
guidance on the Operation of Animals (Scientific Procedures Act 1986) published by Her 
Majesty’s Stationary Office and the Guide for the Care and Use of Laboratory Animals 
of the National Research Council. 
Animals and Quantification of Organ Dysfunction 
This study was performed on 113 wild-type (WT) male C57BL/6 mice (Harlan 
Laboratories, Wyton, UK) and 101 βcR KO male mice (B6.129S1-Csf2rbtm1Cgb/J) on 
a C57BL/6J genetic background (see below for further details) weighing  24.65 ± 1.29 g 
(2 months old) or  32.30 ± 1.34 g (8 months old), receiving a standard diet and water ad 
libitum.  
Animals were either administered vehicle (saline) or EPO (1000 IU kg-1). This 
dose of EPO was chosen as it was previously shown to confer tissue protection in a model 
of endotoxaemia (Aoshiba et al, 2009) which, I wanted to use as a starting point in this 
study.  Although this dose exceeds that given routinely (100 – 200 IU kg-1 week-1; 
Aoshiba et al., 2009) for patients with anaemia, as well as the circulating plasma 
concentrations of EPO (6-32 IU kg-1; Jelkmann, 2011) various studies have demonstrated 
that a larger dose is needed to protect against animal organ injury and dysfunction in 
endotoxaemia/sepsis (Abdelrahman et al., 2004; Kao et al., 2007; Mitra et al., 2007) 
Mice were anaesthetised with a ketamine (100 mg ml-1) and xylazine (20 mg ml-
1) mixture (2:1; 1.5 ml kg-1, i.p.) before sacrifice. At 16-18 h after the administration of 
LPS (9 mg kg-1 i.p.) or 24 h after CLP surgery, cardiac function was assessed by 
echocardiography and/or the isolated Langendorff-perfused heart. Additionally, heart 
samples were taken and stored at -80 0C for further analysis. 
 
βcR KO mice 
βcR KO mice colonies were kindly donated from M. Brines and A. Cerami 
(Kenneth S. Warren Institute, Kitchawan, New York) and these were bred and maintained 
at Queen Mary University of London, Biological Services Unit. These mice are grossly 
normal phenotypically and are fertile (Brines et al., 2004), exhibit a normal baseline 
haematopoiesis except for a low basal circulating eosinophil level (Scott et al., 1998). 
They have been shown to respond normally to infectious insult (Nishinakamura et al., 
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1996) however, ultimately develop a progressive pulmonary fibrosis with advancing age 
(Brines et al., 2004). Breeding was achieved with Trio’s (one male and two females) per 
individually ventilated cage which, were equipped with their nesting material, 
environmental toys and tunnel, to enable nest making for the mice. Litters were weaned 
and transferred into separate male/ female cages after approximately 21 days. Although 
at this age mice were genotyped to confirm identification, confirmation of βcR -/- was 
accomplished for randomly picked mice from different cages by PCR genotyping as 
mentioned below).  
 
Isolation of cDNA 
Approximately 0.2 cm of ear clip was taken from randomly selected βcR KO mice 
and placed into a 0.5 ml Eppendorf tube and stored at -20 0C until ready to digest. The 
ear clips were digested in a 50 μl (to 200 μg ml-1 final concentration) mixture of lysis 
buffer (100 mM Tris pH8, 500 mM KCL, 0.1 mg ml-1 Gelatin, 0.45 % NP-40, 0.45 % 
Tween 20) and protease K (500 μg ml-1). The mixture was first incubated at 55 0C in a 
water bath overnight and then spun briefly the next day. Following incubation at 94 0C 
for 10 min, the mixture was spun at 3, 000 rpm for 5 min in a bench centrifuge fitted with 
a plate carrier, in order to isolate the cDNA.  
 
PCR analysis 
A standard polymerase chain reaction was carried out. Primers (Beta 823, 
GTGTAGACACTGGCCCCCG; Beta 891, 
GAACCTTCAATGCTTCTTTGATGGGAT; Beta Neo F, 
ATATTGGTGAAGAGCTTGGCGGC) were initially reconstituted in dH2O to produce 
stock 100 μM solutions. These were further diluted in dH2O to achieve working 
concentrations of 10 μM. For each ear clip the following components were added to a 
sterile 0.5-ml microcentrifuge tube sitting on ice: 10 uL 10X PCR buffer (200 mM Tris-
HCl pH 8.4, 500 mM KCl) [final concentration was 1x], 2 uL10 mM dNTP mixture final 
concentration was  0.2 mM], 3 uL 50 mM MgCl2 [final concentration was1.5 mM], 5 μL 
each Primer (10 μM each) [final concentration was 0.5 μM], 2 μL Template DNA,  0.5 
μL Taq DNA Polymerase (5 U/μL, New England Biolabs, Hertfordshire, UK), 
Autoclaved distilled water to 100 μL. For multiple ear clips a master mix was prepared. 
The tube was loaded into a PCR thermocycler (G-storm, East Sussex, UK). The 
Chapter 3: Methods 
amplification reactions started at 94 °C for 5 min, cycled at 35 times at 94 °C for 30 sec, 
60 °C for 50 sec, 72 °C for 3 min, a 7 min hold at 72 °C followed by a 4 °C hold. 
 
 
Figure 3.2.3. βcR KO mice genotyping PCR product. The murine mutant βcR gene 
(648 bp) was amplified from ear clip samples of βcR KO mice using three primers for the 
βcR gene (Beta 823, Beta 891, Beta Neo F). Twenty microliters of the PCR product was 
visualised by electrophoresis on a 1 % agarose gel (containing ethidium bromide and 1 x 
Tris borate) alongside a 100 bp DNA ladder. 
Caecal Ligation and Puncture  
Methodology is as described in chapter 2. Based on previous evidence and 
preliminary data (Chapter 2) an 18-G needle was used with the double puncture technique 
in order to generate cardiac dysfunction during the early phase of sepsis (24 h) in aging 
mice.  
Experimental Design 
 Animals were allocated into the following studies, receiving the relevant 
treatment: 
Study 1 - Cardiac function was assessed in 2 months old mice randomized to undergo 
either i) sham operation and treated with either vehicle (Sham + Vehicle) or EPO (Sham 
+ EPO) or ii) subjected to endotoxaemia for 16-18 h and treated with either vehicle (LPS 
+ Vehicle) or EPO (LPS + EPO). 
Study 2 - Cardiac function was assessed in 8 months old mice randomised to undergo 
either i) sham operation and treated with either vehicle (Sham + Vehicle) or EPO (Sham 
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+ EPO) or ii) CLP for 24 h and treated with either vehicle (CLP + Vehicle) or EPO (CLP 
+ EPO). The detailed protocols of the 2 study groups are shown in Figure 3.2.1 
 
Figure 3.2.1 Schematics showing the experimental protocols for mice subjected to 
either (A) endotoxaemia or (B) CLP. 
(A) 
 
(B) 
 
 
Assessment of Cardiac Function in vivo (Echocardiography)  
Methodology is as described in chapter 2. Cardiac function was assessed 18 h after 
administration of LPS or 24 h after CLP surgery. Left ventricular end-diastolic volume 
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(LVEDV) and left ventricular internal dimension-diastole (LVIDD) were calculated from 
M-mode in the parasternal short axis view at the level of the papillary muscles.  
 
Assessment of Cardiac Function ex vivo (isolated Langendorff-perfused heart)  
Cardiac function was assessed in mice by the isolated Langendorff-perfused heart 
ex vivo as reported previously (Kapoor et al., 2010). At 16-18 h after the administration 
of LPS, mice were anaesthetised and heparinised (heparin sodium, 1000 IU/100g, i.p.). 
Following thoracotomy, the heart was excised and rapidly transferred to ice-cold Krebs-
Henseleit buffer (KHB), containing (in mmol/L) NaCl 118, KCl 3.8, MgSO4 1.19, 
NaHCO3 25, CaCl2 1.25, KH2PO4 1.18, sodium pyruvate 5, and glucose 10; equilibrated 
with 95 % O2/ 5 % CO2 (pH 7.4). Aortic cannulation was performed (within 1 min of 
excision), hearts were perfused immediately with filtered KHB, gassed continuously with 
95 % O2/ 5 % CO2 and maintained at 37 
oC. Hearts were retrogradely perfused in a non-
recirculating Langendorff mode at a constant flow. The flow was measured and could be 
adjusted using a flow meter to achieve a coronary perfusion pressure of 75 ± 5 mmHg. A 
small water-filled polyethylene balloon was carefully inserted into the left ventricle (LV) 
via a small incision in the left atrium made near the opening for the pulmonary vein. The 
hearts were electrically paced at ~590 beats per minute via a silver electrode inserted into 
the wall of the right atrium and then allowed to stabilise for at least 10 min before any 
experimental protocols were carried out. Alterations in isovolumic LV developed 
pressure (LVDP) in response to 5 μl incremental intraventricular loading of the balloon 
up to 40 μl were assessed. Pressure volume curves were generated to assess LVDP. 
Western Blot Analysis 
Heart samples were homogenized at 10 % (w v-1) in a Potter Elvehjem 
homogenizer (Wheaton, Millville, NJ, USA) using a homogenization buffer containing 
20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.9, 1 mM 
MgCl2, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 1 % NP-40, 1 mM ethylene 
glycol tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 0.5 mM phenylmethyl 
sulphonyl fluoride (PMSF),  5 µg ml-1 aprotinin, and 2.5 µg ml-1 leupeptin. Homogenates 
were centrifuged at 4, 000 RPM (1323 g) for 5 min at 4 0C, after which the supernatant 
was centrifuged at 14, 000 RPM (16250 g) for 40 min to obtain the cytosololic fraction.  
The pelleted nuclei was resuspended in extraction buffer containing 20mM HEPES, pH 
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7.9, 1.5 mM MgCl2, 0.2mM EDTA, 1mM EGTA, 20 % glycerol, 420 mM NaCl, 1mM 
DTT, 0.5 mM PMSF, 5 µg ml-1 aprotinin, and 2.5 µg ml-1 leupeptin. Pellet was incubated 
in ice for 30 min (with occasional vortexing) and was centrifuged at 14, 000 for 20 min 
at 4 0C. The resulting supernatants containing nuclear proteins were carefully removed, 
and protein content was determined on both nuclear and cytosolic extracts using a 
bicinchoninic acid (BCA) protein assay kit following the manufacturer’s directions 
(Thermo Fisher Scientific, Rockford, IL). Briefly, 30 μl of sample was added to 27 μl of 
dH2O and 570 μl of a mixture (1:50 of Cu2+; BCA reagent). The plate was read at 570 nm 
yielding a graph to enable protein contents of the sample to be determined.   
Fifty µg of cytosolic or nuclear protein was loaded. Proteins were separated by 8 
% sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to a 
polyvinyldenedifluoride membrane, which was then incubated with a solution of albumin 
5 % in PBS for 1 h. Membranes were incubated with primary antibody (rabbit anti-total 
GSK-3β, dilution 1:200; goat anti-pGSK-3β Ser9 dilution 1:200, rabbit anti-total Akt, 
dilution 1:1000, mouse anti-pAkt Ser473, dilution 1:1000, goat anti-peNOS Ser 1177, 
dilution 1:200, rabbit anti-eNOS, dilution 1:200, and rabbit anti-NF-κB, dilution 1:1000) 
over night at 4 0C. Blots were incubated with secondary antibody conjugated with 
horseradish peroxidase for 30 min in at room temperature and developed with the 
enhanced chemiluminescence detection system. The immunoreactive bands were 
visualized by autoradiography and the density of the bands was evaluated 
densitometrically using the Quantity One 1-D Analysis software (Bio-Rad Laboratories 
Ltd, Hertfordshire, UK). The membranes were stripped and incubated with β-actin 
monoclonal antibody for 30 min and subsequently with anti-mouse antibody for 30 min, 
at room temperature, in order to assess gel-loading homogeneity. Relative band intensity 
was assessed and normalized against parallel β-actin expression. In the sham group, the 
immunoreactive bands of the gel were respectively measured and normalised against the 
first immunoreactive band (standard sham sample) and the results of all the bands 
belonging to the same group were expressed as mean ± SEM. This provides SEM for the 
sham group where an average value of 1 is relative to the first immunoreactive band. Each 
group was then adjusted against corresponding sham-control data to establish relative 
protein expression when compared to sham-control animals. 
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 Figure 3.2.2. A representative standard protein curve for western blot analysis 
Quantitative Determination of Tissue IL-1β by ELISA 
The expression of IL-1β in mouse heart samples was determined using a mouse 
IL-1β/IL-1F2 immunoassay kit (R & D systems, Minneapolis, USA) which, is specific to 
recognise natural and recombinant IL1β with no significant cross-reactivity/interference 
between different species. This assay exhibits the sensitivity to detect a minimum 
detectable dose of mouse IL1β in the range from 0.46 – 4.80 pg/ml, with a mean of 2.31 
pg/ml. 
 Heart samples were homogenized at 10 % (w v-1) in a Potter Elvehjem 
homogenizer (Wheaton, Millville, NJ, USA) using a homogenization buffer containing 
20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.9, 1 mM 
MgCl2, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 1 % NP-40, 1 mM ethylene 
glycol tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 0.5 mM phenylmethyl 
sulphonyl fluoride (PMSF),  5 µg ml-1 aprotinin, and 2.5 µg ml-1 leupeptin. Homogenates 
were centrifuged at 4, 000 RPM (1323 g) for 5 min at 4 0C to remove cell debris after 
which aliquots of the cell lysate was removed in preparation for the ELISA analysis. 50 
µl of Assay Diluent RD1N was added to each well of the microplate. Once 50 µl of 
Standard, Control or Sample were added per well, the plate was covered with adhesive 
strip and left to incubate for 2 h at room temperature. Each well was washed with Wash 
Buffer (400 µl) and aspirated, a process that was repeated 4 times. Once 100 µl of mouse 
IL1β Conjugate was added to each well, the plate was covered with an adhesive strip and 
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left to incubate for 2 hrs at room temperature. The plate was aspirated/washed again as 
previously described, followed by the addition of 100 µl of Substrate Solution to each 
well. Subsequently the plate was incubated for 30 min at room temperature, away from 
light. Following the addition of 100 µl of Stop Solution was added to the plate and 
thoroughly mixed, the optical density of each well was determined using a microplate 
reader set at 570 nm. 
 
 
Figure 3.2.3. A representative standard curve for mouse IL-1β ELISA assay 
 
Materials 
All solutions were prepared using non-pyrogenic saline (0.9 % w v-1 NaCl; Baxter 
Healthcare Ltd., Thetford, Norfolk, UK). Escherichia coli LPS (serotype 0111:B4) was 
purchased from Sigma-Aldrich Company Ltd (Poole, Dorset, UK). Recombinant human 
EPO (epoetin beta) was manufactured by Roche Diagnostics (Sussex, UK). The BCA 
protein Assay kit, SuperBlock blocking buffer and ECL detection reagent were from 
Thermo Scientific UK Ltd (Loughborough, UK). Antibodies against rabbit anti-total 
GSK-3β, rabbit anti-total Akt, mouse anti-pAkt Ser473, rabbit anti-NF-κβ p65 were 
purchased from New England Biolabs (Ipswich, MA, US). 
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Statistical Analyses 
All values described in the text and figures are presented as mean ± SEM of n 
observations, where n represents the number of animals studied. Statistical analysis was 
performed using GraphPad Prism 5.0d (GraphPad Software, San Diego, California, 
USA). Data without repeated measurements were assessed by a one-way ANOVA 
followed by Bonferroni post-hoc test. Data with repeated measurements were assessed 
by a two-way ANOVA followed by a Bonferroni post-hoc test. A P-value of less than 
0.05 was considered to be significant. 
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3.3.  Results 
Effect of EPO on the cardiac dysfunction in endotoxaemic WT mice assessed by 
echocardiography and the isolated Langendorff-perfused heart 
To investigate the effect EPO has on the LPS-induced cardiac dysfunction, LV 
function was assessed using echocardiography in WT mice, 18 h after administration of 
vehicle or LPS. There were no differences in LV dimensions (LVIDD and LVEDV) 
between the WT groups (Table 3.3.1). Figure 3.3.1A shows representative M-mode 
echocardiograms of Sham + Vehicle, Sham + EPO, LPS + Vehicle, and LPS + EPO in 
WT mice. When compared to Sham + Vehicle mice, sham mice treated with EPO 
demonstrated no significant alterations in percentage ejection fraction, fractional 
shortening, and fractional area change (P > 0.05) (Figures 3.3.1B-D). When compared to 
sham mice, mice subjected to 18 h of endotoxaemia demonstrated a significant reduction 
in percentage ejection fraction, fractional shortening, and fractional area change (P < 
0.05) (Figures 3.3.1B-D), indicating impairment in systolic contractility in vivo. 
Administration of EPO significantly attenuated the impairment in systolic contractility 
associated with endotoxaemia (P < 0.05) (Figures 3.3.1B-D).   
To investigate whether the impairment in systolic contractility observed in vivo 
can be confirmed in an isolated Langendorff-perfused heart ex vivo (under conditions of 
constant cardiac preload or afterload), the alterations in isovolumic LVDP were assessed 
in WT mice 16-18 h after administration of vehicle or LPS. Pressure volume curves were 
generated to assess alterations in LVDP in response to 5 μl incremental intraventricular 
volume-balloon loading up to 40 μl. When compared to sham mice, WT mice subjected 
to LPS exhibited impairment in systolic contractility, measured as a significant reduction 
in LVDP in response to 30 μl (maximum response) volume loading (P < 0.05) (Figures 
3.3.1E-F). Administration of EPO to endotoxaemic WT mice significantly attenuated the 
impairment in systolic contractility at this volume load (P < 0.05) (Figures 3.3.1E-F, one-
way ANOVA followed by Bonferroni post-hoc test). 
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 Figure 3.3.1. Effect of EPO on the cardiac dysfunction in endotoxaemic WT mice. 
Representative M-mode echocardiograms (A), and percentage ejection fraction (B), fractional 
shortening (C) and fractional area of change (D) 18 h subsequent to sham-operation or LPS 
administration. Volume-pressure curves were generated from isolated Langendorff-perfused 
hearts to assess alterations in isovolumic left ventricular developed pressure in response to 5 µl 
incremental increases in balloon volume (E), and in response to 30 µl (maximum response) 
volume loading (F), 16-18 h subsequent to sham-operation or LPS administration. Mice received 
either LPS (9 mg kg-1 i.p.) or vehicle (5 ml kg-1 0.9% saline i.p.). At one hour after induction of 
endotoxaemia mice were treated either with Erythropoietin (EPO) (1000 IU kg-1 s.c.) or vehicle 
(10 ml kg-1 0.9% saline s.c.). (B-D): Sham + Vehicle (n = 10); Sham + EPO (n = 6); LPS + Vehicle 
(n = 15); LPS + EPO (n = 15). (E-F): Sham + Vehicle (n = 11); LPS + Vehicle (n = 11); LPS + 
EPO (n = 10). Data are expressed as means ± S.E.M. for n number of observations.  P < 0.05 
versus LPS + Vehicle;  P<0.05 Sham + Vehicle versus LPS + Vehicle; ≠ P < 0.05 LPS + Vehicle  
versus LPS + EPO, (Fig B-D + F, one-way ANOVA followed by Bonferroni post-hoc test; Fig 
E, two-way ANOVA followed by Bonferroni post-hoc test). (Figure taken from Master’s thesis 
2010) 
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Effect of EPO on cardiac dysfunction in endotoxaemic βcR KO mice assessed by 
echocardiography and the isolated Langendorff-perfused heart 
To investigate the role of the βcR subunit in the observed beneficial properties of 
EPO reported above, I evaluated the cardioprotective effects of EPO in βcR KO mice. 
There were no differences in LV dimensions between the KO groups with the exception 
of a significant increase in LVIDD between Sham + Vehicle and endotoxtaemic βcR KO 
mice, which was not altered with the administration of EPO (Table 3.3.1). Figure 3.3.2A 
shows representative M-mode echocardiograms of Sham + Vehicle, Sham + EPO, LPS + 
Vehicle, and LPS + EPO in βcR KO mice. When compared to Sham + Vehicle mice, 
sham mice treated with EPO demonstrated no significant alterations in ejection fraction, 
fractional shortening, and fractional area change (P > 0.05) (Figures 3.3.2B-D). When 
compared to sham βcR KO mice, endotoxaemia in βcR KO mice resulted in a significant 
reduction in percentage ejection fraction, fractional shortening, and fractional area change 
(P < 0.05) (Figures 3.3.2B-D), indicating impairment in systolic contractility. 
Administration of EPO to endotoxaemic βcR KO mice did not alter this impairment in 
systolic contractility (P > 0.05) (Figures 3.3.2B-D). 
I sought to confirm these effects in an isolated, perfused heart ex vivo (in the 
absence of any influences of cardiac pre- or afterload). When compared to sham mice, 
βcR KO mice subjected to LPS exhibited impairment in systolic contractility, measured 
as a significant reduction in LVDP in response to 30 μl (maximum response) volume 
loading (P < 0.05) (Figures 3.3.2E-F). Administration of EPO to endotoxaemic βcR KO 
mice caused no significant change in the impairment in systolic contractility associated 
with endotoxaemia (P > 0.05) (Figures 3.3.2E-F).  
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 Figure 3.3.2. Effect of EPO on the cardiac dysfunction in endotoxaemic βcR KO mice. 
Representative M-mode echocardiograms (A), and percentage ejection fraction (B), fractional 
shortening (C) and fractional area of change (D) 18 h subsequent to sham-operation or LPS 
administration. Volume pressure curves were generated from isolated Langendorff-perfused 
hearts to assess alterations in left ventricular developed pressure in response to 5 µl incremental 
increases in balloon volume (E), and in response to 30 µl (maximum response) volume loading 
(F), 16-18 h subsequent to sham-operation or LPS administration. Mice received either LPS (9 
mg/kg i.p.) or vehicle (5 ml kg-1 0.9% saline i.p.). At 1 hour after induction of endotoxaemia, mice 
were treated either with Erythropoietin (EPO) (1000 IU kg-1 s.c.) or vehicle (10 ml kg-1 0.9% 
saline s.c.). (B-D): Sham + Vehicle (n = 9); Sham + EPO (n = 3); LPS + Vehicle (n = 14); LPS + 
EPO (n = 25). (E-F): Sham + Vehicle (n = 11); LPS + Vehicle (n = 9); LPS + EPO (n = 9). Data 
are expressed as means ± S.E.M. for n number of observations. P < 0.05 versus LPS + Vehicle; 
 P < 0.05 Sham + Vehicle versus LPS + Vehicle (Fig B-D + F, one-way ANOVA followed by 
Bonferroni post-hoc test; Fig E, two-way ANOVA followed by Bonferroni post-hoc test). (Figure 
taken from Master’s thesis 2010) 
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Effect of EPO on the phosphorylation of Akt, GSK-3β and eNOS in the hearts of 
endotoxaemic WT and βcR KO mice  
In order to gain a better insight into the potential mechanism(s) underlying the 
observed cardioprotective effects of EPO, I investigated the effects of EPO on cell 
signalling pathways known to confer tissue protection or to inhibit inflammation, by 
semi-quantitative western blot analysis of the heart. When compared to sham mice, WT 
and βcR KO mice subjected to LPS demonstrated no change in the phosphorylation of 
Akt on Ser473  (P > 0.05; 60 kDa) (Figure 3.3.3A), GSK-3β on Ser9 (P > 0.05; 46 kDa) 
(Figure 3.3.3B), and eNOS on Ser1177 (P > 0.05; 140 kDa) (Figure 3.3.3C). Administration 
of EPO to endotoxaemic WT mice, however, resulted in a significant increase in the 
phosphorylation of Akt on Ser473 (P < 0.05) (Figure 3.3.3A), GSK-3β on Ser9 (P < 0.05) 
(Figure 3.3.3B), and eNOS on Ser1177 (P < 0.05) (Figure 3.3.3C). In contrast, 
administration of EPO to endotoxaemic βcR KO mice caused no change in the 
phosphorylation of Akt on Ser473 (P > 0.05) (Figure 3.3.3A), GSK-3β on Ser9 (P > 0.05) 
(Figure 3.3.3B), or eNOS on Ser1177 (P > 0.05) (Figure 3.3.3C). 
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Figure 3.3.3. Effect of EPO on signalling pathways in the hearts of WT and βcR KO 
mice with endotoxaemia. Mice received either LPS (9 mg kg-1 i.p.) or vehicle (5 ml kg-
1 0.9% saline i.p.). One hour after induction of endotoxaemia mice were treated either 
with Erythropoietin (EPO) (1000 IU kg-1 s.c.) or vehicle (10 ml kg-1 0.9% saline s.c.). 
Densitometric analysis (Quantity One 1-D Analysis Software) of the bands is expressed 
as relative optical density (O.D.) of (A) Akt phosphorylation at Ser473 (pSer473), corrected 
for the corresponding total Akt content and normalized using the related sham band, (B) 
GSK-3β phosphorylation at Ser9 (pSer9), corrected for the corresponding total GSK-3β 
content and normalized using the related sham band, (C) eNOS phosphorylation at Ser1177 
(pSer1177), corrected for the corresponding total eNOS content and normalized using the 
related sham band. Each immunoblot is from a single experiment and is representative of 
four separate experiments. Data are expressed as means ± S.E.M. for n number of 
observations. P < 0.05 versus LPS + Vehicle, one-way ANOVA followed by 
Bonferroni post-hoc test. Blots generated by M. Collino, University of Turin. 
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Effect of EPO on the nuclear translocation of the p65 NF-ĸB subunit in the hearts 
of endotoxaemic WT and βcR KO mice  
When compared to hearts from sham mice, the hearts of endotoxaemic WT and 
βcR KO mice exhibited significant increases in the nuclear translocation of the p65 
subunit (P < 0.05) (Figure 3.3.4), indicating activation of NF-ĸB (65 kDa). 
Administration of EPO to endotoxaemic WT mice significantly attenuated the increase in 
nuclear translocation of p65 and, hence, inhibition of activation of NF-ĸB in the heart (P 
< 0.05) (Figure 3.3.4). In contrast, administration of EPO to endotoxaemic βcR KO mice 
did not attenuate the nuclear translocation of p65 caused by LPS (P > 0.05) (Figure 3.3.4). 
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Figure 3.3.4. Effect of EPO on signalling pathways in the hearts of WT and βcR KO 
mice with endotoxaemia. Mice received either LPS (9 mg kg-1 i.p.) or vehicle (5 ml kg-
1 0.9% saline i.p.). One hour after induction of endotoxaemia mice were treated either 
with EPO (1000 IU kg-1 s.c.) or vehicle (10 ml kg-1 0.9% saline s.c.). Densitometric 
analysis (Quantity One 1-D Analysis Software) of the bands is expressed as relative 
optical density (O.D.) of NF-ĸB p65 subunit levels in both cytosolic and nuclear fractions 
and expressed as a nucleus/cytosol ratio. Each immunoblot is from a single experiment 
and is representative of four separate experiments. Data are expressed as means ± S.E.M. 
for n number of observations. P < 0.05 versus LPS + Vehicle, one-way ANOVA 
followed by Bonferroni post-hoc test. Blots generated by M. Collino, University of Turin. 
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Effect of EPO on the expression of IL-1β in the hearts of endotoxaemic WT and βcR 
KO mice  
IL-1β expressed by various cells namely mononuclear leukocytes is a pro-
inflammatory cytokine, known to many of the immunopathological features of the 
response during sepsis (Cannon et al., 1990). This role in sepsis has been well 
documented in numerous reports in experimental models (Hesse et al., 1988) and human 
studies (Hesse et al., 1988; Cannon et al., 1990). Circulating concentrations of IL-1β as 
well as other pro-inflammatory cytokines is not only associated to morbidity and 
mortality in patients with sepsis (Casey et al., 1993) but has also been linked to acting as 
a cardio depressant factor in sepsis (Hoffman et al., 1999; Cain et al., 1999; Fernandes Jr 
& Cesar de Assunca, 2012). 
When compared to hearts from sham mice, the hearts of endotoxaemic WT and 
βcR KO mice demonstrated a significant increase in IL-1β expression (P < 0.05) (Figure 
3.3.5). Administration of EPO to endotoxaemic WT mice significantly attenuated IL-1β 
expression (P < 0.05). In contrast, administration of EPO to endotoxaemic βcR KO mice 
caused no alteration in IL-1β expression (P > 0.05) (Figure 3.3.5). To note, it was 
surprising to find that the baseline IL-1β expression was significantly higher in the Sham 
Vehicle and LPS Vehicle groups of the βcR KO mice compared to their corresponding 
groups in the WT animals. 
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 Figure 3.3.5. Effect of EPO on IL-1β expression in the hearts of WT and βcR KO 
mice with endotoxaemia. Concentration of IL-1β was quantitatively measured in mouse 
heart tissues by using a mouse IL-1β/IL-1F2 Immunoassay kit. WT or βcR KO mice 
received either LPS (9 mg kg-1 i.p. n = 3) or vehicle (5 ml kg-1 0.9% saline i.p. n = 3). 
One hour after induction of endotoxaemia mice were treated either with Erythropoietin 
(EPO) (1000 IU kg-1 s.c. n = 3) or vehicle (10 ml kg-1 0.9% saline s.c.). Data are expressed 
as means ± S.E.M. for n number of observations.  P < 0.05 (one-way ANOVA followed 
by Bonferroni post-hoc test). ELISA experiment was performed by M.Collino, University 
of Turin, Italy.  
 
 
 
 
 
 
Chapter 3: Results 
Effect of EPO on cardiac dysfunction in WT and KO mice that underwent CLP  
The murine model of CLP with fluid resuscitation and antibiotics is regarded as a 
clinically relevant model of abdominal polymicrobial human sepsis. There were no 
differences in LV dimensions (Table 3.3.1) between the WT groups. Figure 3.3.6A shows 
representative M-mode echocardiograms of Sham + Vehicle, Sham + EPO, CLP + 
Vehicle, and CLP + EPO in WT mice. When compared to Sham + Vehicle mice, sham 
mice treated with EPO demonstrated no significant alterations in EF, FS, and FAC (P > 
0.05) (Figures 3.3.6B-D). When compared to sham mice, WT mice subjected to CLP 
demonstrated a significant reduction in percentage EF, FS, and FAC (P < 0.05) (Figures 
3.3.6B-D), indicating the development of impaired systolic contractility in vivo. 
Administration of EPO to WT mice significantly attenuated the impaired systolic 
contractility associated with CLP (P < 0.05) (Figures 3.3.6B-D).  
There were no differences in LV dimensions between the KO groups (Table 
3.3.1). Figure 3.3.7A shows representative M-mode echocardiograms of Sham + Vehicle, 
Sham + EPO, CLP + Vehicle, and CLP + EPO in βcR KO mice. When compared to Sham 
+ Vehicle mice, sham mice treated with EPO demonstrated no significant alterations in 
EF, FS, and FAC (P > 0.05) (Figure 3.3.7B-D). When compared to sham mice, βcR KO 
mice subjected to CLP demonstrated a significant reduction in percentage EF, FS, and 
FAC (P < 0.05) (Figures 3.3.7B-D), indicating the development of impaired systolic 
contractility in vivo. Treatment of βcR KO mice with EPO did not alter this cardiac 
dysfunction (P > 0.05) (Figures 3.3.7B-D). 
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Figure 3.3.6. Effect of EPO on the cardiac dysfunction in WT mice that underwent 
CLP. Representative M-mode echocardiograms (A), and percentage ejection fraction (B), 
fractional shortening (C) and fractional area of change (D), in wild-type mice 24 h 
subsequent to CLP surgery. One hour after induction of CLP, mice were treated either 
with EPO (1000 IU kg-1 s.c.) or vehicle (10 ml kg-1 0.9% saline s.c.). B-D: Sham + Vehicle 
(n = 3); Sham + EPO (n = 3); CLP + Vehicle (n = 9); CLP + EPO (n = 10).  P < 0.05 
versus CLP + Vehicle. 
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Figure 3.3.7. Effect of EPO on the cardiac dysfunction in βcR KO mice that 
underwent CLP. Representative M-mode echocardiograms (A), and percentage ejection 
fraction (B), fractional shortening (C) and fractional area of change (D), 24 h subsequent 
to CLP surgery. One hour after induction of CLP mice were treated either with EPO (1000 
IU kg-1 s.c.) or vehicle (10 ml kg-1 0.9% saline s.c.). B-D: Sham + Vehicle (n = 5); Sham 
+ EPO (n = 2); CLP + Vehicle (n = 7); CLP + EPO (n = 7).  P < 0.05 versus CLP + 
Vehicle. 
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Table 3.3.1: Effect of EPO on echocardiographic parameters (diastolic function) in 
WT or βcR KO mice subjected to endotoxaemia for 16-18 h or CLP for 24 h   
Treatment Group Genotype LVIDD 
(mm) 
LVEDV 
(µl) 
n 
Endotoxaemia in 2 
months old mice 
Sham + Vehicle WT 3.4 ± 0.06 47 ± 2.13 10 
Sham + EPO WT 3.1 ± 0.14 39 ± 4.34 6 
 LPS + Vehicle WT 3.6 ± 0.07 54 ± 2.60 15 
 LPS + EPO WT 3.6 ± 0.08 53 ± 2.61 15 
 Sham + Vehicle KO 3.1 ± 0.09 39 ± 2.91 9 
 Sham + EPO KO 3.5 ± 0.15 52 ± 5.36 3 
 LPS + Vehicle KO 3.5 ± 0.08 53 ± 2.96 14 
 LPS + EPO KO 3.5 ± 0.07 53 ± 2.65 25 
Polymicrobial 
Sepsis in aged mice 
Sham + Vehicle WT 3.5 ± 0.30 51 ± 9.44 3 
Sham + EPO WT 3.5 ± 0.12 51 ± 3.98 3 
 CLP + Vehicle WT 3.9 ± 0.09 68 ± 3.55 9 
 CLP + EPO WT 3.8 ± 0.13 62 ± 5.03 10 
 Sham + Vehicle KO 4.2 ± 0.11 80 ± 4.83 5 
 Sham + EPO KO 3.5 ± 0.00 52 ± 0.76 2 
 CLP + Vehicle KO 3.8 ± 0.12 64 ± 4.24 7 
 CLP + EPO KO 4.1 ± 0.14 74 ± 6.05 7 
 
WT or βcR KO mice received either LPS (9 mg kg-1 i.p.) or vehicle (5 ml kg-1 0.9% saline 
i.p.) or underwent CLP surgery. One hour after induction of endotoxaemia or CLP 
surgery, mice were treated either with Erythropoietin (EPO) (1000 IU kg-1 s.c.) or vehicle 
(10 ml kg-1 0.9% saline s.c.). All echocardiographic images were assessed for changes in 
left ventricular internal dimension-diastole (LVIDD) and left ventricular end-diastolic 
volume (LVEDV).  P < 0.05 versus LPS + Vehicle (KO). 
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3.4.  DISCUSSION 
Sepsis-associated myocardial dysfunction occurs in almost 40 % – 50 % of 
patients and is a major contributor to morbidity and mortality. There continues to be an 
unmet clinical need for the discovery of specific therapeutic interventions for this 
condition. I report here, for the first time, that EPO attenuates the impaired systolic 
contractility caused by endotoxaemia in young mice or polymicrobial sepsis in aged mice, 
an effect not seen in mice where the βcR is knocked out.  The finding that the beneficial 
effects of EPO were of a similar magnitude when cardiac dysfunction was measured 
either in vivo or ex vivo (in an isolated heart) also indicate that the effects of EPO relate 
to a specific improvement in cardiac contractility, independent of changes in preload or 
afterload. Most notably, whether determined in vivo or ex vivo, the observed beneficial 
effect of EPO was lost in βcR KO mice. 
Having discovered that the βcR is essential for the cardioprotective effects of EPO 
in sepsis, I subsequently investigated the molecular pathways that are activated by EPO 
in a βcR-dependent fashion. In summary, EPO activated Akt and eNOS and inhibited 
GSK-3β (an effect secondary to activation of Akt), NF-ĸB and expression of IL-1β 
(Figure 3.3.8). Most notably, all of these beneficial effects of EPO were lost in βcR KO 
mice. 
Akt is a member of the PI3K signal transduction enzyme family, which regulates 
cellular activation, inflammatory responses, chemotaxis, and apoptosis (Cantley, 2002). 
When phosphorylated by its upstream regulator, phosphoinositide-dependent kinase, Akt 
modulates cell survival and growth (Cantley, 2002). In this study, EPO caused a 
significant increase in phosphorylation of Akt on Ser473 (resulting in activation of this 
kinase), an effect, which was lost in βcR KO mice. The hypothesis that activation of Akt 
importantly contributes to the improvement in cardiac contractility afforded by EPO is 
supported by the following findings: i) transgenic mice with cardiac-specific 
overexpression of Akt exhibit a significant increase in cardiac contractility compared with 
WT mice (Condorelli et al., 2002); ii) protection by EPO against doxorubicin-induced 
cardiotoxicity was mediated by PI3K activation (Kim et al., 2008); iii) the reduction of 
infarct size afforded by EPO in a murine model of myocardial infarction were associated 
with activation of Akt (Calvillo et al., 2003); and iii) both the activation of Akt and the 
cardioprotective effects of EPO were lost when animals were pre-treated with an inhibitor 
of the PI3K/Akt pathway (Cai & Semenza, 2004). Interestingly, Recknagel and 
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colleagues demonstrated that PI3K signalling also plays a crucial role in the development 
of liver dysfunction in septic rats (Recknagel et al., 2012). I report here that the increase 
in Ser473 phosphorylation on Akt afforded by EPO was lost in βcR KO mice. Similarly, a 
neutralizing antibody to the βcR subunit in endothelial cells also abolished the 
phosphorylation of Akt caused by EPO in these cells (Su et al., 2011). It is likely that Akt 
is a key molecule for prevention of apoptosis in the heart and that activation by EPO 
elicits its cytoprotective effects through an Akt-dependent pathway, in part by 
antagonizing the effects of TNF-α (Ueba et al., 2010). Taken together, all of the above 
results support the view that activation of Akt, secondary to activation of the βcR subunit, 
by EPO importantly contributes to the improvement in cardiac function afforded by EPO 
in sepsis. 
Activation of Akt is associated with a pronounced increase in the phosphorylation 
of GSK-3β at Ser9. GSK-3β is a serine-threonine kinase that was originally recognized as 
a kinase that phosphorylates glycogen synthase. In contrast to most other kinases, GSK-
3β is active in a resting cell state; however it is inactivated by phosphorylation of Ser9. 
Activation of Akt inactivates GSK-3β by causing Ser9 phosphorylation (Cross et al., 
1995). I report here that EPO caused a significant increase in phosphorylation of GSK-
3β on Ser9 (resulting in inhibition of this kinase), an effect, which was lost in βcR KO 
mice. The hypothesis that inhibition of GSK-3β could contribute to the improvement in 
cardiac contractility afforded by EPO is supported by the following findings: i) inhibition 
of GSK-3β attenuates the multiple organ dysfunction caused by co-administration of LPS 
and peptidoglycan in the rat (Dugo et al., 2005) and improves survival in murine 
endotoxaemia (Martin et al., 2005); ii) the cardioprotective effects of EPO are secondary 
to inhibition of GSK-3β as measured by Ser9 phosphorylation (Nishihara et al., 2006); iii) 
prevention by EPO of vascular integrity in animals with diabetes is dependent on 
activation of Akt and inhibition of GSK-3β (Chong et al., 2011); and iii) prevention of 
the inhibition of GSK-3β in the heart of diabetic mice results in the loss of the 
cardioprotective effects of EPO (Ghaboura et al., 2011). Taken together, all of the above 
results support the view that inhibition of GSK-3β resulting from activation activation of 
the βcR by EPO could contribute to the improvement in systolic contractility afforded by 
EPO in sepsis. 
In addition to inhibiting the activation of GSK-3β, activation of Akt is known to 
phosphorylate eNOS at Serine1177 in endothelial cells (Dimmeler et al., 1999; Fulton et 
al., 1999) and cardiomyocytes (Burger et al., 2006). There is evidence that EPO induces 
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NO production through eNOS phosphorylation (Su et al., 2011; Souza et al., 2012a; Kao 
et al., 2011) and its cardioprotective effects appear, in part, to be mediated by the up-
regulation of eNOS,  in vitro (Burger et al., 2006; Rui et al., 2005), and in vivo (Rui et 
al., 2005). Inhibition of the βcR subunit also abolishes the EPO-induced increase and 
phosphorylation of eNOS, Akt, Src or JAK 2 in endothelial cells (Su et al., 2011). Indeed, 
Sautina and colleagues demonstrated the requirement of the βcR subunit in the EPO 
induction of NO (Sautina et al., 2010). This supports the view that the βcR subunit plays 
a key role in the activation of eNOS by EPO in endothelial cells. I report here that the 
increase in Ser1177 phosphorylation of eNOS by EPO in the heart is lost in βcR KO mice. 
In conditions associated with sepsis, activation of eNOS is beneficial as enhanced 
formation of NO cause’s local vasodilation, inhibition of platelets and neutrophils, and 
regulates angiogenesis (Tyml, 2011; Khan et al., 2010). Thus, it can be said that the 
activation of eNOS may contribute to the beneficial effects of EPO reported here. 
Downstream of GSK-3β, several studies have now reported an association 
between GSK-3β and NF-ĸB activity in vitro (Hoeflich et al., 2000; Schwabe & Brenner, 
2002), and in vivo (Dugo et al., 2005; Dugo et al., 2006). NF-ĸB is a transcriptional factor 
that plays an important role in regulating the transcription of a number of genes, especially 
those involved in producing mediators involved in local and systemic inflammation, such 
as cytokines, chemokines, cell adhesion molecules, apoptotic factors, and other mediators 
(Senftleben & Karin, 2002). Treatment of TNF-α-stimulated hepatocytes with a specific 
GSK-3β inhibitor resulted in a decrease of the NF-ĸB-dependent gene transcription 
(Schwabe & Brenner, 2002). This study also indicated four potential phosphorylation 
sites for GSK-3β on the NF-ĸB subunit, p65. Most notably, pre-treatment with a number 
of chemically distinct inhibitors of GSK-3β attenuates organ injury and dysfunction 
caused by endotoxaemia (Dugo et al., 2005; Martin et al., 2005). This protective effect 
was associated with inhibition of the activation of NF-ĸB and NF-ĸB-dependent pro-
inflammatory genes (e,g, IL-1β and TNF- α) , along with a reduced phosphorylation of 
Ser536 on the NF-ĸB p65 subunit. In addition, GSK-3β may also inhibit the activation of 
NF-ĸB by phosphorylating and degrading IĸBα, which is required to prevent NF-ĸB 
translocation (Takada et al., 2004). In this study, EPO attenuated the activation of NF-ĸB 
caused by endotoxaemia in the heart, an effect, which was lost in βcR KO mice. NF-ĸB 
is involved in the regulation of IL-1β transcription (Cogswell et al., 1994).  EPO 
attenuates neuroimmune activation in neuropathic pain by inhibiting the production of 
TNF-α, IL-1β, and IL-6 (Jia et al., 2009). I report here that mice subjected to LPS show 
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an increase in IL-1β production, which is significantly attenuated following the 
administration of EPO. This effect was lost in endotoxaemic βcR KO mice. 
 
Clinical relevance 
Myocardial function is depressed in sepsis and has a significant impact on 
patients’ outcome (Rudiger et al., 2013).  Using a long-term rat model of faecal 
peritonitis, Rudiger and colleagues demonstrated most recently that significant 
differences in stroke volume and heart rate assessed 6 h after insult could predict a 3-day 
mortality with positive and negative predictive values of 93 % and 80 % respectively. 
Based on these findings the authors suggest a crucial role for early cardiovascular 
performance as a prognosticator with clear therapeutic implications (Rudiger et al., 2013). 
It could be argued that the clinical relevance of the EPO-related improvement in systolic 
contractility is limited.  It is well established that survivors of septic shock present with a 
reversible ventricular dilatation, which is referred to as an adaptation to impaired systolic 
contraction (Parker et al., 1984; Parrillo et al., 1990). These authors showed that the initial 
ejection fraction determined by radionuclide cineangiography was significantly lower in 
the survivors. Improved outcome of “dilators” vs. “non-dilators” was also shown in 
resuscitated murine CLP-induced septic shock (Zanotti Cavazzoni et al., 2010). However, 
other authors demonstrated that mortality was higher (47 % vs. 16 %) in patients with a 
subnormal fractional area contraction upon initial echocardiography (Charpentier et al., 
2004). Moreover, Kumar and colleagues did not find a significant difference in baseline 
LVEF as determined by radionuclide cineangiography, but a lacking increase of LVEF 
during dobutamine infusion allowed distinguishing between survivors and non-survivors 
(Kumar et al., 2008). Finally, it is noteworthy that in the present experiment, any EPO-
induced increase in EF coincided with unchanged end-diastolic diameter and volume. 
Hence, diastolic relaxation was not affected by the treatment. This observation is in 
contrast to a previous study in murine CLP-induced septic shock (Barth et al., 2006); 
genetic deletion and pharmacological blockade of iNOS increased systolic contractility 
and improved myocardial catecholamine responsiveness at the expense of impaired 
diastolic relaxation, i.e. “stiffening of the ventricle”. 
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Limitation 
In retrospect, a limitation of this study is the utilization of two different models in 
two different age groups; a model of endotoxaemia in young mice and a model of 
polymicrobial sepsis in aged mice. The main focus of the study was to be able to 
reproduce the findings of EPO in the endotoxaemic model, in a more clinically relevant 
model of polymicrobial sepsis. Although, I have not investigated the effect of age on the 
cardiac dysfunction caused by LPS, there is very good evidence from a multitude of 
studies documenting that the mortality caused by endotoxins in rodents increases 
significantly with age (Chang et al., 1996; Chorinchath et al., 1996; Tateda et al., 1996). 
It should be noted, however, that an investigation into the effects of age on the 
pathophysiology of sepsis was not the main focus of this study, but rather a by-product 
of the development of a reproducible model of CLP-induced cardiac dysfunction. In 
addition, although I clearly demonstrate here by western blot analysis that EPO exerts its 
cardioprotective effects in both models of endotoxaemia and polymicrobial sepsis 
through activation of survival pathways, one could argue that it is not certain that these 
effects are associated with the pathophysiology of the cardiac dysfunction in these 
models. Therefore, confirmation of the involvement of these pathways in the protective 
effects of EPO could be confirmed by the use of pharmacological inhibitors specific to 
components of these pathways (PI3K, LY294002; GSK-3β, SB216763; eNOS, N (5)-(1-
Iminoethyl)-L-ornithine HCL), to see if there is a reversal of EPO effects. Furthermore, 
due to time and financial constraints it was not possible to generate western blot for Sham-
EPO animals which are important as it would not only confirm that the effects of EPO 
(activation of survival pathways) are solely related to the model but also since the dose 
used here is much more than that generally administered to anaemic patients, its best to 
be sure that there are no toxic effects by EPO. 
Conclusion  
My results show for the first time that the administration of EPO reduces the 
impaired systolic contractility associated with sepsis. In endotoxaemia the observed 
beneficial effects of EPO are associated with i) activation of Akt, ii) inhibition of GSK-
3β, iii) activation of eNOS, iv) inhibition of NF-ĸB, and v) inhibition of the expression 
of IL-1β, in a model of endotoxaemia (Figure 3.3.8). Most notably, attenuation of the 
impairment of systolic contractility as well as all of the above signalling events afforded 
by EPO were dependent on the presence of a functional βcR.  
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 Figure 3.3.8. Schematic overview demonstrating the intracellular signalling 
pathways implicated in EPO’s cardioprotective effects in endotoxaemic WT mice. 
Binding of EPO to the proposed model of the tissue-protective receptor (EpoR-βcR) is 
associated with i) activation of PI3K-Akt signalling pathway, which results in the 
inhibition of the activation of glycogen synthase kinase-3β, which subsequently 
suppresses NF-ĸB activity resulting in a blunted expression of the NF-ĸB-driven gene 
transcription of pro-inflammatory mediators such as interleukin-1β, and ii) activation of 
the PI3K-Akt signalling pathway results in the increased activation of eNOS and thus the 
enhanced formation of NO. 
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The Anti-malarial Drug Artesunate Attenuates 
Cardiac Injury in a Rodent Model of Myocardial 
Infarction 
  
 
 
4.1.  Introduction 
Artesunate (ARS) is a semi-synthetic derivative of artemisinin, a 
sesquiterpenetrioxane lactone, isolated from the plant Artemesia annua (Meshnick et al., 
1996). In the past decade, artemisinin and its derivatives have emerged as the most 
effective drugs for the treatment of severe malaria (Haynes et al., 2001; Rosenthal, 2008). 
ARS, the only artemisinin analogue that can be administered intravenously, results in 
rapid parasite and fever clearance in falciparum malaria (Batty et al., 1998). ARS has a 
very short half-life of approximately 10 min and is rapidly metabolised to 
dihydroartemisinin (DHA), which has a half-life of approximately 1 h and regarded as 
the active metabolite of ARS (Krishna et al., 2004). 
Today we know that ARS has a multitude of pharmacological effects that include 
anti-angiogenic effects (Wartenberg et al., 2003; Huan-huan et al., 2004), anti-viral 
effects (Efferth et al., 2008), as well as induction of cell apoptosis (Huan-huan et al., 
2004) and oxidative stress (Efferth et al., 2008; Ho et al., 2012). Furthermore, there is 
increasing evidence to support the notion that artemisinin and its derivatives also possess 
anti-inflammatory effects (Aldieri et al., 2003; Li et al., 2006; Xu et al., 2007; Li et al., 
2008; Cheng et al., 2011; Souza et al., 2012b; Yang et al., 2012). Indeed, ARS has been 
reported to i) reduce the production of cytokines from TNF-α-stimulated human 
rheumatoid arthritis fibroblast-like synoviocytes (Xu et al., 2007), ii) inhibit 
lipopolysaccharide-induced production of TNF-α, IL-6, and to reduce the expression of 
TLR-4, and TLR-9 in macrophages (Li et al., 2008). 
The exact mechanism of action that mediates these anti-inflammatory effects by 
ARS is not completely understood. However, it could correlate with several other 
sesquiterpene lactones which, are known to inhibit the activation of NF-κB by either 
alkylating it (Garcia-Pineres et al., 2001) or preventing the degradation of its inhibitory 
protein IκB (Wong & Menendez., 1999; Kim et al., 2001). Indeed, various investigators 
have shown ARS (Li et al., 2008) and other artemisinin derivatives (Li et al., 2006) to 
exert anti-inflammatory effects via inhibition of the nuclear translocation of NF-κB. 
Additionally, ARS has been reported to possess inhibitory activity against the PI3K/Akt 
signalling pathway (Xu et al., 2007; Cheng et al., 2011).  
As the PI3K/Akt signalling pathway plays a critical role in the pathogenesis of 
myocardial injury by which, its activation confers protection against I/R injury, I 
investigated the effect of ARS in a model of transient I/R in the rat and explored the 
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mechanism of action of ARS. The rational to use rats instead of mice is due to the 
existence of an already available model of rat myocardial I/R, since setting up a mouse 
model of myocardial I/R is more tricky and time consuming, a luxury I did not have. 
Specifically, I have investigated (i) the effect of ARS on the infarct size 2 h post 
reperfusion; (ii) the mechanisms underlying the observed  effects of ARS including the 
involvement of the RISK pathway; activation of PI3K signalling pathway (the subsequent 
phosphorylation Akt on Ser473) and ERK 1/2 signalling pathway, and the SAFE pathway 
(phosphorylation of STAT3 on Tyr705). In addition, the involvement of downstream 
targets of the above pro-survival pathways were investigated; phosphorylation of GSK-
3β on Ser9, phosphorylation of endothelial NO synthase (eNOS) on Ser1177 and activation 
of nuclear factor NF-κB (measured as nuclear translocation of p65). 
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4.2.  Methods 
This study was carried out on 169 male Wistar rats (Charles River, UK) weighing 
240-340 g receiving a standard diet and water ad libitum. The investigation was 
performed in accordance with the Home Office Guidance on the Operation of the Animals 
(Scientific Procedures) Act 1986, published by HMSO, London. 
 
Surgical Instrumentation and Haemodynamic Measurements  
Rats were anaesthetised with thiopentone sodium (Intraval 120 mg kg-1 i.p.) and 
anaesthesia was maintained by supplementary doses of thiopentone sodium as required. 
The trachea was cannulated and the animals were allowed to artificially respire using a 
Harvard ventilator (inspiratory oxygen concentration: 30 %; 70 strokes/min tidal volume: 
8-10 ml kg-1). It has been reported that a change of 1 0C in temperature affects the infarct 
size (Chien et al., 1994). Thus, body temperature was maintained at 37 ± 1 0C with the 
aid of a rectal probe thermometer attached to a homeothermic blanket unit (Harvard 
Apparatus Ltd., Edenbridge, Kent. U.K.).  
The right carotid artery was cannulated with a polyethylene catheter and 
connected to a pressure transducer (Senso-Nor 844, Senso-Nor, Horten, Norway), to 
monitor mean arterial pressure (MAP) and heart rate (HR), which were displayed on a 
data acquisition system (MacLab 8e, ADI Instruments, Hastings, U.K.), installed on an 
IBM compatible computer. Pressure rate index (PRI), a relative indicator of myocardial 
oxygen consumption (Baller et al., 1981), was calculated as a product of MAP and HR, 
and expressed in mmHg min-1 103. Subsequently, the right jugular vein was cannulated 
for the administration of drugs and saline.  
Myocardial Ischaemia and Reperfusion 
Following anaesthesia and instrumentation of the rat as described above, a 
parasternal thoracotomy was performed, using an electrosurgery device to cauterise the 
intercostal arteries before cutting through three ribs. The chest was retracted and the 
pericardium dissected from the heart. The left anterior descending (LAD) coronary artery 
was isolated, and a snare occluder was placed around the LAD.  
Subsequently, upon completion of the surgical procedure, the retractor was 
removed, and animals were allowed to stabilize for 15 min, after which, the occluder was 
tightened, at time 0. After 25 min of LAD-occlusion, the occluder was released to allow 
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reperfusion of the previously ischaemic myocardium for 2 h. Hemodynamic parameters 
were continuously monitored. Baseline readings were taken prior to treatment, and, 
myocardial I/R injury. Saline was administered immediately after reperfusion and 
throughout reperfusion at a rate of 2 ml kg-1 h-1. 
 
Quantification of myocardial tissue injury 
At the end of the 2 h reperfusion period, the LAD was re-occluded and 1 ml of 
Evans Blue dye (2 % w v-1) was administered via the jugular vein. The dose of Evans 
Blue dye used in this study is within the range shown to exclusively bind to plasma 
proteins (Lindner & Heinle, 1982). This dye stains perfusable tissue, therefore the non-
perfused (occluded) vascular tissue remains un-coloured. Each animal was killed with an 
overdose of anaesthetic, the heart excised, and excess dye washed off. The heart was then 
sectioned into 3 slices of 3-4 mm, the right ventricular wall was removed, and the area at 
risk (AAR) – essentially the non-perfused and, hence, non-stained myocardium was 
separated from the non-ischemic (blue) tissue. The ischaemic and non-ischaemic tissue 
was weighed, and the AAR expressed as a percentage of the left ventricle. The tissue from 
the AAR was cut into small pieces and incubated with p-nitroblue tetrazolium (NBT, 0.5 
mg ml-1) for 30 min at 37 0C. NBT is a reducing agent that reacts with formazon. In the 
presence of intact dehydrogenase enzyme enzymes, found in normally perfused 
myocardium tissue, NBT forms a dark blue formazon, whilst infarcted tissue (non-
viable), lacking dehydrogenase activity will fail to stain (Nachlas & Shnitka, 1963). The 
stained tissue was separated from the infarcted tissue, weighed, and the infarct size 
expressed as a percentage of the AAR. 
 
Experimental Design 
 Initially, the aim was to establish the optimal dose of and vehicle for ARS to be 
used for this study. As there was no data regarding the use of ARS in an in vivo model of 
myocardial I/R three vehicles were used to determine which is best to completely dissolve 
the ARS and not have adverse effects in this model. Additionally, differential doses of 
ARS was used to determine which dose would result in the maximum reduction in infarct 
size.  
Animals were randomized into 23 Groups and were either subjected to i) surgical 
procedure alone with no LAD occlusion and reperfusion and treated with vehicle  
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 (dimethylsulphoxide [DMSO] 10 % v v-1) (sham vehicle), or ii) surgical procedure with 
LAD occlusion and reperfusion and treated with either vehicle [DMSO, sodium 
bicarbonate (NaHCO3), or cyclodextrine (CD 30 % v v
-1)] (‘control’ animals) or ARS 
(‘treated’ animals) at the start of reperfusion, with/without pre-treatment with LY294002 
(LY) or U0126 10 mins before occlusion of the LAD. For experiments that served as 
positive controls, an additional group of animals were subjected to surgical procedure 
followed by either 2 cycles of ischaemic preconditioning (IPC – 1 cycle: 5 min ischaemia 
and 5 min reperfusion) or pre-treated 10 mins before initiation of IPC with LY or U0126, 
followed by LAD occlusion and reperfusion and treated with vehicle. The involvement 
of the PI3K/Akt pathway (Xu et al., 2007) and ERK (Lee, et al., 2012) in the action of 
ART have been established. Therefore, in order to determine whether these pathways are 
involved in this model of myocardial I/R LY and UO126, highly selective inhibitors of 
PI3K and ERK, respectively were used. The surgical protocols and experimental groups 
of the 23 study groups are shown in Figure 4.2.1 and Table 4.2.1 respectively. 
 
Figure 4.2.1. Surgical protocols of animals subjected to LAD occlusion and 
reperfusion 
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Table 4.2.1. Experimental groups of animals subjected to LAD occlusion and 
reperfusion 
Group n Ischaemia 
(min) 
Reperfusion 
(h) 
Sham vehicle (1 ml kg-1; 10 % DMSO) 6 N/A N/A 
MI Vehicle (1 ml kg-1; 10 % DMSO) 14 25 2 
MI Vehicle (1 ml kg-1; 30 % Cyclodextrin) 7 25 2 
MI Vehicle (1 ml kg-1; NaHCO3) 5 25 2 
MI + ARS (0.1 mg kg-1; 10 % DMSO) 3 25 2 
MI + ARS (0.3 mg kg-1; 10 % DMSO) 7 25 2 
MI + ARS (1 mg kg-1; 10 % DMSO) 7 25 2 
MI + ARS (0.3 mg kg-1; 30 % Cyclodextrin) 7 25 2 
MI + ARS (1 mg kg-1; 30 % Cyclodextrin) 7 25 2 
MI + ARS (0.1 mg kg-1; NaHCO3) 4 25 2 
MI + ARS (0.3 mg kg-1; NaHCO3) 5 25 2 
MI + ARS (1 mg kg-1; NaHCO3) 12 25 2 
MI + LY (0.3 mg kg-1)+ ARS (1 mg kg-1; NaHCO3) 10 25 2 
MI + U0126 (0.2 mg kg-1) + ARS (1 mg kg-1; 
NaHCO3) 
11 25 2 
MI + IPC 12 25 2 
MI + LY (0.3 mg kg-1) + IPC 7 25 2 
MI + U0126 (0.2 mg kg-1)+ IPC 5 25 2 
MI + DHA (mg kg-1; 10 % DMSO) 6 25 2 
Sham Vehicle (1 ml kg-1)(Western blot samples) 7 
 
N/A 
 
N/A 
MI Vehicle (1 ml kg-1) (Western blot samples) 9 25 2 
MI + ARS (1 mg kg-1) (Western blot samples) 10 25 2 
Sham Vehicle + ARS (1 mg kg-1; NaHCO3) 
(Samples for pharmacokinetic) 
4 N/A N/A 
MI Vehicle + ARS (1 mg kg-1; NaHCO3) 
(Samples for pharmacokinetic) 
4 25 2 
 
ARS = Artesunate; DHA = Dihydroartesunate; I = Ischaemia; IPC = Ischaemic 
preconditioning; R = Reperfusion; 
LY = LY294002; N/A = Not applicable; 
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Western Blot Analysis  
 Western blot analysis was carried out as previously described in chapter 3, with 
only slight modifications. A total of sixty µg of total protein was loaded. In addition to 
the already mentioned antibodies in chapter 3, membranes were also incubated with 
primary rabbit anti-total STAT3, dilution 1:1000, anti-pSTAT3 Tyr705, dilution 1:1000. 
 
 
Figure 4.2.2. A representative standard protein curve for western blot analysis  
 
Materials 
Unless otherwise stated, all compounds used in this study were obtained from 
Sigma-Aldrich Company Ltd. (Poole, Dorset, UK). Thiopentone sodium (Intraval 
Sodium®) was obtained from Rhône Mérieux Ltd. (Harlow, Essex, UK). Unless otherwise 
stated, all stock solutions were prepared in non-pyrogenic saline (0.9 % NaCl; Baxter 
Healthcare Ltd., Thetford, Norfolk, UK). ARS was obtained from Guilin Pharmaceutical 
Co. (Guilin, Guangxi, China). LY and U0126 were obtained from Tocris Bioscience 
(Bristol, UK). Antibodies against pAkt (Ser473) and total Akt were from Cell Signalling 
Technology (Beverly, MA, USA) and against pSTAT3 (Tyr705) and total STAT3 were 
purchased from New England Biolabs Ltd (Hitchen, Hertfordshire, UK). Antibodies 
against pGSK-3β (Ser9), total GSK-3β, eNOS, anti-goat, anti-mouse and anti-rabbit Ig 
horseradish peroxidase-linked whole antibodies were purchased from Santa Cruz 
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Biotechnology (Santa Cruz, California, USA). Luminol ECL detection reagents were 
from Amersham (Buckinghamshire, UK). 
 
Statistical Analysis 
 All data are presented as mean ± SEM of n observations, where n represents the 
number of animals or samples studied. Haemodynamic parameters were analysed via a 
two-way analysis of variance (ANOVA) with repeated measures, followed by a 
Bonferroni post-test. Data without repeated measurements were analysed by one-way 
ANOVA, followed by a Bonferroni post hoc test for multiple comparisons. P < 0.05 was 
considered statistically significant. 
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4.3.  Results 
Alterations in haemodynamic parameters in animals subjected to LAD occlusion 
and reperfusion  
The mean baseline values of MAP in all groups of animals ranged from 101 ± 
7.14 to 130 ± 4.06 mmHg, and were not significantly different between groups (P > 0.05, 
Table 4.3.1). When compared to Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle in either 10 % DMSO or 30 % Cyclodextrin exhibited 
a progressive decline in MAP [MI Vehicle (DMSO), 106 ± 4.07 to 90 ± 4.63; MI Vehicle 
(Cyclodextrin), 119 ± 4.90 to 99 ± 5.26 (P > 0.05, Table 4.3.1). Animals undergoing 2 
cycles of IPC before occlusion of the LAD or that were pre-treated with LY or U0126 10 
min before initiation of IPC did not exhibit significant changes in MAP (P > 0.05, Table 
4.3.1). When compared to MI-animals treated with their respective vehicle, bolus 
treatment of animals with ARS in either 10 % DMSO (0.1, 3, 1 mg kg-1) or30 % 
Cyclodextrin (0.3, 1 mg kg-1) at the start of reperfusion did not cause any significant 
changes in MAP (P > 0.05, Table 4.3.1). 
 The mean baseline values of HR in all groups of animals ranged from 370 ± 10.19 
to 443 ± 5.33 bpm, and were not significantly different between groups (P > 0.05, Table 
4.3.1). When compared to Sham Vehicle animals, animals subjected to LAD occlusion 
and treated with vehicle in either 10 % DMSO or 30 % Cyclodextrin exhibited a 
progressive decline in MAP [MI Vehicle (DMSO), 413 ± 13.21 to 418 ± 12.76; MI 
Vehicle (Cyclodextrin), 393 ± 14.10 to 421 ± 6.37 (P > 0.05, Table 4.3.1). Animals 
undergoing 2 cycles of IPC before occlusion of the LAD or that were pre-treated with LY 
or UO126 10 min prior to initiation of IPC did not exhibit any significant changes in HR 
when compared to MI Vehicle (DMSO) treated animals (P > 0.05, Table 4.3.1). When 
compared to MI-animals treated with their respective vehicle, bolus treatment of animals 
with ARS in either [10 % DMSO (0.1, 3, 1 mg kg-1) or 30 % Cyclodextrin (0.3, 1 mg kg-
1) at the start of reperfusion did not cause any significant changes in HR (P > 0.05, Table 
4.3.1). 
PRI, a relative indicator of myocardial oxygen consumption, was derived as a 
product of MAP and HR. The mean baseline values of PRI in all groups of animals ranged 
from 38 ± 1.95 to 54 ± 1.80 mmHg bpm x 103, and were not significantly different 
between groups (P > 0.05, Table 4.3.1). When compared to Sham Vehicle animals, MI-
animals treated with either 10 % DMSO or 30% Cyclodextrin exhibited a decline in PRI  
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(P > 0.05, Table 4.3.1). Animals undergoing 2 cycles of IPC before occlusion of the LAD 
or that were pre-treated with LY or U0126 before initiation of IPC did not exhibit 
significant changes in PRI (P > 0.05, Table 4.3.1). When compared to MI-animals treated 
with their respective vehicle, bolus treatment of animals with ARS in either 10 % DMSO 
(0.1, 3, 1 mg kg-1) or 30 % Cyclodextrin (0.3, 1 mg kg-1) at the start of reperfusion did 
not show any significant changes in PRI (P > 0.05, Table 4.3.1). 
 
Table 4.3.1. MAP, HR and PRI in animals subjected to LAD occlusion and 
reperfusion 
 Ischaemia Reperfusion 
Group 0 5 15 20 25 55 85 145 
Sham Vehicle (n = 6) 
MAP 120 ± 
2.86 
119 ± 
2.32 
115 ± 
2.73 
115 ± 
2.07 
111 ± 
3.13 
106 ± 
6.09 
105 ± 
4.02 
102 ± 
4.83 
HR 443 ± 
5.33 
439 ± 
4.11 
439 ± 
5.89 
439 ± 
8.92 
437 ± 
9.95 
418 ± 
5.22 
418 ± 
11.71 
419 ± 
6.32 
PRI 53 ± 
1.11 
52 ± 
0.74 
50 ± 
0.95 
50 ± 
1.53 
49 ± 
2.09 
44 ± 
3.04 
44 ± 
2.77 
43 ± 
2.43 
MI Vehicle (DMSO) (n = 13) 
MAP 106 ± 
4.07 
112 ± 
3.70 
106 ± 
2.25 
103 ± 
2.51 
100 ± 
3.21 
98 ± 
5.23 
92 ± 
5.32 
90 ± 
4.63 
HR 413 ± 
13.21 
433 ± 
12.38 
428 ± 
12.47 
424 ± 
12.79 
407 ± 
19.53 
409 ± 
10.02 
414 ± 
13.49 
418 ± 
12.76 
PRI 44 ± 
2.47 
48 ± 
2.22 
45 ± 
1.64 
44 ± 
1.61 
41 ± 
2.58 
40 ± 
2.28 
38 ± 
2.98 
38 ± 
2.21 
MI + ARS (0.1; DMSO) (n =7) 
MAP 130 ± 
4.06 
128 ± 
6.89 
127 ± 
5.51 
126 ± 
4.73 
126 ± 
4.18 
118 ± 
0.58 
104 ± 
1.45 
101 ± 
5.70 
HR 417 ± 
4.18 
433 ± 
6.81 
422 ± 
9.26 
419 ± 
9.64 
418 ± 
9.39 
441 ± 
11.53 
429 ± 
7.45 
438 ± 
11.79 
PRI 54 ± 
1.80 
56 ± 
3.71 
54 ± 
3.36 
53 ± 
3.14 
53 ± 
2.63 
52 ± 
1.46 
45 ± 
0.50 
44 ± 
2.04 
MI + ARS (0.3; DMSO) (n=7) 
MAP 125 ± 
5.44 
126 ± 
5.41 
119 ± 
4.87 
116 ± 
5.13 
115 ± 
6.10 
94 ± 
10.87 
89 ± 
7.48 
87 ± 
4.87 
HR 426 ± 
8.95 
443 ± 
5.12 
432 ± 
5.72 
426 ± 
6.13 
422 ± 
6.71 
416 ± 
13.14 
413 ± 
10.65 
405 ± 
3.96 
PRI 54 ± 
2.99 
56 ± 
2.72 
51 ± 
2.12 
50 ± 
2.29 
48 ± 
2.79 
40 ± 
5.24 
37 ± 
3.67 
35 ± 
2.19 
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Table 4.3.1. MAP, HR and PRI in animals subjected to LAD occlusion and 
reperfusion continued 
 Ischaemia Reperfusion 
Group 0 5 15 20 25 55 85 145 
MI + ARS (1; DMSO) (n = 7) 
MAP 119 ± 
2.15 
117 ± 
7.75 
116 ± 
3.07 
112 ± 
3.87 
109 ± 
3.41 
112 ± 
5.97 
95 ± 
6.66 
86 ± 
8.69 
HR 407 ± 
16.90 
432 ± 
11.42 
418 ± 
14.96 
409 ± 
16.78 
407 ± 
15.94 
416 ± 
14.05 
410 ± 
14.47 
430 ± 
15.30 
PRI 48 ± 
2.48 
51 ± 
4.07 
49 ± 
2.73 
46 ± 
3.27 
45 ± 
2.85 
47 ± 
3.44 
39 ± 
3.91 
37 ± 
4.14 
MI + IPC (n = 9) 
MAP 101 ± 
7.14 
118 ± 
3.70 
112 ± 
5.33 
111 ± 
5.12 
119 ± 
4.12 
102 ± 
6.12 
98 ± 
3.67 
94 ± 
7.13 
HR 406 ± 
13.39 
419 ± 
10.08 
405 ± 
11.74 
402 ± 
11.54 
405 ± 
10.52 
414 ± 
11.59 
407 ± 
10.14 
428 ± 
15.71 
PRI 41 ± 
2.75 
49 ± 
2.05 
46 ± 
2.52 
45 ± 
2.34 
48 ± 
2.04 
42 ± 
2.32 
40 ± 
1.69 
41 ± 
3.63 
MI + LY294002 + IPC (n = 7) 
MAP 102 ± 
2.82 
107 ± 
3.34 
105 ± 
3.53 
103 ± 
3.71 
103 ± 
3.20 
90 ± 
3.52 
89 ± 
3.35 
86 ± 
4.02 
HR 370 ± 
10.19 
377 ± 
10.43 
370 ± 
11.25 
366 ± 
11.15 
362 ± 
11.17 
366 ± 
14.41 
385 ± 
13.97 
383 ± 
10.73 
PRI 38 ± 
1.95 
40 ± 
2.31 
39 ± 
2.25 
38 ± 
2.19 
37 ± 
2.08 
33 ± 
2.21 
34 ± 
1.95 
33 ± 
2.30 
MI + UO126 + IPC (n = 2) 
MAP 107  114 ± 
4.00 
111 ± 
4.00 
112 ± 
2.00 
107 ± 
4.50 
96 ± 
8.50 
90 ± 
9.00 
85 ± 
2.50 
HR 353 ± 
50.00 
380 ± 
22.00 
383 ± 
7.50 
381 ± 
8.50 
379 ± 
6.00 
370 ± 
14.50 
366 ± 
17.00 
360 ± 
30.50 
PRI 38 ± 
5.35 
43 ± 
4.03 
42 ± 
2.36 
43 ± 
1.71 
40 ± 
2.34 
35 ± 
4.53 
35 ± 
4.82 
30 ± 
3.48 
MI Vehicle (Cyclodextrin) (n = 6) 
MAP 119 ± 
4.90 
121 ± 
4.65 
115 ± 
4.64 
112 ± 
4.00 
111 ± 
4.26 
103 ± 
5.67 
98 ± 
5.40 
99 ± 
5.26 
HR 393 ± 
14.10 
426 ± 
10.83 
403 ± 
12.73 
396 ± 
13.74 
393 ± 
14.20 
382 ± 
15.01 
396 ± 
15.88 
421 ± 
6.37 
PRI 47 ± 
3.23 
52 ± 
2.98 
46 ± 
3.14 
45 ± 
3.05 
44 ± 
3.12 
40 ± 
3.50 
39 ± 
3.28 
42 ± 
3.45 
 
 
 
 
Chapter 4: Results 
Table 4.3.1. MAP, HR and PRI in animals subjected to LAD occlusion and 
reperfusion continued 
 Ischaemia Reperfusion 
Group 0 5 15 20 25 55 85 145 
MI + ARS (0.3; Cyclodextrin) (n = 7) 
MAP 118 ± 
5.02 
114 ± 
9.36 
118 ± 
4.54 
116 ± 
4.12 
111 ± 
4.87 
103 ± 
6.77 
92 ± 
6.46 
92 ± 
4.72 
HR 430 ± 
19.41 
440 ± 
21.06 
432 ± 
19.11 
429 ± 
17.10 
423 ± 
16.58 
417 ± 
12.53 
423 ± 
11.47 
423 ± 
8.66 
PRI 51 ± 
4.10 
50 ± 
5.45 
51 ± 
3.57 
50 ± 
3.14 
47 ± 
3.15 
43 ± 
3.93 
39 ± 
3.65 
39 ± 
2.52 
MI + ARS (1; Cyclodextrin) (n =7) 
MAP 107 ± 
5.08 
121 ± 
3.30 
114 ± 
4.16 
106 ± 
6.00 
109 ± 
4.72 
95 ± 
3.41 
89 ± 
2.45 
94 ± 
4.31 
HR 419 ± 
16.82 
439 ± 
10.99 
417 ± 
13.03 
406 ± 
15.12 
406 ± 
13.38 
397 ± 
14.15 
409 ± 
10.57 
397 ± 
17.79 
PRI 45 ± 
2.31 
53 ± 
1.94 
48 ± 
2.74 
43 ± 
3.52 
44 ± 
2.61 
38 ± 
2.74 
37 ± 
1.24 
38 ± 
3.16 
 
Alterations in MAP (mmHg), HR (bpm), and PRI (mmHg bpm 103) in rats subjected to 
either i) surgical procedure alone and treated with vehicle (Sham Vehicle), ii) 25 min 
ischaemia and 120 min reperfusion and treated with vehicle [(MI Vehicle) in either 10 % 
DMSO, 30 % Cyclodextrin or NaHCO3], iii) 25 min ischaemia and 120 min reperfusion 
and treated at the start of reperfusion with artesunate (MI + ARS) in either 10 % DMSO 
(0.1, 0.3, 1 mg kg-1 i.v.), 30 % Cyclodextrin (0.3, 1 mg kg-1 i.v.) or NaHCO3, (0.1, 0.3, 1 
mg kg-1 i.v.), iv) treated with either LY294002 (MI + LY 0.3 mg kg-1 + ARS) or U0126 
(MI + U0126 0.2 mg kg-1 + ARS) 10 min before ischaemia, followed by 25 min ischaemia 
and 120 min reperfusion and treated at the start of reperfusion with ARS, v) treated with 
either vehicle (MI + IPC), LY294002 (MI + LY + IPC) or U0126 (MI + U0126 + IPC) 
10 min before 2 cycles of preconditioning followed by 25 min ischaemia and 120 min 
reperfusion. Data are expressed as means ± S.E.M. for n number of observations (two-
way analysis of variance with repeated measures, with Bonferroni post-test). 
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Effect of regional MI and ARS (in NaHCO3) on haemodynamic parameters 
The baseline values of MAP in all groups of animals ranged from 104 ± 5.89 to 
120 ± 2.86 mmHg, and were not significantly different between groups (P > 0.05, Figure 
4.3.1.1A). When compared to Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle [MI Vehicle (NaHCO3)] exhibited a progressive 
decline in MAP from  107 ± 7.41 to 82 ± 13.72 mmHg at the end of the experiment 
(Figure 4.3.1.1A). Bolus treatment of animals with ARS at doses 0.1 mg kg-1, 0.3 mg kg1, 
or 1 mg kg-1 at the start of reperfusion did not cause any significant changes in MAP when 
compared to MI-animals treated with vehicle (NaHCO3) (P > 0.05, Figure 4.3.1.1A).  
 Baseline values of HR in all groups ranged from 418 ± 10.00 to 468 ± 
14.50 bpm, and were not significantly different between groups (P > 0.05, Figure 
4.3.1.1B). When compared to Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle [MI Vehicle (NaHCO3)] caused a progressive decline 
in HR from 433 ± 16.93 to 415 ± 14.91 bpm at the end of the experiment (Figure 
4.3.1.1B). Bolus treatment of animals with ARS at doses 0.1 mg kg-1, 0.3 mg kg-1, or 1 
mg kg-1 at the start of reperfusion did not have a significant effect on the HR when 
compared to MI-animals treated with vehicle (NaHCO3)  (P > 0.05, Figure 4.3.1.1B).  
 Baseline values of PRI in all groups of animals ranged from 44 ± 3.10 to 
53 ± 1.11 mmHg min-1 103 and were not significantly different between groups (P > 0.05, 
Figure 4.3.1.1C). When compared to Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle [MI Vehicle (NaHCO3)] exhibited a progressive 
decline in PRI from 46.46 ± 3.86 to 34 ± 5.57 mmHg min-1 103 at the end of the 
experiment (Figure 4.3.1.1C). Bolus treatment of animals with ARS at doses 0.1 mg kg1, 
0.3 mg kg-1, or 1 mg kg-1 at the start of reperfusion did not have a significant effect on the 
PRI when compared to MI-animals treated with vehicle (NaHCO3) (P > 0.05, Figure 
4.3.1.1C).  
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 Figure 4.3.1.1. (A) Mean arterial pressure, (B) heart rate, and (C) pressure rate 
index of rats subjected to surgical procedure alone an treated with vehicle (Sham Vehicle, 
n = 6), or 25 min ischaemia and 120 min reperfusion and treated with vehicle [MI Vehicle 
(NaHCO3), n = 5], or 25 min ischaemia and 120 min reperfusion and treated with 
artesunate in NaHCO3 (ARS 0.1 mg kg
-1i.v., n = 3, 0.3 mg kg-1i.v., n = 4, 1 mg kg-1i.v., n 
= 11), (two-way analysis of variance with repeated measures, with Bonferroni post-test). 
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Comparison of the effects of using a dose of 1 mg kg-1 of ARS in the different vehicle 
on haemodynamic parameters 
 The baseline values of mean arterial blood pressure in all groups of 
animals ranged from 104 ± 5.89 to 120 ± 2.86 mmHg, and were not significantly different 
between groups (P > 0.05, Figure 4.3.1.2A). When compared to Sham Vehicle animals, 
animals subjected to LAD occlusion and treated with vehicle in either 10 % DMSO, 
NaHCO3 or 30 % Cyclodextrin exhibited a progressive decline in MAP (DMSO, 112 ± 
3.70 to 90 ± 4.63; NaHCO3, 107 ± 7.41 to 82 ± 13.72; 30 % Cyclodextrin, 121 ± 4.65 to 
99 ± 5.26) mmHg at the end of the experiment (Figure 4.3.1.2A). Bolus treatment of 
animals with ARS at dose of 1 mg kg-1 at the start of reperfusion in all three vehicles did 
not cause any significant changes in MAP when compared to MI-animals treated with 
their respective vehicle (P > 0.05, Figure 4.3.1.2A).  
 Baseline values of HR in all groups ranged from 393 ± 14.10 to 443 ± 
16.59 bpm, and were not significantly different between groups (P > 0.05, Figure 
4.3.1.2B). When compared to Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle in either 10 % DMSO, 30 % Cyclodextrin or NaHCO3 
exhibited a progressive decline in HR (DMSO, 433 ± 12.38 to 418 ± 12.76, Cyclodextrin, 
426 ± 10.83 to 421 ± 16.37; NaHCO3, 433 ± 16.93 to 415 ± 14.91) bpm at the end of the 
experiment (Figure 4.3.1.2B). Bolus treatment of animals with ARS at dose of 1 mg kg-1 
at the start of reperfusion in all three vehicles did not cause any significant changes in HR 
when compared to MI-animals treated with their respective vehicle (P > 0.05, Figure 
4.3.1.2B).  
 Baseline values of PRI in all groups of animals ranged from 44 ± 3.10 to 
53 ± 1.11 mmHg min-1 103 and were not significantly different between groups (P > 0.05, 
Figure 4.3.1.2C). When compared to Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle in either 10 % DMSO, 30 % Cyclodextrin or NaHCO3 
exhibited a decline in PRI (DMSO, 48 ± 2.22 to 38 ± 2.21; Cyclodextrin, 52 ± 2.98 to 42 
± 3.45; NaHCO3, 46 ± 3.86 to 34 ± 5.57) mmHg min
-1 103 at the end of the experiment 
(Figure 1.4C). Bolus treatment of animals with ARS at dose of 1 mg/kg at the start of 
reperfusion in all three vehicles did not cause any significant changes in PRI when 
compared to MI-animals treated with their respective vehicle (P > 0.05, Figure 4.3.1.2C). 
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 Figure 4.3.1.2. (A) Mean arterial pressure, (B) heart rate, and (C) pressure rate 
index of rats subjected to surgical procedure alone an treated with vehicle (Sham Vehicle, 
10 % DMSO 1 ml/kg i.v., n = 6), or 25 min ischaemia and 120 min reperfusion and treated 
with vehicle (MI Vehicle) in either 10 % DMSO  (n = 13), 30 % Cyclodextrin (n = 7), or 
NaHCO3 (n = 5), or 25 min ischaemia and 120 min reperfusion and treated with artesunate 
(ARS) in either 10 % DMSO (1 mg kg-1i.v., n = 7), 30 % Cyclodextrin (1 mg kg-1i.v., n 
= 6), or NaHCO3 (1 mg kg
-1i.v., n = 11), (two-way analysis of variance with repeated 
measures, with Bonferroni post-test). 
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Effect of inhibition of survival pathways in the ARS-induced effects on 
haemodynamic parameters 
 The baseline values of MAP in all groups of animals ranged from 100 ± 
8.52 to 120 ± 2.86 mmHg, and were not significantly different between groups (P > 0.05, 
Figure 4.3.1.3A). When compared to Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle [MI Vehicle (NaHCO3)] caused a progressive decline 
in MAP from 107 ± 7.41 to 82 ± 13.72 mmHg at the end of the experiment (Figure 
4.3.1.3A). Bolus treatment of animals with ARS (1 mg kg-1) at the start of reperfusion did 
not cause any significant changes in MAP when compared to MI-animals treated with 
vehicle (NaHCO3) (P > 0.05, Figure 4.3.1.3A). Furthermore, Bolus administration of 
animals with LY294002 (0.3 mg kg-1) or UO126 (0.2 mg kg-1) 10 min before occlusion 
of the LAD did not cause any significant changes in MAP (P > 0.05, Figure 4.3.1.3A). 
 Baseline values of HR in all groups ranged from 418 ± 10.00 to 443 ± 16.59 bpm, 
and were not significantly different between groups (P > 0.05, Figure 4.3.1.3B). When 
compared to Sham Vehicle animals, animals subjected to LAD occlusion and treated with 
vehicle [MI Vehicle (NaHCO3)] caused a progressive decline in HR from 433 ± 16.59 to 
415 ± 14.91 mmHg at the end of the experiment (Figure 4.3.1.3B). Bolus treatment of 
animals with ARS (1 mg kg-1) at the start of reperfusion did not cause any significant 
changes in HR when compared to MI-animals treated with vehicle (NaHCO3) (P > 0.05, 
Figure 4.3.1.3B). Furthermore, Bolus administration of animals with LY294002 (0.3 mg 
kg-1) or UO126 (0.2 mg kg-1) 10 min before occlusion of the LAD did not cause any 
significant changes in HR (P > 0.05, Figure 4.3.1.3B). 
 Baseline values of PRI in all groups of animals ranged from 44 ± 3.10 to 53 ± 1.11 
mmHg min-1 103 and were not significantly different between groups (P > 0.05, Figure 
4.3.1.3C). When compared to Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle [MI Vehicle (NaHCO3)] exhibited a progressive 
decline in PRI (46 ± 3.86 to 34 ± 5.57 mmHg min-1 103) at the end of the experiment 
(Figure 4.3.1.3C). Bolus treatment of animals with ARS (1 mg kg-1) at the start of 
reperfusion did not cause any significant changes in PRI when compared to MI-animals 
treated with vehicle (NaHCO3) (P > 0.05, Figure 4.3.1.3C). Furthermore, Bolus 
administration of animals with LY294002 (0.3 mg kg-1) or UO126 (0.2 mg kg-1) 10 min 
before occlusion of the LAD did not cause any significant changes in PRI (P > 0.05, 
Figure 4.3.1.3C). 
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 Figure 4.3.1.3. (A) Mean arterial pressure, (B) heart rate, and (C) pressure rate 
index of rats subjected to surgical procedure alone and treated with vehicle (Sham 
Vehicle, n = 6), or 25 min ischaemia and 120 min reperfusion and treated with vehicle in 
NaHCO3 [MI Vehicle (NaHCO3) n = 5], or 25 min ischaemia and 120 min reperfusion 
and treated with artesunate in NaHCO3 [MI + ARS (1 mg kg
-1i.v.), n = 11]  at the start of 
reperfusion, or pre-treated with either LY294002 or UO126 10 min before ischaemia, 
followed by 25 min of ischaemia and 120 min reperfusion and treated at the start of 
reperfusion with artesunate in NaHCO3 (MI + ARS + LY 0.3 mg kg
-1i.v., n = 8; MI + 
ARS + UO126 0.2 mg kg-1i.v., n = 10), (two-way analysis of variance with repeated 
measures, with Bonferroni post-test).  
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Effect of DHA on haemodynamic parameters 
 The baseline values of MAP in all groups of animals ranged from 106 ± 4.07 to 
130 ± 4.06 mmHg, and were not significantly different between groups (P > 0.05, Figure 
4.3.1.4A). When compared to Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle [MI Vehicle (DMSO)] exhibited a progressive decline 
in MAP (112 ± 3.70 to 90 ± 4.63 mmHg at the end of the experiment (Figure 4.3.1.4A). 
Bolus treatment of animals with ARS (0.1 mg kg-1) resulted in a significant change in 
MAP when compared to MI Vehicle (DMSO) only at the 25 min point (126 ± 4.18 vs. 
101 ± 3.21). Whereas, bolus treatment DHA (0.1 mg kg-1) upon reperfusion did not cause 
any significant changes in MAP when compared to MI-animals treated with vehicle 
(DMSO) (P > 0.05, Figure 4.3.1.4A).  
 Baseline values of HR in all groups ranged from 413 ± 13.21 to 449 ± 10.59 bpm, 
and were not significantly different between groups (P > 0.05, Figure 4.3.1.4B). When 
compared to Sham Vehicle animals, animals subjected to LAD occlusion and treated with 
vehicle [MI Vehicle (DMSO)] exhibited a progressive decline in HR (433 ± 12.38 to 418 
± 12.76) bpm at the end of the experiment (Figure 4.3.1.4B). Bolus treatment of animals 
with either ARS (0.1 mg kg-1) or DHA (0.1 mg kg-1) upon reperfusion did not cause any 
significant changes in HR when compared to MI-animals treated with vehicle (DMSO) 
(P > 0.05, Figure 4.3.1.4B). 
 Baseline values of PRI in all groups of animals ranged from 44 ± 2.47 to 54 ± 1.80 
mmHg min-1 103 and were not significantly different between groups (P > 0.05, Figure 
4.3.1.4C). When compared to Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle [(MI Vehicle (DMSO)] exhibited a progressive decline 
in PRI (48 ± 2.22 to 38 ± 2.21 mmHg min-1 103) at the end of the experiment (Figure 
4.3.1.4C). Bolus treatment of animals with either ARS (0.1 mg kg-1) or DHA (0.1 mg kg-
1) upon reperfusion did not cause any significant changes in PRI when compared to MI-
animals treated with vehicle (DMSO) (P > 0.05, Figure 4.3.1.4C). 
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 Figure 4.3.1.4 (A) Mean arterial pressure, (B) heart rate, and (C) pressure rate index 
of rats subjected to either surgical procedure alone and treated with vehicle (Sham, n = 
6), or 25 min ischaemia and 120 min reperfusion and treated with either vehicle in 10 % 
DMSO (MI Vehicle, n = 13), artesunate (MI + ARS, 0.1 mg kg-1, n = 3) or 
dihydroartemisinin (MI + DHA, 0.1 mg kg-1, n = 6) at the start of reperfusion. P < 0.05 
vs. MI Vehicle (DMSO), (two-way analysis of variance with repeated measures, with 
Bonferroni post-test).  
.  
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Effect on the area at risk 
 There was no significant difference in the area at risk (AAR) between any of the 
groups studied (Table 4.3.2.). 
 
Table 4.3.2. List of all the experimental groups with their respective AAR, expressed 
as a percentage of the left ventricle.  
Group n Area at risk % of left 
ventricle 
Sham vehicle (1 ml kg-1; 10 % DMSO) 6 54.67  ± 1.96 
MI Vehicle (1 ml kg-1; 10 % DMSO) 14 51.26 ± 1.59 
MI Vehicle (1 ml kg-1; 30 % Cyclodextrin) 7 52.29 ± 1.23 
MI Vehicle (1 ml kg-1; NaHCO3) 5 55.20 ± 3.12 
MI + ARS (0.1 mg kg-1; 10 % DMSO) 3 49.00 ± 3.79 
MI + ARS (0.3 mg kg-1; 10 % DMSO) 7 51.86 ± 2.12 
MI + ARS (1 mg kg-1; 10 % DMSO) 7 50.00 ± 2.10 
MI + ARS (0.3 mg kg-1; 30 % Cyclodextrin) 7 48.00 ± 4.08 
MI + ARS (1 mg kg-1; 30 % Cyclodextrin) 7 49.43 ± 1.23 
MI + ARS (0.1 mg kg-1; NaHCO3) 4 47.25 ±  2.72 
MI + ARS (0.3 mg kg-1; NaHCO3) 5 49.80 ± 4.77 
MI + ARS (1 mg kg-1; NaHCO3) 12 48.17 ± 2.44 
MI + LY (0.3 mg kg-1)+ ARS (1 mg kg-1; 
NaHCO3) 
10 53.30 ±  1.51 
MI + U0126 (0.2 mg kg-1) + ARS (1 mg kg-1; 
NaHCO3) 
11 52.34 ± 2.48 
MI + IPC 12 50.42 ± 3.14 
MI + LY (0.3 mg kg-1) + IPC 7 50.14 ± 2.09 
MI + U0126 (0.2 mg kg-1)+ IPC 5 44.20 ± 3.84 
MI + DHA (mg kg-1; 10 % DMSO) 6 51.00 ± 2.37 
 
ARS = Artesunate; DHA = Dihydroartemisinin;  
IPC = Ischaemic preconditioning; LY = LY294002; MI = Myocardial infarction 
 
The area at risk (AAR) in rats subjected to either i) surgical procedure alone and treated 
with vehicle (Sham Vehicle), ii) 25 min ischaemia and 120 min reperfusion and treated  
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with vehicle [(MI Vehicle) in either 10 % DMSO, 30 % Cyclodextrin or NaHCO3], iii) 
25 min ischaemia and 120 min reperfusion and treated at the start of reperfusion with 
artesunate [(MI + ARS) in either 10 % DMSO (0.1, 0.3, 1 mg kg-1 i.v.), 30 % Cyclodextrin 
(0.3, 1 mg kg-1 i.v.) or NaHCO3 (0.1, 0.3, 1 mg kg
-1 i.v.), iv) treated with either LY294002 
(MI + LY 0.3 mg kg-1 + ARS) or U0126 (MI + U0126 0.2 mg kg-1 + ARS) 10 min before 
ischaemia, followed by 25 min ischaemia and 120 min reperfusion and treated at the start 
of reperfusion with ARS, v) treated with either vehicle (MI + IPC), LY294002 (MI + LY 
+ IPC) or U0126 (MI + U0126 + IPC) 10 min before 2 cycles of preconditioning followed 
by 25 min ischaemia and 120 min reperfusion, or vi) 25 min ischaemia and 120 min 
reperfusion and treated at the start of reperfusion with DHA (MI + DHA 0.1 mg kg-1). 
Data are expressed as means ± S.E.M. for n number of observations (one-way analysis of 
variance with Bonferroni post-test). 
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Chapter 4: Results 
Effect of ARS on the infarct size, in animals that underwent transient I/R injury  
 Animals subjected to surgical procedure alone (Sham Vehicle) exhibited an 
infarct size of approximately 6 %. When compared to Sham Vehicle animals, animals 
subjected to LAD occlusion and treated with vehicle [MI Vehicle (DMSO)] demonstrated 
a significant increase in infarct size (P < 0.05, Figure 4.3.2A).  When compared with MI 
animals treated with vehicle, administration of ARS at doses of 0.1 and 0.3 mg kg-1, at 
the start of reperfusion, had no significant effect on infarct size (P > 0.05, Figure 4.3.2A). 
Whereas, when compared to MI animals treated with vehicle (MI Vehicle), 
administration of ARS at a higher dose of 1 mg kg-1 at the start of reperfusion, caused a 
significant reduction in infarct size (P < 0.05, Figure 4.3.2A). 
 When compared to Sham Vehicle animals, animals subjected to LAD occlusion 
and treated with vehicle (MI Vehicle - 30 % CD) demonstrated a significant increase in 
infarct size (P < 0.05, Figure 4.3.2B). When compared with MI animals treated with 
vehicle (MI Vehicle- 30 % CD), administration of ARS at a dose of 0.3 mg kg-1, at the 
start of reperfusion, had no significant effect on infarct size (P > 0.05, Figure 4.3.2B). 
When compared to MI animals treated with vehicle (MI Vehicle - 30 % CD), 
administration of ARS at a dose of 1 mg kg-1 at the start of reperfusion, caused a 
significant reduction in infarct size (P < 0.05, Figure 4.3.2B). 
 When compared to Sham Vehicle animals, animals subjected to LAD occlusion 
and treated with vehicle (MI Vehicle – NaHCO3) demonstrated a significant increase in 
infarct size (P < 0.05, Figure 4.3.2C). When compared with MI animals treated with 
vehicle (MI Vehicle – NaHCO3), administration of ARS at a dose of 0.1 mg kg-1, at the 
start of reperfusion, had no significant effect on the infarct size (P > 0.05, Figure 4.3.2C). 
When compared to MI animals treated with vehicle (MI Vehicle – NaHCO3), 
administration of ARS at a dose of 0.3 mg kg-1 at the start of reperfusion, attenuated the 
increase in infarct size (P < 0.05, Figure 4.3.2C), while a higher dose of 1 mg kg-1 of ARS 
had an even greater effect (P < 0.05, Figure 4.3.2C). 
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Figure 4.3.2. Infarct size in animals that underwent transient I/R injury. Rats 
were subjected to surgical procedure alone and treated with vehicle (Sham Vehicle, n 
= 6), or 25 min ischaemia and 120 min reperfusion and treated with vehicle (MI 
Vehicle) in either 10 % DMSO (panel A, n = 14), 30 % Cyclodextrin (CD, panel B, n 
= 7) and NaHCO3 (panel C, n = 5), or 25 min ischaemia and 120 min reperfusion and 
treated at the start of reperfusion, with artesunate (MI + ARS) in either 10 % DMSO 
(0.1, 0.3, 1 mg kg-1 i.v., panel A), 30 % CD (0.3, 1 mg kg-1 i.v., panel B) and NaHCO3 
(0.1, 0.3, 1 mg kg-1 i.v., panel C). Panel D shows a combined figure of MI Vehicle in 
10 % DMSO, 30 % CD and NaHCO3 against their respective treatment groups with 
artesunate (1 mg kg-1 i.v). Data are expressed as means ± S.E.M. for n number of 
observations.  P < 0.05. 
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Effect of ARS on the infarct size, in animals that underwent transient I/R injury 
following inhibition of survival pathways 
To determine the role of activating components of the RISK survival pathway; 
PI3K/Akt and ERK 1/2  in the cardioprotective effects of ARS, rats were treated with 
LY294002 and U0126, a PI3K and ERK 1/2 inhibitor, respectively, 10 min prior to 
initiation of 25 min ischaemia (followed by 2 h of reperfusion). Animals subjected to 
surgical procedure alone (Sham Vehicle) exhibited an infarct size of approximately 6 %. 
When compared to Sham Vehicle animals, animals treated with vehicle (MI Vehicle – 
NaHCO3), demonstrated a significant increase in infarct size (P < 0.05, Figure 4.3.3.1) to 
~ 60 %.  When compared with MI animals treated with vehicle (MI Vehicle – NaHCO3), 
administration of artesunate (ARS) at a dose of 1 mg kg-1, at the start of reperfusion, 
attenuated the increase in infarct size (P < 0.05, Figure 4.3.3.1)  to ~ 40 %. This effect 
afforded by ARS was abolished following the administration of LY294002 and U0126, 
inhibitors of the PI3K/Akt and ERK 1/2 pathway, respectively (P < 0.05, Figure 4.3.3.1) 
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Figure 4.3.3.1 Effect of inhibition of components of the RISK pathway on 
infarct size in animals that underwent transient I/R injury.  Rats were subjected 
to surgical procedure alone and treated with vehicle (Sham Vehicle, n = 6), or 25 
min ischaemia and 120 min reperfusion and treated with vehicle [MI Vehicle 
(NaHCO)3, n = 5], or 25 min ischaemia and 120 min reperfusion and treated at the 
start of reperfusion, with either artesunate (MI + ARS 1 mg kg-1 i.v., n = 12), or pre-
treated with either LY294002  or U0126 10 min before ischaemia, followed by 25 
min ischaemia and 120 min reperfusion and treated at the start of reperfusion, with 
artesunate (MI + ARS + LY 0.3 mg kg-1 i.v., n = 10; MI + ARS + U0126 0.2 mg kg-
1 i.v., n = 11). Data are expressed as means ± S.E.M. for n number of observations. 
 P < 0.05 vs. MI Vehicle (NaHCO3). 
 
 
 
 
 (NaCO3). 
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Effect of inhibition of the RISK pathway on infarct size, in animals that underwent 
transient I/R injury subsequent to IPC 
To confirm that activation of the RISK pathway is pivotal in mediating the IPC-
induced cardioprotection, rats were treated with LY and U0126, PI3K/Akt and ERK 1/2 
inhibitors respectively, 10 min prior to initiating the IPC stimulus. Animals subjected to 
surgical procedure alone (Sham Vehicle) exhibited an infarct size of approximately 6 %. 
When compared to Sham Vehicle animals, those subjected to LAD occlusion and treated 
with vehicle (MI Vehicle - 10 % DMSO), demonstrated a significant increase in infarct 
size (P < 0.05, Figure 4.3.3.2).  This was reduced significantly when animals went 
through 2 cycles of IPC before occlusion of the LAD (P < 0.05, Figure 4.3.3.2). This 
effect afforded by IPC was abolished following the administration of LY and U0126 
which were both given 10 min before the initiation of IPC (P < 0.05, Figure 4.3.3.2). 
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Figure 4.3.3.2 Effect of inhibition of components of the RISK pathway on 
infarct size in animals that underwent transient I/R injury subsequent to an 
IPC stimulus. Rats were subjected to surgical procedure alone and treated with 
vehicle (Sham Vehicle, n = 6), or 25 min ischaemia and 120 min reperfusion and 
treated with  vehicle [MI Vehicle (DMSO), n = 14], or 2 cycles of preconditioning 
followed by 25 min ischaemia and 120 min reperfusion and treated with vehicle 
(MI + IPC n = 12), or pre-treated with either LY29400 (MI + IPC + LY 0.3 mg 
kg-1 i.v., n = 7) or U0126 (MI + IPC + U0126, 0.2 mg kg-1 i.v., n = 5) 10 min before 
the 2 cycles of preconditioning followed by 25 min ischaemia and 120 min 
reperfusion. Data are expressed as means ± S.E.M. for n number of observations. 
 P < 0.05 vs. MI Vehicle (DMSO). 
 
 
 
 
 (NaCO3). 
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Effect of ARS on the phosphorylation of Akt and GSK-3β, in the hearts of animals 
that underwent transient I/R injury 
 In order to explore which downstream effectors are involved in mediating the 
ARS-induced cardioprotection, following activation of the survival pathways mentioned 
above, western blot analysis was carried out in hearts of animals subjected to LAD 
occlusion and reperfusion. When compared to hearts from Sham Vehicle animals, 
animals subjected to LAD occlusion and treated with vehicle (MI Vehicle) demonstrated 
no change in the phosphorylation of Akt on Ser473 and GSK-3β on Ser9 (P > 0.05, Figures 
4.3.4.1A and B). Administration of ARS at the start of reperfusion to animals subjected 
to LAD occlusion, resulted in a significant increase in the phosphorylation of Akt on 
Ser473 and GSK-3β on Ser9 (P < 0.05, Figures 4.3.4.1A and B). 
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Figure 4.3.4.1. Effect of ARS on the phosphorylation of Akt and GSK-3β on 
Ser473 and Ser9 residue, respectively, in the hearts of animals that underwent 
transient I/R injury. Each immunoblot is from a single experiment and is 
representative of four separate experiments in which rats were subjected to surgical 
procedure alone and treated with vehicle (Sham Vehicle, n = 4), or 25 min ischemia 
and 120 min reperfusion and treated with either vehicle (MI  Vehicle, n = 4), or 
ARS (MI + ARS, n = 4) at the start of reperfusion. Densitometric analysis of the 
bands is expressed as relative optical density of Akt and GSK-3β phosphorylation 
at Ser473 and Ser9, corrected for the corresponding Akt and GSK-3β  content and 
normalised using the related sham-operated band. Data are expressed as means ± 
S.E.M. for n number of observations. P < 0.05 vs. MI Vehicle. (Western blot 
generated by M. Collino, University of Turin) 
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Effect of ARS on the nuclear translocation of the p65 NF-κB subunit in the hearts 
of animals that underwent transient I/R injury  
 When compared to hearts of Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle (MI Vehicle) exhibited significant increases in the 
nuclear translocation of the p65 subunit (P < 0.05, Figure 4.3.4.2) indicating activation of 
NF-κB. Administration of ARS at the start of reperfusion to animals subjected to LAD 
occlusion significantly attenuated the increase in nuclear translocation of p65 and, hence, 
inhibition of activation of NF-κB in the heart (P < 0.05, Figure 4.3.4.2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Results 
  
 
 
 
 
 
 
 
 
 
Figure 4.3.4.2. Effect of ARS on NF-κB in the hearts of animals that 
underwent transient I/R injury. Each immunoblot is from a single experiment 
and is representative of four separate experiments in which rats were subjected 
to surgical procedure alone and treated with vehicle (Sham Vehicle, n = 4), or 
25 min ischemia and 120 min reperfusion and treated with either vehicle (MI  
Vehicle, n = 4), or ARS (MI + ARS, n = 4) at the start of reperfusion. NF-κB 
translocation from the cytosol to the nucleus was evaluated measuring NF-κB 
p65 subunit levels in both cytosol and nuclear fractions and expressing the 
results as nucleus/cytosol ratio. Data are expressed as means ± S.E.M. for n 
number of observations.  P < 0.05 vs. MI Vehicle. (Western blot generated by 
M. Collino, University of Turin) 
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Effect of ARS on the expression of eNOS in the hearts of animals that underwent 
transient I/R injury 
 When compared to hearts from Sham Vehicle animals, animals subjected to LAD 
occlusion and treated with vehicle (MI Vehicle) demonstrated no change in the expression 
of eNOS on Ser1177 (P > 0.05, Figure 4.3.4.3). Administration of ARS at the start of 
reperfusion to animals that underwent LAD occlusion however, resulted in a significant 
increase in the expression of eNOS on Ser1177 (P < 0.05, Figure 4.3.4.3). 
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Figure 4.3.4.3. Effect of ARS on the expression of eNOS in the hearts of animals 
that underwent transient I/R injury. Each immunoblot is from a single experiment 
and is representative of four separate experiments in which rats were subjected to 
surgical procedure alone and treated with vehicle (Sham Vehicle, n = 4), or 25 min 
ischemia and 120 min reperfusion and treated with either vehicle (MI  Vehicle, n = 
4), or ARS (MI + ARS, n = 4) at the start of reperfusion. Densitometric analysis of 
the bands is expressed as relative optical density of eNOS and corrected for the 
corresponding total eNOS content and normalized using the related sham band. Data 
are expressed as means ± S.E.M. for n number of observations.  P < 0.05 vs. MI 
Vehicle. (Western blot generated by M. Collino, University of Turin) 
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Effect of ARS on the phosphorylation of STAT3, in the hearts of animals that 
underwent transient I/R injury 
 STAT3 is a vital mediator in the SAFE pathway and is known to mediate 
cardioprotection when activated by mechanical procedures (e.g. pre-and 
postconditioning) as well as various pharmacological interventions. To elucidate whether 
STAT3 is also involved in the ARS-induced cardioprotection, western blot analysis was 
carried out in hearts of animals subjected to LAD occlusion and reperfusion. When 
compared to hearts from Sham Vehicle animals, animals subjected to LAD occlusion and 
treated with vehicle (MI Vehicle) demonstrated no change in the phosphorylation of 
STAT3 (P > 0.05, Figures 4.3.4.4). Administration of ARS at the start of reperfusion to 
animals subjected to LAD occlusion, resulted in a significant increase in the 
phosphorylation of STAT3 (P < 0.05, Figures 4.3.4.4). 
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Figure 4.3.4.4. Effect of ARS on the expression of STAT3 in the hearts of 
animals that underwent transient I/R injury. Each immunoblot is from a single 
experiment and is representative of six separate experiments in which rats were 
subjected to surgical procedure alone and treated with vehicle [Sham Vehicle (S), 
n = 3], or 25 min ischemia and 120 min reperfusion and treated with either vehicle 
[MI Vehicle (C), n = 5], or ARS [MI + ARS (T), 1 mg kg-1 i.v., n = 6] at the start of 
reperfusion. Representative blot showing densitometric analysis of the bands, 
expressed as relative optical density of STAT3 and corrected for the corresponding 
total STAT3 content and normalized using the related sham band. Data are 
expressed as means ± S.E.M. for n number of observations.  P < 0.05 vs. MI 
Vehicle. 
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Plasma concentration-time profiles of ARS and its metabolite DHA 
Maximal plasma concentrations (Cmax) of ARS and DHA, 39.7 and 223 ng ml
-1 
respectively, were detected at a Tmax of 10 min (or less) in sham vehicle rats (Figure 
4.3.4.5A). Plasma concentrations of ARS and DHA began to fall by 20 and 125 min, 
respectively. 
Rats that underwent MI demonstrated a Cmax of 67.9 and 187.3 ng ml
-1 for ARS 
and DHA respectively, at a Tmax of 10 min (Figure 4.3.4.5B). Plasma concentrations of 
ARS and DHA began to fall by 35 and 65 min, respectively. 
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Figure 4.3.4.5. Plasma concentration-time profiles of ARS and DHA following a 
single intravenous (i.v.) dose of ARS. Rats were either subjected to surgical 
procedure alone (A) and treated with artesunate (1 mg kg-1 i.v., n = 4), or 25 min 
ischaemia and 120 min reperfusion (B) and treated with artesunate (1 mg kg-1 i.v., n = 
4). Data are expressed as means ± S.E.M. for n number of observations. (Analysis 
performed by Prof. Laurent Decosterd’s lab, Centre Hospitalier Universitaire 
Vaudois) 
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Effect of DHA on the infarct size in animals that underwent transient I/R injury 
To determine whether DHA, the active metabolite of many artemisinin 
derivatives, exerts cardioprotective effects, rats were treated with DHA at the start of 
reperfusion. Due to the poor solubility of DHA in water and oils (Li et al., 2009) a dose 
of 0.1 mg kg-1 was used since it was not possible to fully dissolve the drug down to any 
other concentration, using various vehicles suitable for i.v. administration. Therefore here 
I compare it to a similar dose of ARS (in DMSO) which was shown previously not to be 
effective in reducing the infarct size (Figure 4.3.2 A). Animals subjected to surgical 
procedure alone (Sham Vehicle) exhibited an infarct size of approximately 6 %. When 
compared to Sham Vehicle animals, animals subjected to LAD occlusion and treated with 
vehicle (MI Vehicle - 10 % DMSO), demonstrated a significant increase in infarct size 
(P < 0.05, Figure 4.3.5A).  Administration of ARS to rats that underwent MI at a dose of 
0.1 mg kg-1 had no significant effect on infarct size (P > 0.05, Figure 4.3.5). Whereas, the 
administration of DHA at dose of 0.1 mg kg-1 caused a significant reduction in infarct 
size (P < 0.05, Figure 4.3.5). 
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Figure 4.3.5. Infarct size in animals that underwent transient I/R injury. Rats 
were subjected to either surgical procedure alone and treated with vehicle (Sham, n = 
6), or 25 min ischaemia and 120 min reperfusion and treated with either vehicle in 10 
% DMSO (MI Vehicle, n = 14), ARS (MI + ARS, 0.1 mg kg-1, n = 3) or DHA (MI + 
DHA, 0.1 mg kg-1, n = 6) at the start of reperfusion. P < 0.05 vs. MI Vehicle. 
 
 
 
 
 (NaCO3). 
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4.4.  Discussion 
 Ischaemic heart disease remains the leading cause of morbidity and mortality in 
the Western world. Although several interventions aimed at reducing the I/R injury have 
shown efficacy in experimental studies, they continue to fail to translate in a clinical 
setting, a reason believed to be due to the inaccurate timing of the intervention. Thus, 
there continues to be a growing need to uncover novel translatable interventions that could 
lessen the global impact of this disease on society.  
I report here for the first time that rats treated with ARS at a dose of 1 mg kg-1 at 
the start of reperfusion results in a significant reduction in infarct size, resulting from 
myocardial I/R injury.  
I demonstrate that an intravenous injection of ARS (1 mg kg-1) administered in 
various types of vehicles (10 % DMSO, 30 % CD, and NaHCO3) exhibited protection, 
i.e. reduction in infarct size in a rat model of transient I/R. It is clear, however, that the 
solubility in 10 % DMSO confers the biggest reduction in infarct size compared with the 
other two vehicles. DMSO, an amphipathic molecule with a high polar domain and two 
apolar methyl groups, rendering it soluble in both aqueous and organic media, is a widely 
used solvent for hydrophobic drugs (Guimarães et al., 2010). Studies have shown it to 
exhibit various protective roles, including antioxidant (Guimarães et al., 2010) to anti-
inflammatory (DeForge et al., 1992; Kelly et al., 1994; Chang et al., 2001). However, 
DMSO is associated with several systemic side effects such as diastolic and systolic 
hypertension (Hameroff et al., 1981), bradycardia (Santos et al., 2003), heart block 
(Shlafer et al., 1976; Rapoport et al., 1991) and rarely cardiac arrest (Baum et al., 1992).  
Although formulation of ARS in DMSO yielded the most effective reduction in infarct 
size, it must be taken into account the translatable ability of drug administration in the 
clinical setting. As an injectable formulation of ARS in NaHCO3 was commercially 
available, this formulation was used for a large number of the studies in this chapter. 
PI3Ks, and their downstream target serine/threonine kinase Akt, are a conserved 
family of signal transduction enzymes, involved in the regulation of inflammatory 
responses, cellular activation and apoptosis (Cantley, 2002). This pathway is thought to 
serve as an endogenous negative feedback regulator and/or compensatory mechanism 
limiting pro-inflammatory and apoptotic events in response to I/R injury (William et al.,  
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2006; Ha et al., 2008). Activation of the PI3K/Akt survival pathway has been implicated 
in preventing cardiac myocyte apoptosis (Matsui et al., 1999; Aikawa et al., 2000; Negoro 
et al., 2001) and in protecting the myocardium against I/R injury (Fujio et al., 2000). I 
demonstrate here that PI3K inhibition by LY, a specific PI3K inhibitor, abolished the 
ARS-induced cardioprotection. In addition, western blotting studies probing for 
phosphorylated Akt protein, show Akt the downstream kinase of PI3K becomes 
phosphorylated at Ser473, following treatment with ARS. This data confirms that the ARS-
induced cardioprotection is mediated through a PI3K/Akt-dependent mechanism. 
Activation of this pathway is also the key driver of the cardioprotective effects afforded 
by ischaemic preconditioning. 
Akt phosphorylates eNOS (Dimmeler et al., 1999; Fulton et al., 1999; Michell et al., 
1999) and the resulting eNOS activation has anti-apoptotic (Kim et al., 1997), anti-
inflammatory (Lamas et al., 1998) and antioxidant effects (Motterlini et al., 1996). I 
demonstrate that the cardioprotection afforded by ARS is partly due to an increase in 
phosphorylation of eNOS at Ser1177, secondary to activation of the PI3K/Akt pathway. 
Although this effect on eNOS would need to be confirmed by using a pharmacological 
inhibitor such as N(5)-(1-Iminoethyl)-L-ornithine HCL to see if there is a reversal of 
effect of ARS, it’s in line with various studies showing that activation of the PI3K-Akt-
eNOS pathway plays a role in cardioprotection; i) ischaemic post-conditioning in a 
remodelled rat myocardium was shown to be via increased phosphorylation of Akt-
downstream targets such as eNOS, secondary to activation of the PI3K/Akt pathway (Zhu 
et al., 2006), and ii) using a model of splanchnic artery occlusion, protection conferred 
by Akt was through phosphorylation of eNOS (Roviezzo et al., 2007).  
The serine/threonine kinase GSK-3 plays a vital role in glycogen metabolism, via 
the phosphorylation and inactivation of glycogen synthase (Embi et al., 1980). The two 
known isoforms, GSK-3α and GSK-3β, also regulate various cellular processes such as 
survival and apoptosis (Frame & Cohen, 2001; Song et al., 2009). Phosphorylation of 
GSK-3β at Ser9 by Akt results in its inactivation (Cross et al., 1995). Inactivation of GSK-
3β plays a key role in the cardioprotection afforded by various pharmacological agents in 
the setting of I/R injury. Yin and colleagues demonstrated that adrenomedullin protects 
against apoptosis-induced by I/R injury through activation of an Akt-GSK-3-caspase 
signalling pathway (Yin et al., 2004). The cardioprotection afforded by bradykinin is  
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associated with modulation of mPTP opening secondary to inhibition of GSK-3β, via 
activation of the PI3K/Akt pathway (Park et al., 2006). Intermedin-mediated 
cardioprotection in I/R injury is also associated with inhibition of the mitochondrial-
mediated myocardial apoptosis, secondary to activation of the Akt/ GSK-3β signalling 
pathway (Song et al., 2009). I clearly show in this chapter that ARS activates the 
PI3K/Akt pathway resulting in the phosphorylation of GSK-3β at Ser9. 
 NF-κB is a downstream target of GSK-3β, as this kinase regulates the activation 
of NF-κB at the level of the transcriptional complex (Hoeflich et al., 2000; Steinbrecher 
et al., 2005; Dugo et al., 2006). Under physiological conditions, NF-κB is found 
complexed with a family of inhibitory proteins in the cytoplasm known as I-κB 
(Baueuerle & Baltimore, 1988). Activation and, thus, liberation of NF-κB is a consequent 
step following the phosphorylation of IκB, which triggers its polyubiquitination and 
subsequent proteosomal degradation. Once liberated, NF-κB rapidly translocates to the 
nucleus, where it regulates inflammatory gene expression (Li & Stark, 2002). Inhibition 
of NF-κB by GSK-3β is a potential mechanism of cardioprotection (Gao et al., 2008). 
GSK-3β inhibition by 4-benzyl-2-methyl-1, 2, 4-thiadiazolidine-3, 5-dione (TDZD-8) 
conferred cardioprotection in rats undergoing 30 min ischaemia followed by 6 h 
reperfusion, an effect associated with inhibition of NF-κB. Recently, Collino and 
colleagues demonstrated GSK-3β inhibition with either insulin or TDZD-8 was 
associated with a significant reduction of the nuclear NF-κB activity, in diabetic rats 
subjected to I/R injury (Collino et al., 2009). Blockade of NF-κB activation by NF-κB 
decoys (Morishita et al., 1997; Sawa et al., 1997), non-anticoagulant heparin (Thourani 
et al., 2000), a vitamin E-like antioxidant (Altavilla et al., 2000), and pyrrolidine 
dithiocarbamate (Muller et al., 2000) have been reported to attenuate myocardial I/R 
injury and to improve cardiac functional recovery (Sawa et al., 1997). I demonstrate in 
this chapter that treatment with ARS prevents the translocation of the p65 subunit of NF-
κB from the cytosol to the nucleus. 
MAPK’s play a pivotal role in a diverse repertoire of biological process such as 
metabolism, survival and apoptosis (Rose et al., 2010). Members of the MAPK cascade 
have been implicated in regulating myocyte survival after I/R injury and oxidative stress 
(Lips et al., 2004). Indeed, ERK 1/2 signalling has been identified as one of the major 
components of the RISK pathway. As a result, many investigators have shown that 
activation of the ERK pathway by various stimuli leads to cardioprotection during  
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reperfusion. Inhibition of ERK signalling was demonstrated to increase daunomycin-
induced apoptosis in cultured neonatal rat cardiomyocytes, whereas p38 MAPK is 
involved in the induction of cardiomyocyte apoptosis (Zhu et al., 1999). Treatment of 
isolated hearts with the MAPK/ERK kinase inhibitor PD98059 prior to global 
ischaemia/reoxygenation attenuated functional recovery and, hence, worsened I/R injury 
caused (Yue et al., 2000). Lips and colleagues demonstrated that although ERK 1 
nullizygous gene-targeted mice were resistant to I/R injury, ERK 2+/- gene-targeted mice 
exhibited enhanced infarction areas, suggesting ERK 2 signalling is a vital as a mediator 
of cardioprotection (Lips et al., 2004). Furthermore, more recently, a study by Lee and 
colleagues demonstrated ARS to attenuate the LPS-induced inflammatory response in 
microglial BV2 cells via activation of ERK 1/2 (Lee et al., 2012). Using a specific ERK 
1/2 inhibitor, U0126, I show that activation of this pathway is vital in the cardioprotection 
conferred by ARS. Activation of this pathway is also shared with the IPC-induced 
cardioprotection. 
The activation of the SAFE pathway which, comprise of TNF-α and STAT3 as 
the key players is now a well-recognised independent ‘RISK-free’ pathway conferring 
protection in ischaemic pre- and postconditioning (Lecour et al., 2005; Suleman et al., 
2008; Lacerda et al., 2009). STAT3 is a latent transcription factor, originally identified 
as a mediator of cytokine signalling (Kishimto et al., 1994), is now known to play a role 
in various cell functions from proliferation (Shirogane et al., 1999), differentiation 
(Minami et al., 1996; Nakajima et al., 1996) to survival (Catlett-Falcone et al., 1999; 
Bromberg et al., 1999). Oshima and colleagues demonstrated using cardiac-specific 
transgenic mice expressing constitutively active STAT3 and exposed to I/R injury to 
exhibit a dramatic reduction in infarct size when compared with non-transgenic 
littermates (Oshima et al., 2005). Recently, it was shown that sphingosine-1 phosphate-
induced reduction in myocardial infarct size was dependent on STAT3 and Akt activation 
(Somers et al., 2012). I demonstrate that there is a significant up-regulation in STAT3 
activation in hearts that were subjected to transient I/R and treated with ARS when 
compared to control animals. 
Is ARS itself the active component? or does it function as an i.v. injectable pro-
drug, which is converted to an active metabolite? Studies have shown that ARS becomes 
rapidly hydrolysed in vivo to DHA, which is a common active metabolite (in malaria) 
shared by the artemisinin derivatives (White, 1994). Intravenous ARS has a half-life of  
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less than 15 min in man, as it is metabolised through esterase-catalysed hydrolysis to 
DHA (Gautam et al., 2009). This conversion occurs rapidly following i.v. administration, 
indicated by the swift decline in ARS concentrations in the early post-dose period (Morris 
et al., 2011). DHA metabolism occurs through conjugation by the UDP-
glucuronosyltransferase system, with UGT1A9 and UGT2B7 being the main responsible 
isoforms (Llett et al., 2002). The metabolism of DHA occurs more slowly with an average 
half-life estimates for DHA following i.v. ARS administration of 1 – 2 h (Morris et al., 
2011). I showed that peak plasma concentrations of both ARS (39.7 ng ml-1) and DHA 
(223 ng ml-1) were achieved in the rat within 5 min of the injection of ARS. This 
demonstrates a very rapid conversion of ARS to DHA in the rat, and this metabolism was 
unaltered in rats subjected to myocardial I/R. The peak plasma concentrations seen here 
in the sham treated rats are much lower than those exhibited in healthy human volunteers, 
whereby, a similar dose of ARS (1 mg kg-1) resulted in a peak plasma concentration of 
ARS and DHA of around 6128 ng ml-1 and 800 ng ml-1 , respectively (Li et al., 2009).  
The efficacy of ARS in malaria has been attributed to i) attaining a high rapid initial Cmax, 
and ii) its swift hydrolysis to DHA (Batty et al., 1998; Navaratnam et al., 2000; Li et al., 
2009). This could mean that DHA is more potent than ARS in malaria and potentially 
other conditions. I show here that a dose of 0.1 mg kg-1 or DHA caused a significant 
reduction in infarct size, while the same dose of ARS was not effective. This indicates 
that DHA is the effective mediator of the cardioprotective effects of ARS (although I 
cannot exclude that ARS has at least some cardioprotective effects in its own right).   
 
Limitations of the study 
A major limitation of my study was the method of quantifying the infarct size. In this 
study the tetrazolium method (NBT stain) was used to determine the infarct size of 
various animal groups. This method although is widely considered a low cost, easily 
performed, reliable and reproducible method (Csonka et al., 2010), I found was not only 
very time consuming but due to the fact that at time visual interpretation of heart pieces 
may be subjective in cases of poor viable/non-viable contrast, it made the process quite 
laborious. Due to the fact that measuring the infarct size for each animal consumed over 
an hour, I was limited to performing myocardial infarction surgery on 4 a time. This, in 
addition to the time limitation I had I not only couldn’t increase the n number for certain 
study groups but also couldn’t perform extra experiments for certain study groups such 
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as determining the effect of ARS alone in sham treated animals. Although I don’t expect 
there to be any adverse effect of ARS in sham treated animals, since various studies done 
on healthy human volunteers using the same dose I have here, have demonstrated that 
ARS was well tolerated, exhibiting no adverse effects including no deleterious 
haemodynamic or ECG effects (Li et al., 2009; Miller et al., 2012). Nevertheless, as part 
of good experimental practice, it is always vital to include sham groups treated with drug 
just to confirm that the drug doesn’t have adverse effects besides those effects that you 
are measuring in your study. 
 
Conclusion  
I report here for the first time that the administration of ARS at the onset of 
reperfusion attenuates the myocardial injury associated with I/R. The observed beneficial 
effects of ARS are associated with i) activation of the PI3K/Akt/ERK 1/2 (RISK) 
pathway, ii) activation of eNOS, iii) inhibition of GSK-3β, iv) inhibition of NF-ĸB, and 
v) activation of the STAT3 (SAFE) pathway. Thus, ARS may represent a novel highly 
translatable approach for the therapy of acute MI in man.  
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General Discussion 
 
 
 
 
 
 
 
 
5.1 Overview 
Protein kinases have long been integrated in various signal transduction pathways 
to help regulate cardiac function in both health and disease. Not only are they involved in 
maintaining cardiac function, there is strong evidence that the PI3K/Akt pathway 
mediates cardioprotection. Indeed, decreased myocardial Akt activation is characteristic 
of sepsis, and prevention of Akt activation ameliorates cardiovascular dysfunction (Ha et 
al., 2008). In addition, activation of PI3K/Akt by ischaemic preconditioning (Li et al., 
2011) or with the use of pharmacological agents such as insulin (Baines et al., 1999) or 
erythropoietin (EPO) (Kim et al., 2008) is crucial for salvaging the ischaemic/reperfused 
myocardium. 
The research presented here has explored this common cardioprotective pathway, 
namely the PI3K/Akt pathway, in animal models of sepsis-induced cardiac dysfunction 
and acute myocardial I/R injury, respectively, utilising two clinically established 
pharmacological agents, namely EPO and artesunate (ARS). The main findings of this 
thesis are: 
i. A 24 h model of CLP was set up in aged (8 months old) C57BL/6 mice, employing 
fluid resuscitation and antibiotic therapy at 6 h and 12 h post-surgery. In contrast 
to the young mice (2 months old), the aged mice exhibited a reproducible degree 
of renal dysfunction, liver injury and most notably cardiac dysfunction. Thus, it 
was evident that susceptibility to develop cardiac dysfunction increased with age 
(chapter 2). 
ii. Subsequently, the study to investigate the effect of EPO on cardiac dysfunction 
was carried out in a model of endotoxaemia in young mice and polymicrobial 
sepsis in aged mice. I demonstrated for the first time that administration of EPO 
(1000 IU kg-1) 1 h post endotoxaemia or CLP improved cardiac contractility, 
measured by improvements in echocardiographic parameters (EF, FS and FAC), 
an effect that was seen in both models, to a similar extent (chapter 3). 
This cardioprotective effect was associated with phosphorylation and, thus, 
activation of Akt, which led to; i) inhibition of the activation of GSK-3β and NF-
ĸB, ii) reduced expression of NF-ĸB driven gene transcription of pro-
inflammatory mediators such as IL-1β; and iii) phosphorylation and, subsequent 
activation of eNOS. All of these effects were secondary to activation of the EpoR- 
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βcR heterocomplex, as these effects of EPO were lost in βcR KO mice. 
Furthermore, the observed increases in EF afforded by EPO were not independent 
of changes in end-diastolic diameter and volume,   hence, diastolic relaxation was 
not affected by EPO (chapter 4).  
iii. Moreover, ARS an established antimalarial drug was used to investigate its effects 
in an acute model of myocardial I/R in the rat. I demonstrate for the first time that 
a single bolus of low dose ARS (1 mg kg-1) given at the time of reperfusion 
resulted in a significant and substantial reduction in myocardial infarct size. This 
cardioprotective effect of ARS was associated with the activation of the PI3K/Akt 
and ERK 1/2 (RISK pathway) and STAT-3 (SAFE pathway) (chapter 4). The 
involvement of the PI3K/Akt pathway in this effect was confirmed by using a 
pharmacological inhibitor against PI3K with western blot analysis detecting 
phosphorylated Akt at Ser473. This correlates with various studies showing that 
pharmacological agents administered at the time of reperfusion as well as an 
ischaemic preconditioning stimulus confers cardioprotection by activation of the 
RISK pathway (Baines et al., 1999; Hausenloy et al., 2005; Kim et al., 2008). 
Specifically, I have demonstrated that the reduction in infarct size observed 
following treatment with ARS was associated with activation of i) Akt which led 
to inhibition of the activation of GSK-3β and NF-ĸB and activation of eNOS and 
ii) activation of ERK 1/2.  Additionally, western blot analysis probing for the 
phosphorylation and thus activation of STAT-3 at Tyr705 confirmed that activation 
of this pathway is necessary for the cardioprotective effects of ARS in this model 
(chapter 5). 
Furthermore, the studyshows that ARS is rapidly metabolised in the rat to DHA, 
and that this metabolism is not affected by myocardial I/R. This supports the 
notion that DHA is the active metabolite of many artemisinin derivatives. Indeed, 
injection of DHA (0.1 mg kg-1) at the start of reperfusion does reduce infarct size 
while a similar dose of ARS did not.  
 
5.2  A need for a new model?  
Most existing animal models provide at best a crude approximation of human 
sepsis as most fail to take into account that the outcome in the clinical setting is generally  
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influenced by various factors such as genetic background, therapeutic interventions and 
therapeutic care, age and pre-existing conditions. Indeed, it is evident that many 
therapeutic interventions after being tested in in vitro and in vivo studies in both healthy 
animals and animal models of disease have failed to translate to human subjects, 
highlighting the urgent need for an improved, more representative sepsis model, which 
can help expedite this process. The involvement of various responses ranging from 
inflammatory to coagulation in the sepsis-induced response underlay the rationale for the 
mediator-modulating approach which, dominated the development of new therapies for 
sepsis (Cohen, 2002; Marshall, 2003). Examples include targeting ad blocking the early 
pro-inflammatory cytokine TNF-α and the modulation of NO production. Prophylactic 
administration of anti-TNF-α monoclonal antibody protected Gram-negative bacteraemic 
baboons against hypotension, organ failure and death (Tracey et al., 1987) and 
endotoxaemic mice against the lethal effects of endotoxaemia (Beutler et al., 1985), 
respectively. Likewise, administration of monoclonal anti-TNF-α in various studies 
conferred protection when given as a treatment post bacterial insult (Hinshaw et al., 1990; 
Hinshaw et al., 1992; Hinshaw et al., 1994). Subsequently, clinical trials followed which 
proved to either be without success (Buras et al., 2005) or were halted early due to harm 
(Fisher et al., 1996). With the association of excess NO production as a vital player in the 
pathogenesis of vascular hyporeactivity and septic shock came along efforts which not 
only showed a raise in blood pressure (Kilbourn et al., 1990; Nava et al., 1991), but also 
an increase in mortality (Cobb et al., 1992, Fukatsu et al., 1996, Strand et al., 1997) in 
various animal models. Nevertheless, a multi-center double-blind study of a nonspecific 
NO synthase inhibitor, N(G)-mono-methyl-l-arginine (546C88) to septic shock patients, 
led to termination of a phase III study due to increased mortality (Lopez et al, 2004). 
These are just two of many examples, which were tried and tested in experimental models 
before being implemented in clinical trials unsuccessfully. So why the disparity? Possible 
explanations include timing and dosage of intervention and diseases severity (Buras et 
al., 2005). Although the time of onset in patients is often unknown with patients 
presenting in hospital with a clinically manifest sepsis state after days have elapsed, the 
majority of animal models receive therapeutic intervention either before or within a few 
hours of the microbial or toxin insult (Dyson & Singer, 2009). Sepsis is characterised by 
a pro-inflammatory phase followed by a compensatory anti-inflammatory response and 
immunosuppression, with the latter increasing the susceptibility of critically ill patients  
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to nosocomial infection (Hotchkiss & Karl, 2003). Thus, not only does targeting early 
pro-inflammatory mediators such as TNF-α provide only a small window of opportunity 
for therapeutic intervention, but also controlling the extent of inhibition is vital as many 
of these mediators play central roles in host defence (Dyson & Singer, 2009).  
Furthermore, the role that dosing plays in the lack of translation from bench to bedside is 
seen in the NO synthase inhibitor in patients (Lopez et al., 2004). Although N (G)-mono-
methyl-l-arginine was titrated against blood pressure, the values attained were 
considerably higher than that achieved with catecholamines in the placebo group. 
Additionally, the increased survival demonstrated by the quartile of patients that received 
a low dose this NO synthase inhibitor compared to control patients was overshadowed by 
a resulting ‘opposite effect in survival (e.g. an increase in mortality)’ in patient group 
receiving moderate-to-high doses (Lopez et al., 2004). Moreover, the animal models of 
sepsis themselves are known to range in terms of complexity and degree of translation to 
the clinical setting. This can be attributable to various factors which, for simplicity could 
be divided into ‘variation between human and experimental animal populations’ i.e. 
choice of species and gender and ‘physiologic and pharmacologic support in animal 
models’ i.e. fluid resuscitation, antibiotics and analgaesia/anaesthesia (Dyson & Singer, 
2009) as well as gender and co-morbidities. 
I set about trying to improve and increase the clinical relevance of the CLP model 
to provide a better platform to test the drug of interest, EPO, in the treatment of sepsis-
induced cardiac dysfunction. It was evident that there was an increased susceptibility of 
C57BL/6 mice to develop a reproducible degree of renal dysfunction, liver injury and 
most notably cardiac dysfunction, with age.  This is in line with the clinical situation, as 
both incidence and severity of sepsis and septic shock increases in the older population 
(Girard et al., 2005). 
However, although I believe that having such a model, which employs a clinically 
feasible fluid resuscitation and antibiotics therapy strategy, is a step forward in cementing 
the translatable ability of using EPO for the treatment of cardiac dysfunction, it does not 
come without its limitation. Firstly, I only used male mice in this 24 h model, which is 
not akin to the clinical setting, where 40 % of septic patients are female (Wichmann et 
al., 2000).  In addition, it is estimated that more than 50 % of septic patients present with 
at least one co-morbid condition (Moss, 2005), influencing outcome among both acutely 
ill patients (Knaus et al., 1991) and patients with sepsis (Pittet et al., 1993). Indeed, recent  
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investigators have reported that untreated type 1 and 2 diabetes exacerbates the sepsis-
induced inflammation and subsequent mortality in CLP (Osuchowski et al., 2010; Jacob 
et al., 2008). In addition, Doi and colleagues showed that pre-existing renal disease 
worsens outcome following CLP (Doi et al., 2008). 
Therefore, incorporating co-morbidity conditions into my current model is one 
approach by which mimicking clinical sepsis could be improved. Moreover, the mice 
utilised in this aged CLP model are inbred, a common model system used for various 
studies to help exclude the inter-subject variability, thus making results more 
reproducible. However, I do not believe that using only inbred mice is an accurate model 
for human conditions, whereby the population exhibits heterogeneity in terms of their 
septic response. Thus, for future experiments, it would be interesting to investigate the 
response of outbred mice undergoing the same approach I took in the CLP model 
described in this thesis. 
 
 
5.3 Cardioprotection by EPO 
Over the years, the use of EPO has gained momentum for its use as a 
cardioprotective agent, specifically in reducing injury of the heart following I/R (Calvillo 
et al., 2003; Cai et al., 2003; Sato et al., 2010). In addition, although EPO has been 
demonstrated to exhibit tissue protective effects in sepsis studies ranging from attenuation 
of acute kidney dysfunction (Coldewey et al., 2013) to improvement in skeletal muscle 
microcirculation (Kao et al., 2011) and  survival (Aoshiba et al., 2009), none have focused 
on exploiting the existing cardioprotective effects of EPO in a model of sepsis-induced 
cardiac dysfunction. I show for the first time that EPO’s cardioprotective effects do 
extend to protection against the cardiac dysfunction accompanying sepsis. It is imperative 
that this cardioprotective effect is dependent on activation of the proposed ‘tissue 
protective’ receptor as opposed to the haematopoietic receptor. Thus, targeting the EpoR-
βcR heterocomplex could be a potential therapeutic strategy to treat the cardiac 
dysfunction associated with sepsis. 
As with all studies, there are certain limitations, which need to be addressed and 
improved on. Firstly, the timing of drug administration currently stands as 1 h post 
endotoxaemia or CLP. Although treatment is given post insult, it can still be considered  
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as an early intervention, which can fail to translate effectively in the clinical setting 
whereby patients more often present with sepsis once the disease has progressed past the 
early stages. Thus, it would be natural to try and see if EPO still exhibits these 
cardioprotective effects when given at a much later time point following the induction of 
endotoxaemia or polymicrobial sepsis. A second limitation may be the potentially high 
dose of EPO used in this study, which, although is considered to be less than that used in 
many other clinical studies (Corwin et al., 2007; Napolitano et al., 2008). could lead to 
activation of the haematopoietic receptor and thereby, increase the risk of hypertension 
and/or thrombovascular events (Brines & Cerami, 2008). In its haematopoietic role, EPO 
circulates at concentrations in the low picomolar range (1–7 pmol L-1; reviewed in 
Jelkmann , 2007) and the afﬁnity of the homodimeric receptor for EPO is 100–200 pmol 
L-1 (Brines & Cerami, 2008). In contrast to its hormonal role, the local concentrations of 
EPO in its tissue-protective roles are higher and the affinity of the receptor lower (1-20 
nmol L-1) (Brines & Cerami, 2008), requiring a brief exposure to EPO to elicit a continual 
response. Thus, in order to achieve tissue-protective dose, higher doses of EPO are 
needed, as demonstrated by various studies (Abdelrahman et al., 2004; Kao et al., 2007; 
Mitra et al., 2007). Although this exceeds a minimum level required for tissue protection, 
the continued maintenance of serum levels above the haematopoietic range, 
administration of EPO clinically is typically associated with excessive production of 
erythrocytes (Brines & Cerami, 2008). Therefore, it is still strongly advisable to try and 
have an alternative way of separating EPO tissue protective effects from its 
haematopoietic effects.   
Taking the last point into account, it is clear that the translatable ability of EPO 
into clinical practice is hindered by the expected caution regarding the classic properties 
of EPO to stimulate red blood cell production and, thus, increase the risk of thrombosis. 
For instance, in a multi-center clinical trial, Corwin and colleagues demonstrated that 
critically ill trauma patients treated with EPO exhibited significant survival benefit at 29 
and 140 days and this effect was associated with an increase in clinically relevant 
thrombovascular events (Corwin et al., 2007). The desire to eliminate the ‘cross-talk’ 
between both the haematopoietic and tissue-protective systems when utilising exogenous 
EPO, prompted a search to develop molecules that would retain the tissue-protective 
properties of EPO, without stimulating erythropoiesis. Chemical modifications of EPO 
(e.g. carbamylated EPO) or the generation of peptides that mimic the structure of EPO 
have resulted in the generation of proteins/peptides that are tissue-protective, without 
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causing erythropoiesis. Pyroglutamate surface B helix peptide (pHBSP) is an 11-amino 
acid peptide, the structure of which, is modelled on the three-dimensional structure of 
helix B of EPO, has been shown to confer protection in models of haemorrhagic shock 
(Patel et al., 2011), renal I/R (Patel et al., 2012) and myocardial I/R (Ahmet et al., 2011) 
which, is an effect believed to be mediated via activation of the EpoR-βcR heterocomplex. 
Therefore, the next step would entail determining whether pHBSP, can confer 
cardioprotection in my model of CLP-induced cardiac dysfunction.   
  
5.4 Not just an antimalarial  
 Similar to EPO, ARS has over the years gone from being used just as an anti-
malarial agent to one that might be used under conditions where inflammation is required 
to be blocked (Xu et al., 2007; Lee et al., 2012). I demonstrate for the first time that ARS 
exhibits cardioprotective effects in an in vivo model of rat I/R. I believe that this is an 
exciting area to develop further, with the  potential of ARS to be translated into the clinical 
setting, as the doses used here to reduce myocardial I/R are lower than the doses used 
safely in patients with severe malaria (2.4 mg kg-1) (Dondorp et al., 2005; Dondorp et al., 
2010). I also show that either ARS or DHA can be administered at the time of reperfusion, 
which could indicate that ARS may be given as an adjunctive therapy to current 
reperfusion strategies such as thrombolysis and primary coronary angioplasty to provide 
further cardioprotection in the setting of an acute myocardial infarction. Moreover, with 
the strong evidence that pharmacological activation of pro-survival (e.g. PI3K/Akt) 
pathways at the time of reperfusion induces cardioprotection through the phosphorylation 
of various downstream effectors which, converge on the mitochondrial mPTP, the next 
step would be to investigate whether the ARS-induced activation of the RISK and SAFE 
pathway converges on the mPTP (Davidson et al., 2006; reviewed in Miura & Tanno, 
2012). Subsequently, although I have shown that ARS exhibits cardioprotective potential 
in an acute (2 h) model of myocardial I/R, I would also like to extend these observations 
to a recovery (chronic) model of regional myocardial I/R in order to elucidate whether 
the observed cardioprotective effect of ARS are sustained after longer reperfusion 
periods. This would also enable me to investigate the effect of ARS in infarct size 
(measured by histology) and on the functional impairment (evaluation by 
echocardiography) associated with myocardial infarction. 
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Conclusion 
This thesis set out to investigate the potential of EPO and ARS that have 
previously demonstrated efficacy in protecting different animal models of disease, in their 
role in activating a well-known survival pathway shown to confer cardioprotection in 
various models of cardiac injury/dysfunction. I believe that the work reported in this 
thesis i) advances our knowledge of the tissue protective effects of EPO to sepsis-induced 
cardiac dysfunction and ii) brings to light the novel use of an antimalarial agent in the 
protection against myocardial I/R injury. However, as mentioned above, the models used 
in these studies are not without imperfections and prior to commencing clinical trials, 
further experiments in large animal models of disease (sepsis and MI) ideally with co-
morbidities and clinically relevant pharmacological interventions (e.g. resuscitation and 
antibiotics in sepsis) are warranted. It should be noted that the MHRA has approved the 
data contained in this thesis together with the relevant background literature as ‘complete 
preclinical package’ for future phase II clinical trials aimed at evaluating the efficacy of 
ARS in patients with acute MI and other disorders (letter from MHRA to Prof C 
Thiemermann, October 2013). 
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Erythropoietin attenuates acute kidney dysfunction
in murine experimental sepsis by activation of
the b-common receptor
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The b-common receptor (bcR) plays a pivotal role in the
nonhematopoietic tissue-protective effects of erythropoietin
(EPO). Here we determined whether EPO reduces the acute
kidney injury (AKI) caused by sepsis and whether this effect is
mediated by the bcR. In young (2 months old) C57BL/6 wild-
type and bcR knockout mice, lipopolysaccharide caused a
significant increase in serum urea and creatinine, hence AKI.
This AKI was not associated with any overt morphological
alterations in the kidney and was attenuated by EPO given
1h after lipopolysaccharide in wild-type but not in bcR
knockout mice. In the kidneys of endotoxemic wild-type
mice, EPO enhanced the phosphorylation of Akt, glycogen
synthase kinase-3b, and endothelial nitric oxide synthase,
and inhibited the activation of nuclear factor-jB. All these
effects of EPO were lost in bcR knockout mice. Since sepsis is
more severe in older animals or patients, we tested whether
EPO was renoprotective in 8-month-old wild-type and bcR
knockout mice that underwent cecal ligation and puncture.
These older mice developed AKI at 24h, which was
attenuated by EPO treatment 1h post cecal ligation and
puncture in wild-type mice but not in bcR knockout mice.
Thus, activation of the bcR by EPO is essential for the
observed reduction in AKI in either endotoxemic young mice
or older mice with polymicrobial sepsis, and for the activation
of well-known signaling pathways by EPO.
Kidney International (2013) 84, 482–490; doi:10.1038/ki.2013.118;
published online 17 April 2013
KEYWORDS: acute kidney injury; cell signaling; erythropoietin; inflammation;
sepsis
Despite a substantially improved knowledge of the patho-
physiology of sepsis, the treatment of this condition is still
a clinical challenge. To date, therapies have been mostly
supportive and all specific therapeutic approaches, except
early administration of antibiotics and ‘early goal-directed
therapy,’1,2 have failed to be translated successfully into the
clinical setting. Hence, new pharmacological strategies are
urgently needed to improve this condition. ‘In sepsis, some
organs can escape relatively unscathed, whereas others
become affected both early and severely.’3 The kidney is one
such organ that can be affected early with the development of
acute kidney injury (AKI). This dysfunction is one of the
most frequent and serious complications of sepsis and septic
shock.4 According to the Acute Kidney Injury Network
consensus conference in 2007, AKI is diagnosed ‘as an abrupt
(within 48 hours) reduction in kidney function defined as
an absolute increase in serum creatinine (X26.4 mmol/l), a
percentage increase in serum creatinine (X1.5-fold from
baseline), or a reduction in urine output (p0.5ml/kg per h
for more than 6 h).’5 It is interesting to note that this defini-
tion does not take into consideration histological evidence of
tissue injury and is solely based on rise in creatinine or fall in
urinary output, even though the word ‘injury’ may imply the
existence of morphological evidence of injury.6
Interestingly, the incidence of AKI increases with the
severity of sepsis, occurring in 19% of patients with sepsis,
23% patients with severe sepsis, and 51% patients with septic
shock.7 Sepsis occurs more frequently and severely in older
patients8 and there is some evidence that the elderly septic
patient is more susceptible to the development of AKI.9
Similarly, in animal models of experimental sepsis, systemic
inflammation and the release of proinflammatory cytokines
are greater in older animals,10–12 and the severity of septic
bas i c re sea rch http://www.kidney-international.org
& 2013 International Society of Nephrology
Correspondence: Sina M. Coldewey or Christoph Thiemermann, Centre for
Translational Medicine and Therapeutics, William Harvey Research Institute,
Barts and The London School of Medicine & Dentistry, Queen Mary
University of London, Charterhouse Square, London, EC1M 6BQ, UK.
E-mail: s.m.coldewey@qmul.ac.uk or c.thiemermann@qmul.ac.uk
8These authors contributed equally to this work.
Received 1 July 2012; revised 24 December 2012; accepted 31 January
2013; published online 17 April 2013
482 Kidney International (2013) 84, 482–490
AKI was recently reported to be age dependent in female
mice.13 It has been proposed that the increase in the severity
of sepsis in aging animals is secondary to changes in gut
flora.14 Emerging evidence suggests that the pathogenesis of
septic renal dysfunction involves distinct mechanisms when
compared with a nonseptic etiology.15 There is evidence in
humans that AKI caused by sepsis is not associated (or at least
solely explained) with significant morphological changes
such as extensive tubular necrosis.6,16 The proposed
pathophysiological mechanisms of sepsis-associated AKI
include systemic vasodilatation, intrarenal vasoconstriction,
inflammation, and bioenergetics failure.6,7,15,17,18
The pleiotropic hormone erythropoietin (EPO) is known
to possess organ-protective properties that are independent
from its well-established hematopoietic effects.19 Endogenous
EPO is primarily produced by renal cortical fibroblasts, and
the fact that erythropoietin receptors (EPO-Rs) are expressed
in glomerular, endothelial, and tubular epithelial cells,20,21
suggests that endogenous EPO may function in a paracrine
manner to limit the extent of injury after a noxious stimulus.20
Furthermore, studies have proposed that the tissue-protective
effects of EPO are mediated through a ‘tissue-protective’
receptor that is pharmacologically distinct from the classical
hematopoietic EPO-R.22 This tissue-protective receptor is a
heterocomplex composed of EPO-R and the b-common
receptor (bcR) that exhibits a lower affinity for EPO.23 Over
the years, EPO has been shown to be protective in various
animal models of injury including cerebral ischemia,24,25
myocardial ischemia,26–28 and renal injury.29–31 Indeed, in a
model of bilateral renal artery occlusion in the rat, EPO
inhibits apoptotic cell death, promotes renal functional
recovery, and enhances tubular epithelial regeneration.20
It should be noted that the effects of EPO in sepsis-
induced AKI are controversial.32–37 Some studies report no
beneficial effect of EPO in models of endotoxemia in the rat or
pig.32,33 In contrast, other studies have shown that EPO exerts
beneficial effects in experimental sepsis. In 2007, Mitra et al.35
reported for the first time that pretreatment with EPO reduces
renal dysfunction in the mouse. Moreover, administration of
EPO given 1h after endotoxin or cecal ligation and puncture
(CLP) reduces renal dysfunction and mortality in mice.36 de
Souza et al.37recently reported their extensive investigation that
pre- or post-treatment with high-dose EPO (4000 IU/kg)
exhibited anti-inflammatory effects and improved survival as
well as renal function in a rat model of sepsis. However, none of
the above (positive) studies investigated the role of bcR in either
the observed effects or the signaling events initiated by EPO.
This study investigates the effects of EPO and, specifically, the
role of bcR in renal dysfunction caused by endotoxemia
(lipopolysaccharide (LPS)) or polymicrobial sepsis (CLP).
RESULTS
Effect of EPO on renal dysfunction in endotoxemic wild-type
and bcR knockout mice
EPO administration had no effect on serum urea and
creatinine levels of sham wild-type (WT) and bcR knockout
(KO) mice (Figure 1). When compared with sham mice
treated with saline, WT mice subjected to 18 h of endo-
toxemia demonstrated a significant increase in both serum
urea (7.3±0.27 vs. 33.1±1.75mmol/l, Po0.05; Figure 1a) and
serum creatinine (25.9±0.92 vs. 57.1±4.72mmol/l, Po0.05;
Figure 1c), indicating the development of AKI. Administration
of EPO significantly attenuated the rise in serum urea
(33.1±1.75 vs. 25.9±3.2mmol/l, Po0.05; Figure 1a) and
creatinine (57.1±4.72 vs. 38.2±2.47mmol/l, Po0.05;
Figure 1c). To investigate the role of bcR in LPS-induced
AKI for the beneficial properties of EPO reported above, we
have evaluated the effect of EPO on serum urea and creatinine
in bcR KO mice. When compared with sham bcR KO mice
treated with saline, bcR KO mice subjected to 18 h of
endotoxemia demonstrated a significant increase in serum
urea (8.3±0.55 vs. 33.0±1.94mmol/l, Po0.05; Figure 1b)
and creatinine (27.8±0.81 vs. 59.4±5.06mmol/l, Po0.05;
Figure 1d). Most notably, the renal dysfunction caused by
endotoxemia in bcR KO mice was not attenuated by EPO (urea
33.0±1.94 vs. 34±1.27mmol/l, P40.05; Figure 1b; creatinine
59.4±5.06 vs. 54.9±3.06mmol/l, P40.05; Figure 1d).
Effects of endotoxemia and/or EPO on renal morphology and
immunohistochemical staining for cleaved caspase-3 (CC-3)
and kidney injury molecule-1 (Kim-1)
To gain a better understanding of the mechanisms underlying
the observed renal dysfunction in endotoxemia, we carried
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Figure 1 | Effect of erythropoietin (EPO) on renal dysfunction
in endotoxemic wild-type (WT) and b-common receptor
(bcR) knockout (KO) mice. (a, b) Serum urea and (c, d) serum
creatinine were measured 18 h subsequent to sham operation or
lipopolysaccharide (LPS) administration. Mice received either LPS
(9mg/kg intraperitoneally (i.p.)) or vehicle (5ml/kg 0.9% saline i.p.). At
1 h after induction of endotoxemia, mice were treated with either
EPO (1000 IU/kg EPO subcutaneously (s.c.)) or vehicle (10ml/kg 0.9%
saline s.c.). (a, c; WT mice): shamþ saline (n¼ 3), shamþ EPO (n¼ 3),
LPSþ saline (n¼ 9), and LPSþ EPO (n¼ 10). (b, d; bcR KO mice):
shamþ saline (n¼ 3), shamþ EPO (n¼ 3), LPSþ saline (n¼ 9), and
LPSþ EPO (n¼ 20). Data are expressed as means±s.e.m. for n
number of observations. *Po0.05 vs. LPSþ saline of WT or KO
animals, respectively.
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out an extensive histological analysis in all experimental
groups. Evaluation by light microscopy (hematoxylin and
eosin staining) revealed that there was no overt morpholo-
gical evidence of proximal tubular epithelial cell injury,
interstitial edema, interstitial inflammation, vasculopathy,
or glomerular abnormality in any of the study groups
(Figure 2a–f). Therefore, the results of the hematoxylin and
eosin pathology evaluation produced no significant treat-
ment-related changes. To further investigate the potential role
of apoptosis in the observed renal dysfunction, we analyzed
all sections for the active fragment of caspase-3, which plays a
key role in apoptosis. Immunohistochemical analysis for CC-
3 revealed that CC-3 staining was characterized by generally
minimal or very minimal staining of individual or small
clumps of cells predominantly within the medulla, but
scattered positively stained cells were also visible throughout
the kidney within glomeruli/tubulointerstitial spaces and
blood vessels. Overall, we found no staining in sham-
operated animals and a small increase in staining in all
animals subjected to endotoxemia with no significant
treatment-related changes (P40.05, Figure 2g). To further
investigate the potential role of proximal tubular injury in
the observed renal dysfunction, we analyzed all sections for
Kim-1, an early biomarker of proximal tubular injury. Kim-1
staining was characterized by generally diffuse staining of
the whole kidney with positive staining presenting as areas
of multifocal to diffuse increased staining intensity within the
pars recta region of the kidney. Compared with sham WT
animals, evaluation of Kim-1 immunohistochemistry showed
slightly increased staining in the endotoxemic WT mice,
which appeared reduced after treatment with EPO. However,
the magnitude of changes was small. This evaluation was,
therefore, repeated by blind re-reading of groups by the
original study pathologist and by a second pathologist (data
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Figure 2 | Effects of endotoxemia and/or erythropoietin (EPO) on renal morphology (hematoxylin and eosin (HE) staining) and
immunohistochemical staining for cleaved caspase-3 (CC-3) and kidney injury molecule-1 (Kim-1). (a–f) Morphological evaluation
(HE staining) and immunohistochemistry (IHC)-based scoring of (g) CC-3 and (h) Kim-1 were performed in kidneys obtained from mice 18 h
after sham operation or lipopolysaccharide (LPS) administration. Mice received either LPS (9mg/kg intraperitoneally (i.p.)) or vehicle (5ml/kg
0.9% saline i.p.). At 1 h after induction of endotoxemia, mice were treated with either EPO (1000 IU/kg EPO subcutaneously (s.c.)) or vehicle
(10ml/kg 0.9% saline s.c.). (a–f) Evaluation of HE-stained specimens revealed that there was no overt morphological evidence of proximal
tubular epithelial cell injury, interstitial edema, interstitial inflammation, vasculopathy, or glomerular abnormality in any of the study groups
and no treatment-related changes could be observed. Wild-type (WT) mice: (a) shamþ saline (n¼ 4), (b) LPSþ saline (n¼ 3), and (c) LPSþ EPO
(n¼ 3). b-Common receptor (bcR) knockout (KO) mice: (d) shamþ saline (n¼ 4), (e) LPSþ saline (n¼ 4), and (f) LPSþ EPO (n¼ 4).
(g) Analysis of CC-3 sections revealed no staining in sham-operated animals and a small increase in staining in all animals subjected to
endotoxemia with no significant treatment-related changes in the CC-3 score (P40.05). (h) The results of the Kim-1 IHC pathology evaluation
showed slightly increased staining in the endotoxemic WT mice, which appeared reduced after treatment with EPO. There was no treatment-
related change in the bcR KO mice. Overall, none of the observed changes in Kim-1 IHC scores were statistically significant (P40.05).
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not shown) to confirm that there was indeed a small
difference. There was no treatment-related change in the
bcR KO mice. Overall, none of the observed changes in
Kim-1 immunohistochemistry were statistically significant
(P40.05; Figure 2h).
Effect of EPO on the phosphorylation of Akt, glycogen
synthase kinase-3b (GSK-3b), and endothelial nitric oxide
synthase (eNOS), and on the nuclear translocation of the
p65 nuclear factor (NF)-jB subunit in the kidneys of
endotoxemic WT and bcR KO mice
To gain a better insight into the potential mechanism(s)
underlying the observed beneficial effects of EPO, we
investigated the effects of this hormone on cell signaling
pathways in the kidneys of WT and bcR KO mice, known to
confer tissue protection or to inhibit inflammation. When
compared with kidneys of sham mice treated with saline,
kidneys of WT and bcR KO mice subjected to LPS
demonstrated no change in the total Akt content and
the phosphorylation of Akt on Ser473 (Figure 3a), total
GSK-3b content and the phosphorylation of GSK-3b on
Ser9 (Figure 3b), or total eNOS content and phosphory-
lation of eNOS on Ser1177 (Figure 3c). Treatment of
endotoxemic WT mice with EPO, however, resulted
in a substantial increase in the phosphorylation of serine
residues on Akt (Figure 3a), GSK-3b (Figure 3b), and
eNOS (Figure 3c). In contrast, administration of EPO to
endotoxemic bcR KO mice caused no change in the
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Figure 3 | Effect of erythropoietin (EPO) on the phosphorylation of Akt, glycogen synthase kinase-3b (GSK-3b), and endothelial nitric
oxide synthase (eNOS), and on the nuclear translocation of the p65 nuclear factor (NF-kB) subunit in the kidneys of wild-type (WT) and
b-common receptor (bcR) knockout (KO) mice with endotoxemia. Mice received either lipopolysaccharide (LPS; 9mg/kg intraperitoneally
(i.p.)) or vehicle (5ml/kg 0.9% saline i.p.). At 1 h after induction of endotoxemia, mice were treated with either EPO (1000 IU/kg EPO
subcutaneously (s.c.)) or vehicle (10ml/kg 0.9% saline s.c.). Each band is from a single western blot experiment that is representative of three
separate experiments. Data are expressed as means±s.e.m. for n number of observations. *Po0.05 versus LPSþ saline of WT or KO animals,
respectively (white bars). Po0.05 vs. LPSþ saline of WT or KO animals respectively (black bars). (a–c) Densitometric analysis of the bands
(semiquantitative western blot analysis) is expressed for all groups studied as relative optical density (OD) of (a) phosphorylated Akt (pSer473)
and the corresponding total Akt content (S Akt); (b) phosphorylated GSK-3b (pSer9) and the corresponding total GSK-3b content (S GSK-3b);
and (c) phosphorylated eNOS (pSer1177) and the corresponding total eNOS content (S eNOS). All values were corrected for the corresponding
b-actin and normalized using the related sham-operated band. (d) Densitometric analysis of the bands is expressed for all groups studied as
relative OD for NF-kB p65 subunit levels in both cytosolic and nuclear fractions normalized using the related sham-operated band.
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phosphorylation of Akt (Figure 3a), GSK-3b (Figure 3b), or
eNOS (Figure 3c).
When compared with kidneys from sham mice treated
with saline, the kidneys of endotoxemic WT and bcR KO
mice exhibited significant increases in the nuclear transloca-
tion of the p65 NF-kB subunit (Figure 3d), indicating the
activation of NF-kB. Treatment of endotoxemic WT mice
with EPO resulted in a significant reduction in nuclear trans-
location of p65 and, hence, inhibition of NF-kB activation in
the kidney (Figure 3d). In contrast, administration of EPO to
endotoxemic bcR KO mice did not attenuate the nuclear
translocation of p65 caused by LPS (Figure 3d).
Development of renal dysfunction in aging mice following
CLP
The development of renal dysfunction in our short and
severe model of polymicrobial sepsis via CLP is strongly
age dependent (Figure 4). Compared with sham-operated
animals (26.3±0.72 mmol/l), we could not determine a
significant renal dysfunction (determined by changes in
serum creatinine) 24 h after CLP in 2-month-old
(25.7±1.13 mmol/l) and 5-month-old (38.1±6.2 mmol/l)
WT mice that underwent CLP surgery. However, when
compared with sham-operated mice, 8-month-old WT
mice that underwent CLP surgery developed a significant
and reliable increase in serum creatinine (26.3±0.72 vs.
84.6±7.34 mmol/l, Po0.05).
Effect of EPO on renal dysfunction in WT and bcR KO mice
that underwent CLP
When compared with sham-operated WTmice, 8-month-old
WT and bcR KO mice that underwent CLP surgery
demonstrated a significant increase in serum creatinine
(WT mice 26.3±0.72 vs. 76.3±8.01 mmol/l, Po0.05,
Figure 5a; KO mice 23.2±6.44 vs. 82.1±11.77 mmol/l,
Po0.05, Figure 5b). Administration of EPO to septic WT
mice significantly attenuated the rise in serum creatinine
(76.3±8.01 vs. 49.9±6.54 mmol/l, Po0.05; Figure 5a). Most
notably, the creatinine increase caused by CLP in bcR KO
mice was not attenuated by EPO (creatinine 82.1±11.77 vs.
71.4±10.81 mmol/l, P40.05; Figure 5b).
Detection of Csf2rb mRNA expression in medulla and cortex
of the kidneys from WT sham mice
To gain a better insight into where the bcR was expressed in
the mouse kidneys, we determined the Csf2rb (encodes the
murine bcR) gene expression in cortex and medulla. We
could clearly detect the presence of bcR mRNA in both cortex
and medulla (Figure 6). Comparison of the consensus
sequence of our PCR product with the published Csf2rb
gene (accession no. NM_007780.4) revealed 100% sequence
identity.
DISCUSSION
Here we demonstrate that administration of 1000 IU/kg EPO
subcutaneously 1 h after LPS administration or CLP
attenuates AKI. Most notably, we describe for the first time
that the observed beneficial effects of EPO in WT mice
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Figure 4 | The development of renal dysfunction in aging mice
following cecal ligation and puncture (CLP). Serum creatinine
levels were measured 24 h subsequent to sham operation or CLP
surgery in wild-type (WT) mice at different ages (2, 5, and 8 months).
Data are expressed as means±s.e.m. for n number of observations.
*Po0.05 versus sham. Sham (2 months, n¼ 3); CLP (2 months, n¼ 3);
CLP (5 months, n¼ 5); and CLP (8 months, n¼ 10).
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Figure 5 | Effect of erythropoietin (EPO) on renal dysfunction in septic wild-type (WT) and b-common receptor (bcR) knockout (KO)
mice. Serum creatinine levels were measured 24 h subsequent to sham operation (no cecal ligation and puncture (CLP)) or CLP surgery
in (a) WT and (b) bcR KO mice. At 1 h after CLP surgery, mice were treated subcutaneously (s.c.) with either EPO (1000 IU/kg EPO s.c.) or vehicle
(10ml/kg 0.9% saline s.c.). (a; WT mice): shamþ saline (n¼ 3), shamþ EPO (n¼ 3), CLPþ saline (n¼ 10), and CLPþ EPO (n¼ 12). (b; bcR KO
mice): shamþ saline (n¼ 3), CLPþ saline (n¼ 6), and CLPþ EPO (n¼ 20). Data are expressed as means±s.e.m. for n number of observations.
*Po0.05 versus CLPþ saline of WT or bcR KO animals, respectively.
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subjected to either endotoxemia or sepsis were not observed
in mice that lacked bcR. In 2004, Brines et al.23 proposed
that the tissue-protective effects of EPO and its derivatives
might be mediated (at least in part) by the bcR functionally
associated with EPO-R generating an EPO-R/bcR
complex.38,39 The bcR is a signal transduction subunit that
is shared by the a-chain subunits of the interleukin-5, inter-
leukin-3, and granulocyte macrophage colony-stimulating
factor receptors.40 The a-chains are able to bind their ligand
with low affinity, but the heteroreceptors are not able to
signal in the absence of the bcR. On the other hand, the bcR
does not measurably bind a ligand by itself, but it amplifies a
signal once a ligand has bound.41,42 The bcR is not required
for erythropoiesis, as bcR KO mice have normal erythrocyte
maturation.23 In mice, bcR mRNA was expressed in both the
cortex and medulla of the kidney. Our finding that the
renoprotective effects of EPO in endotoxemia/sepsis are lost
in bcR KO mice supports our hypothesis that bcR is essential
for the beneficial effects of EPO in sepsis.
There is now increasing evidence that the renal dysfunc-
tion associated with sepsis in patients is secondary to
functional rather than structural changes.6,18 Although
some morphological abnormalities have been reported in
kidneys from patients who died from sepsis, these changes
were relatively small and are unlikely to account for the
profound renal dysfunction observed in these patients.18 For
instance, despite a high prevalence of AKI (65%) in 20
patients who died from sepsis, only one patient had evidence
of kidney necrosis, as reported by Hotchkiss et al.16
Furthermore, no renal tubular or glomerular cell apoptosis
was seen in any of these patients. Thus, renal histology did
not reflect the severity of renal injury indicated by the
observed decrease in kidney function.16 We show here that
mice subjected to endotoxemia for 18 h have a profound
renal dysfunction in the absence of overt morphological
alterations or even increases in biomarkers of apoptosis
(CC-3) or proximal tubular injury (Kim-1) in the kidney.
As EPO did not affect any of the above (minimal) signs of
injury, it is unlikely that the reduction in renal dysfunc-
tion afforded by EPO in sepsis is secondary to prevention of
renal injury.
What then are the signaling events that are activated
by EPO via the bcR? There is evidence that the beneficial
effects of EPO are secondary to the activation of the survival
kinase Akt.43–46 Akt is a member of the phosphoinositide
3-kinase signal transduction enzyme family that regulates
cellular activation, inflammatory responses, chemotaxis, and
apoptosis.47 When phosphorylated by its upstream regulator,
phosphoinositide-dependent kinase, Akt modulates cell
survival and growth.47 We document here that EPO causes
the activation of Akt in WT mice subjected to endotoxemia,
whereas the activation of this pathway by EPO was lost in
bcR KO mice. The above findings support the view that both
bcR and the activation of Akt are essential for the reported
beneficial effects of EPO.
What, then are the downstream targets of Akt? There is
good evidence that activation of Akt results in Ser9 phos-
phorylation of GSK-3b.48–50 GSK-3b is a serine–threonine
kinase that was originally recognized as a kinase that
phosphorylates glycogen synthase. In contrast to most other
kinases, GSK-3b is active in a resting cell state and is
regulated by multiple signaling pathways including the Akt
pathway that inhibits this kinase by causing Ser9 phos-
phorylation.48,49 Specific inhibitors of GSK-3b activation
attenuate the AKI caused by co-administration of LPS and
peptidoglycan51 and improve survival in endotoxemia.52
Agents that activate the PI3K/Akt pathway48 also inhibit
GSK-3b. We have previously reported that insulin activates
Akt, inhibits GSK-3b, and reduces AKI caused by LPS and
peptidoglycan.53 We report here that EPO enhances the
phosphorylation of the Ser9 residue of GSK-3b, resulting in
the inhibition of this kinase. This effect of EPO was lost
in bcR KO mice.
Downstream of GSK-3b, several studies have now
reported an association between GSK-3b and NF-kB activity
in vitro54,55 and in vivo.51,53 Treatment of tumor necrosis
factor-a-stimulated hepatocytes with a specific GSK-3b
inhibitor resulted in a decrease in the NF-kB-dependent
gene transcription.56 NF-kB is a transcription factor that
plays an important role in regulating expression of genes
encoding mediators of local and systemic inflammation, such
as cytokines, chemokines, cell adhesion molecules, apoptotic
factors, and others.57 The protective effects of inhibitors of
GSK-3b in endotoxemia/sepsis have been attributed to
inhibition of NF-kB secondary to either phosphorylation of
Ser536 on the p65 subunit of NF-kB51 or to prevention of the
association of cAMP response element-binding (CREB) with
p65.52 In addition, GSK-3b may also inhibit the activation of
Csf2rb
326 bp
1 2 3 4 5 6
WT sham
medulla
WT sham
cortex
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Figure 6 | Detection of Csf2rb gene expression in kidney medulla
and cortex. The Csf2rb gene encodes the mouse colony stimulating
factor 2 receptor b (bcR). Messenger RNA was extracted from medulla
or cortex of wild-type (WT) sham mice (n¼ 3) and subjected to
reverse transcription. PCR amplification of a Csf2rb gene fragment
and a fragment of the murine glyceraldehyde 3-phosphate
dehydrogenase (Gapdh) gene (mRNA extraction and gel loading
control) was performed using the cDNA from medulla or cortex of the
kidneys as template. When separated in a 1% agarose gel, amplicons
with a calculated molecular size of 326 bp for the Csf2rb fragment
could be detected for both kidney cortex (lanes 1–3) and medulla
(lanes 3–6). Intensity of the 175 bp Gapdh band in lanes 1 to 6
confirmed comparative loading of the gel.
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NF-kB by phosphorylating and degrading IkBa, which is
required to prevent NF-kB translocation.55 All of these effects
may contribute to the reported beneficial effects of inhibitors
of GSK-3b in sepsis. We report here that EPO prevents the
nuclear translocation of p65 and, hence, the activation of
NF-kB. This effect of EPO was lost in bcR KO mice. All of
the above findings support the view that EPO enhances the
activation of Akt, resulting in inhibition of GSK-3b and
inhibition of the activation of NF-kB in a bcR-dependent
manner.
In addition to inhibiting the activation of GSK-3b,
activation of Akt results in the phosphorylation of eNOS
on Ser1177, which in turn causes activation of eNOS, resulting
in an enhanced formation of NO in the microcirculation.
There is evidence that EPO enhances the phosphorylation of
serine residues on eNOS, resulting in its activation.37,58,59 In
endothelial cells, EPO caused eNOS activation, whereas
inhibition of EPO-R or bcR by neutralizing antibodies or
small interfering RNA abolished the EPO-induced NO
formation.59 Most notably, inhibition of the bcR abolished
the EPO-induced increase and the phosphorylation of eNOS,
Akt, Src, or Janus kinase 2.59 These findings support the view
that bcR plays a key role in the activation of eNOS by EPO in
endothelial cells.59 We report here that the increase in Ser1177
phosphorylation of eNOS by EPO in the kidney is lost in bcR
KO mice. While our study was underway, de Souza et al.37
also showed that the attenuation of sepsis-induced AKI by
EPO in the rat is associated with an increased expression
of eNOS and inhibition of the activation of NF-kB, which
the authors attributed to an anti-inflammatory and endo-
thelial protective effect. In line with this study, Rodrigues
et al.17 reported recently in the same animal model that
a 24-h pretreatment with continuous erythropoietin receptor
activator protected against sepsis-induced AKI at 24 h, which
was in part attributable to a suppression of the inflammatory
response. Interestingly, their results revealed that renal EPO-
R expression, which was downregulated in their model of
sepsis, was preserved by pretreatment with continuous
erythropoietin receptor activator.
In conditions associated with sepsis, activation of eNOS is
beneficial as the enhanced formation of NO causes local
vasodilation, inhibits adhesion of platelets and neutrophils,
and regulates angiogenesis.60,61 Agents that release NO or
enhance the formation of endogenous NO may attenuate
excessive intrarenal vasoconstriction and reduce renal dys-
function.62,63 Thus, activation of eNOS (possibly secondary
to activation of Akt) may contribute to the beneficial effects
of EPO reported here.
All of the above findings support the view that bcR is
essential for the following effects of EPO in mice with
endotoxemia: (1) reduction of AKI, (2) activation of Akt,
(3) activation of eNOS, (4) inhibition of GSK-3b, and
(5) inhibition of the activation of NF-kB.
In order to investigate whether the bcR is also essential for
the effects of EPO in polymicrobial sepsis, we developed a
model of CLP-induced AKI. We found that the degree of
renal dysfunction increased with the age of the animals. We
were unable to document a significant degree of AKI at 24 h
after CLP in young (2 and 5 months old) mice, whereas
8-month-old mice exhibited a very large increase in creati-
nine within 24 h after CLP. Most notably, administration of
EPO (1 h after CLP) attenuated the AKI caused by
polymicrobial sepsis in aging mice. In order to investigate
the role of the bcR in this effect of EPO, we bred aged-
matched bcR KO mice. Using these animals, we demonstrate
that the beneficial effects of EPO were lost in 8-month-old
bcR KO mice.
In conclusion, our findings show convincingly for the first
time that bcR is essential for EPO-mediated attenuation of
AKI in experimental sepsis as well as for all of the signaling
events traditionally associated with the well-documented
beneficial effects of EPO.
MATERIALS AND METHODS
Additional details on the methods are provided in the Supplemen-
tary Material online.
Animals
The animal protocols followed in this study were approved by the
local Animal Use and Care Committee in accordance with the
derivatives of both the Home Office guidance on the Operation of
Animals (Scientific Procedures Act 1986) published by Her Majesty’s
Stationary Office and the Guide for the Care and Use of Laboratory
Animals of the National Research Council. This study was carried
out on 73 male WT C57BL/6 mice (Harlan Laboratories, Wyton,
UK) and 73 male bcR KO mice (B6.129S1-Csf2rbtm1Cgb/J) on a C57/
BL-6J genetic background (bred and maintained at Queen Mary
University of London Biological Services Unit) receiving a standard
diet and water ad libitum. We employed young (2 months old) mice
for the model of endotoxemia and old (8 months old) mice for the
model of polymicrobial sepsis.
Endotoxemia
In the model of endotoxemia-induced AKI, 2-month-old mice
received either LPS (9mg/kg in 5ml/kg 0.9% saline intraperitone-
ally) or vehicle (5ml/kg 0.9% saline intraperitoneally). At 1 h after
induction of endotoxemia, mice were treated either with EPO
(1000 IU/kg recombinant human EPO in 10ml/kg 0.9% saline) or
vehicle (10ml/kg 0.9% saline subcutaneously). Sham mice were not
subjected to LPS injection, but were otherwise treated in the same
way. At 18 h, the experiment was terminated and kidney and blood
samples were collected for quantification of organ injury. WT mice
and bcR KO mice were randomly allocated into eight different
groups.
Polymicrobial sepsis
The detailed CLP procedure is described in the Supplementary
Material online. We evaluated the susceptibility of aging mice
(2, 5, and 8 months old) to develop AKI 24 h after CLP. Finally, we
established a model of severe polymicrobial sepsis in 8-month-old
male WT mice that developed reliable renal dysfunction 24 h after
CLP. This model was used to verify the effects of EPO on renal
function obtained in the model of endotoxemia following the same
treatment protocol.
488 Kidney International (2013) 84, 482–490
bas i c resea rch SM Coldewey et al.: EPO reduces septic AKI via the bcR
Quantification of organ injury
Blood and kidney samples were harvested at the end of the
experiment and processed as described in the Supplementary
Material online for evaluation of serum creatinine/urea, western
blot analysis, and histological evaluation (Supplementary Figure S1
online).
Western blot analysis
We assessed the degree of phosphorylation of Akt on Ser473, GSK-3b
on Ser9, eNOS on Ser1177, and the nuclear translocation of the p65
subunit of NF-kB. Semiquantitative western blot analysis was
carried out as described previously64 and outlined in detail in the
Supplementary Material online.
Csf2rbmRNA expression in the medulla and cortex of kidneys
from WT sham mice
Details are available in the Supplementary Material online.
Statistical analyses
All values described in the text and figures are presented as
mean±s.e.m. of n observations, where n represents the number of
animals studied. Statistical analysis was performed using GraphPad
Prism 5.0d (GraphPad Software, San Diego, CA). Data without
repeated measurements were assessed by one-way analysis of
variance followed by Dunnett’s post hoc test. A P-value of o0.05
was considered to be statistically significant.
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An abstract entitled ‘Erythropoietin reduces the acute kidney injury
in experimental sepsis via activation of the b-common receptor’ was
recently presented at the 35th Annual Conference on Shock in Miami.
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kidneys.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
REFERENCES
1. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the
treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:
1368–1377.
2. Rivers EP, Katranji M, Jaehne KA et al. Early interventions in severe sepsis
and septic shock: a review of the evidence one decade later.. Minerva
Anestesiol 2012; 78: 712–724.
3. Abraham E, Singer M. Mechanisms of sepsis-induced organ dysfunction.
Crit Care Med 2007; 35: 2408–2416.
4. Zarjou A, Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol
2011; 22: 999–1006.
5. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report
of an initiative to improve outcomes in acute kidney injury. Crit Care
2007; 11: R31.
6. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet 2012; 380:
756–766.
7. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004;
351: 159–169.
8. Girard TD, Opal SM, Ely EW. Insights into severe sepsis in older patients:
from epidemiology to evidence-based management. Clin Infect Dis
2005; 40: 719–727.
9. Yegenaga I, Hoste E, Van Biesen W et al. Clinical characteristics of patients
developing ARF due to sepsis/systemic inflammatory response
syndrome: results of a prospective study. Am J Kidney Dis 2004; 43:
817–824.
10. Turnbull IR, Wlzorek JJ, Osborne D et al. Effects of age on mortality
and antibiotic efficacy in cecal ligation and puncture. Shock 2003; 19:
310–313.
11. Turnbull IR, Clark AT, Stromberg PE et al. Effects of aging on the
immunopathologic response to sepsis. Crit Care Med 2009; 37:
1018–1023.
12. Saito H, Sherwood ER, Varma TK et al. Effects of aging on mortality,
hypothermia, and cytokine induction in mice with endotoxemia or sepsis.
Mech Ageing Dev 2003; 124: 1047–1058.
13. Maddens B, Vandendriessche B, Demon D et al. Severity of sepsis-induced
acute kidney injury in a novel mouse model is age dependent.
Crit Care Med 2012; 40: 2638–2646.
14. Hyde SR, Stith RD, McCallum RE. Mortality and bacteriology of sepsis
following cecal ligation and puncture in aged mice. Infect Immun 1990;
58: 619–624.
15. Chvojka J, Sykora R, Karvunidis T et al. New developments in septic acute
kidney injury. Physiol Res 2010; 59: 859–869.
16. Hotchkiss RS, Swanson PE, Freeman BD et al. Apoptotic cell death in
patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med
1999; 27: 1230–1251.
17. Rodrigues CE, Sanches TR, Volpini RA et al. Effects of continuous
erythropoietin receptor activator in sepsis-induced acute kidney injury
and multi-organ dysfunction. PLoS One 2012; 7: e29893.
18. Rudiger A, Singer M. Acute kidney injury. Lancet 2012; 380: 1904.
19. Patel NS, Collino M, Yaqoob MM et al. Erythropoietin in the intensive
care unit: beyond treatment of anemia. Ann Intensive Care 2011; 1: 40.
20. Johnson DW, Pat B, Vesey DA et al. Delayed administration of
darbepoetin or erythropoietin protects against ischemic acute renal
injury and failure. Kidney Int 2006; 69: 1806–1813.
21. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney
cells express functional erythropoietin receptors. Kidney Int 1999; 55:
808–820.
22. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that
are tissue protective but not erythropoietic. Science 2004; 305:
239–242.
23. Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates
tissue protection through an erythropoietin and common
beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004; 101:
14907–14912.
24. Bernaudin M, Marti HH, Roussel S et al. A potential role for erythropoietin
in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab
1999; 19: 643–651.
25. Wen TC, Sadamoto Y, Tanaka J et al. Erythropoietin protects neurons
against chemical hypoxia and cerebral ischemic injury by up-regulating
Bcl-xL expression. J Neurosci Res 2002; 67: 795–803.
26. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required
for erythropoietin-mediated acute protection against myocardial
ischemia/reperfusion injury. Circulation 2004; 109: 2050–2053.
27. Cai Z, Manalo DJ, Wei G et al. Hearts from rodents exposed to
intermittent hypoxia or erythropoietin are protected against
ischemia-reperfusion injury. Circulation 2003; 108: 79–85.
28. Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin
protects the myocardium from ischemia-reperfusion injury and
promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100:
4802–4806.
Kidney International (2013) 84, 482–490 489
SM Coldewey et al.: EPO reduces septic AKI via the bcR bas i c resea rch
29. Patel NS, Sharples EJ, Cuzzocrea S et al. Pretreatment with EPO reduces
the injury and dysfunction caused by ischemia/reperfusion in the mouse
kidney in vivo. Kidney Int 2004; 66: 983–989.
30. Sharples EJ, Patel N, Brown P et al. Erythropoietin protects the kidney
against the injury and dysfunction caused by ischemia-reperfusion.
J Am Soc Nephrol 2004; 15: 2115–2124.
31. Vesey DA, Cheung C, Pat B et al. Erythropoietin protects against
ischaemic acute renal injury. Nephrol Dial Transplant 2004; 19: 348–355.
32. Abdelrahman M, Sharples EJ, McDonald MC et al. Erythropoietin
attenuates the tissue injury associated with hemorrhagic shock and
myocardial ischemia. Shock 2004; 22: 63–69.
33. Solling C, Christensen AT, Nygaard U et al. Erythropoietin does not
attenuate renal dysfunction or inflammation in a porcine model of
endotoxemia. Acta Anaesthesiol Scand 2011; 55: 411–421.
34. Wu WT, Hu TM, Lin NT et al. Low-dose erythropoietin aggravates
endotoxin-induced organ damage in conscious rats. Cytokine 2010; 49:
155–162.
35. Mitra A, Bansal S, Wang W et al. Erythropoietin ameliorates renal
dysfunction during endotoxaemia. Nephrol Dial Transplant 2007; 22:
2349–2353.
36. Aoshiba K, Onizawa S, Tsuji T et al. Therapeutic effects of erythropoietin
in murine models of endotoxin shock. Crit Care Med 2009; 37:
889–898.
37. de Souza AC, Volpini RA, Shimizu MH et al. Erythropoietin prevents
sepsis-related acute kidney injury in rats by inhibiting NF-kappaB and
upregulating endothelial nitric oxide synthase. Am J Physiol Renal Physiol
2012; 302: F1045–F1054.
38. Hanazono Y, Sasaki K, Nitta H et al. Erythropoietin induces tyrosine
phosphorylation of the beta chain of the GM-CSF receptor. Biochem
Biophys Res Commun 1995; 208: 1060–1066.
39. Jubinsky PT, Krijanovski OI, Nathan DG et al. The beta chain of the
interleukin-3 receptor functionally associates with the erythropoietin
receptor. Blood 1997; 90: 1867–1873.
40. Murphy JM, Young IG. IL-3, IL-5, and GM-CSF signaling: crystal structure
of the human beta-common receptor. Vitam Horm 2006; 74: 1–30.
41. Stomski FC, Woodcock JM, Zacharakis B et al. Identification of a Cys motif
in the common beta chain of the interleukin 3, granulocyte-macrophage
colony-stimulating factor, and interleukin 5 receptors essential for
disulfide-linked receptor heterodimerization and activation of all three
receptors. J Biol Chem 1998; 273: 1192–1199.
42. Carr PD, Gustin SE, Church AP et al. Structure of the complete
extracellular domain of the common beta subunit of the human GM-CSF,
IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell 2001;
104: 291–300.
43. Burger D, Xenocostas A, Feng QP. Molecular basis of cardioprotection by
erythropoietin. Curr Mol Pharmacol 2009; 2: 56–69.
44. Fliser D, Bahlmann FH, Haller H. EPO: renoprotection beyond anemia
correction. Pediatr Nephrol 2006; 21: 1785–1789.
45. Sanghera KP, Mathalone N, Baigi R et al. The PI3K/Akt/mTOR pathway
mediates retinal progenitor cell survival under hypoxic and superoxide
stress. Mol Cell Neurosci 2011; 47: 145–153.
46. Brines M, Cerami A. Emerging biological roles for erythropoietin in the
nervous system. Nat Rev Neurosci 2005; 6: 484–494.
47. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:
1655–1657.
48. Cross DA, Alessi DR, Cohen P et al. Inhibition of glycogen synthase
kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:
785–789.
49. Moule SK, Welsh GI, Edgell NJ et al. Regulation of protein kinase B
and glycogen synthase kinase-3 by insulin and beta-adrenergic
agonists in rat epididymal fat cells. Activation of protein kinase B by
wortmannin-sensitive and -insensitive mechanisms. J Biol Chem 1997;
272: 7713–7719.
50. Hurel SJ, Rochford JJ, Borthwick AC et al. Insulin action in cultured human
myoblasts: contribution of different signalling pathways to regulation of
glycogen synthesis. Biochem J 1996; 320(Pt 3): 871–877.
51. Dugo L, Collin M, Allen DA et al. GSK-3beta inhibitors attenuate the organ
injury/dysfunction caused by endotoxemia in the rat. Crit Care Med
2005; 33: 1903–1912.
52. Martin M, Rehani K, Jope RS et al. Toll-like receptor-mediated cytokine
production is differentially regulated by glycogen synthase kinase 3.
Nat Immunol 2005; 6: 777–784.
53. Dugo L, Collin M, Allen DA et al. Insulin reduces the multiple organ injury
and dysfunction caused by coadministration of lipopolysaccharide and
peptidoglycan independently of blood glucose: role of glycogen
synthase kinase-3beta inhibition. Crit Care Med 2006; 34: 1489–1496.
54. Hoeflich KP, Luo J, Rubie EA et al. Requirement for glycogen synthase
kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406:
86–90.
55. Takada Y, Fang X, Jamaluddin MS et al. Genetic deletion of glycogen
synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK,
Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor
necrosis factor. J Biol Chem 2004; 279: 39541–39554.
56. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in
TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes.
Am J Physiol Gastrointest Liver Physiol 2002; 283: G204–G211.
57. Senftleben U, Karin M. The IKK/NF-kappa B pathway. Crit Care Med 2002;
30: S18–S26.
58. Kao RL, Martin CM, Xenocostas A et al. Erythropoietin improves skeletal
muscle microcirculation through the activation of eNOS in a mouse
sepsis model. J Trauma 2011; 71: S462–S467.
59. Su KH, Shyue SK, Kou YR et al. beta Common receptor integrates the
erythropoietin signaling in activation of endothelial nitric oxide synthase.
J Cell Physiol 2011; 226: 3330–3339.
60. Khan R, Kirschenbaum LA, LaRow C et al. Augmentation of platelet
and endothelial cell eNOS activity decreases sepsis-related neutrophil-
endothelial cell interactions. Shock 2010; 33: 242–246.
61. Tyml K. Critical role for oxidative stress, platelets, and coagulation in
capillary blood flow impairment in sepsis. Microcirculation 2011; 18:
152–162.
62. Lopez-Neblina F, Paez AJ, Toledo AH et al. Role of nitric oxide in ischemia/
reperfusion of the rat kidney. Circ Shock 1994; 44: 91–95.
63. Kwon O, Hong SM, Ramesh G. Diminished NO generation by injured
endothelium and loss of macula densa nNOS may contribute to sustained
acute kidney injury after ischemia-reperfusion. Am J Physiol Renal Physiol
2009; 296: F25–F33.
64. Collino M, Aragno M, Mastrocola R et al. Oxidative stress and
inflammatory response evoked by transient cerebral ischemia/
reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol
Med 2006; 41: 579–589.
490 Kidney International (2013) 84, 482–490
bas i c resea rch SM Coldewey et al.: EPO reduces septic AKI via the bcR
INTRODUCTION
Erythropoietin (EPO) is widely used for the treatment of anemia
in patients (Drüeke et al., 2006). However, during the past two
decades, our understanding of the actions of EPO has shifted from
a belief that the hormone acts exclusively on erythroid progenitor
cells to the knowledge that this agent exerts significant protection
in conditions such as myocardial ischemia-reperfusion (Calvillo et
al., 2003) and haemorrhagic shock (Abdelrahman et al., 2004), and
improves survival in sepsis (Aoshiba et al., 2009). The beneficial
effects of EPO are allegedly mediated by a putative ‘tissue-protective
receptor’ that is distinct from the ‘classical’ EPO receptor (EpoR)
known to mediate erythropoiesis (Leist et al., 2004). This receptor
has been proposed to be a heteromer between the EPO receptor
and the β-common receptor (βcR; also called CD131) (Brines et
al., 2004). βcR is a common subunit of other heteroceptors,
including those of interleukin (IL)-3, IL-5 and granulocyte-
macrophage colony stimulating factor (Murphy and Young, 2006).
The ‘tissue-protective receptor’ specifically binds to EPO with a
lower affinity than does the classical EpoR (Masuda et al., 1993).
Indeed, Brines et al. were able to demonstrate cellular colocalization
of EPO, βcR and EpoR in spinal cord neurons and cardiomyocytes
(Brines et al., 2004). Furthermore, the structural importance of an
interaction between EPO and βcR was first highlighted by Sautina
et al. (Sautina et al., 2010); however, the clinical implication of this
in sepsis is unknown.
Sepsis, the systemic inflammatory response syndrome to
infection, has high incidence and mortality rates around the world
(Fernandes and Cesar de Assuncao, 2012; Rudiger and Singer, 2007).
Myocardial dysfunction is a recognized manifestation of sepsis and
septic shock, with myocardial depression occurring in almost 40-
50% of patients (Rudiger and Singer, 2007). Contractile dysfunction
is characterized by biventricular dilatation, blunted blood pressure
response to intravenous fluids, a reversible reduction in ejection
fraction (EF) and a diminished ability to augment cardiac output
despite increased levels of circulating catecholamines (Flynn et al.,
2010; Hoesel et al., 2007). Various mechanisms have been proposed
for this myocardial dysfunction, including excessive cardiac
inflammation (Merx and Weber, 2007), mitochondrial dysfunction
(Suliman et al., 2004; Watts et al., 2004), cardiac cell death by
apoptosis or necrosis (Sharma, 2007), impaired contractility
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SUMMARY
There is limited evidence that the tissue-protective effects of erythropoietin are mediated by a heterocomplex of the erythropoietin receptor and
the β-common receptor (‘tissue-protective receptor’), which is pharmacologically distinct from the ‘classical’ erythropoietin receptor homodimer
that is responsible for erythropoiesis. However, the role of the β-common receptor and/or erythropoietin in sepsis-induced cardiac dysfunction (a
well known, serious complication of sepsis) is unknown. Here we report for the first time that the β-common receptor is essential for the improvements
in the impaired systolic contractility afforded by erythropoietin in experimental sepsis. Cardiac function was assessed in vivo (echocardiography)
and ex vivo (Langendorff-perfused heart) in wild-type and β-common receptor knockout mice, that were subjected to lipopolysaccharide (9 mg/kg
body weight; young mice) for 16-18 hours or cecal ligation and puncture (aged mice) for 24 hours. Mice received erythropoietin (1000 IU/kg body
weight) 1 hour after lipopolysaccharide or cecal ligation and puncture. Erythropoietin reduced the impaired systolic contractility (in vivo and ex vivo)
caused by endotoxemia or sepsis in young as well as old wild-type mice in a β-common-receptor-dependent fashion. Activation by erythropoietin
of the β-common receptor also resulted in the activation of well-known survival pathways (Akt and endothelial nitric oxide synthase) and inhibition
of pro-inflammatory pathways (glycogen synthase kinase-3β, nuclear factor-κB and interleukin-1β). All the above pleiotropic effects of erythropoietin
were lost in β-common receptor knockout mice. Erythropoietin attenuates the impaired systolic contractility associated with sepsis by activation of
the β-common receptor, which, in turn, results in activation of survival pathways and inhibition of inflammation.
Erythropoietin attenuates cardiac dysfunction in
experimental sepsis in mice via activation of the 
β-common receptor
Areeg I. Khan1,*,‡, Sina M. Coldewey1,2,*, Nimesh S. A. Patel1, Mara Rogazzo3, Massimo Collino3, Muhammed M. Yaqoob4, 
Peter Radermacher5, Amar Kapoor1 and Christoph Thiemermann1,‡
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secondary to the generation of TNFα (Khadour et al., 2002) or
induction of inducible nitric oxide synthase (iNOS) (Khadour et
al., 2002; Barth et al., 2006). The effects of EPO in sepsis-induced
cardiac dysfunction are unknown.
This study investigates the effects of EPO and, specifically, the
role of βcR in the cardiac dysfunction associated with endotoxemia
[caused by lipopolysaccharide (LPS)] and polymicrobial sepsis
[caused by cecal ligation and puncture (CLP)]. Specifically, we have
investigated: (1) the effect that EPO has on the impairment of
systolic contractility (measured in vivo by echocardiography or ex
vivo in the isolated Langendorff-perfused heart) associated with
endotoxemia and polymicrobial sepsis using wild-type (WT)
C57BL/6 mice; (2) whether the effect of EPO is mediated through
the proposed tissue protective receptor, with the use of βcR
knockout (KO) mice; (3) the mechanisms underlying the observed
beneficial effects of EPO, including the phosphorylation of Akt on
Ser473, phosphorylation of glycogen synthase kinase-3β (GSK-3β)
on Ser9, phosphorylation of endothelial nitric oxide synthase
(eNOS) on Ser1177, activation of nuclear factor (NF)κB (measured
as nuclear translocation of p65) and expression of interleukin-1beta
(IL-1β). Because sepsis most frequently occurs in aging patients
(Girard et al., 2005), we then investigated the effects of EPO and
the role of βcR in aging animals with sepsis.
RESULTS
Effect of EPO on cardiac dysfunction in endotoxemic WT mice
assessed by echocardiography and the isolated Langendorff-
perfused heart
To investigate the effect that EPO has on the cardiac dysfunction
caused by LPS, left ventricular (LV) function was assessed using
echocardiography in WT mice, 18 hours after administration of
vehicle or LPS. We saw no differences in LV dimensions {left
ventricular internal-diastolic dimension [LVID(D)] and left
ventricular end-diastolic volume (LVEDV)} between the WT
groups (Table 1). Fig. 1A shows representative M-mode
echocardiograms of sham + vehicle, sham + EPO, LPS + vehicle,
and LPS + EPO in WT mice. When compared with sham + vehicle
mice, sham mice treated with EPO demonstrated no significant
alterations in percentage EF, fractional shortening (FS) or fractional
area of change (FAC) (P>0.05) (Fig. 1B-D). When compared with
sham mice, mice subjected to 18 hours of endotoxemia
demonstrated a significant reduction in percentage EF, FS and FAC
(P<0.05) (Fig. 1B-D), indicating impairment in systolic contractility
in vivo. Administration of EPO significantly attenuated the
impairment in systolic contractility associated with endotoxemia
(P<0.05) (Fig. 1B-D).
To investigate whether the impairment in systolic contractility
observed in vivo can be confirmed in an isolated Langendorff-
perfused heart ex vivo (under conditions of constant cardiac preload
or afterload), the alterations in isovolumic left ventricular developed
pressure (LVDP) were assessed in WT mice 16-18 hours after
administration of vehicle or LPS. Pressure-volume curves were
generated to assess alterations in LVDP in response to 5 μl
incremental intraventricular volume-balloon loading up to 40 μl
(Fig. 1E). When compared with sham mice, WT mice subjected to
LPS exhibited impairment in systolic contractility, measured as a
significant reduction in LVDP in response to 30 μl (maximum
response) volume loading (P<0.05) (Fig. 1E,F). Administration of EPO
to endotoxemic WT mice significantly attenuated the impairment
in systolic contractility at this volume load (P<0.05) (Fig. 1E,F).
Effect of EPO on cardiac dysfunction in endotoxemic βcR KO mice
assessed by echocardiography and the isolated Langendorff-
perfused heart
To investigate the role of the βcR subunit in the observed beneficial
properties of EPO reported above, we evaluated the cardioprotective
effects of EPO in βcR KO mice. We saw no differences in LV
dimensions between the KO groups with the exception of a significant
increase in LVID(D) between sham + vehicle and endotoxemic βcR
KO mice, which was not altered with the administration of EPO
(Table 1). Fig. 2A shows representative M-mode echocardiograms
of sham + vehicle, sham + EPO, LPS + vehicle, and LPS + EPO in
βcR KO mice. When compared with sham + vehicle mice, sham mice
treated with EPO demonstrated no significant alterations in EF, FS
and FAC (P>0.05) (Fig. 2B-D). When compared with sham βcR KO
dmm.biologists.org1022
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TRANSLATIONAL IMPACT
Clinical issue
Myocardial dysfunction occurs as a complication in almost 40-50% of sepsis
cases and is a major contributor to morbidity and mortality in these patients.
There are currently no specific therapeutic interventions available to treat this
condition. In the last decade, erythropoietin (EPO), a key player in
erythropoiesis, has emerged as a pleiotropic cytokine that protects against
tissue injury and dysfunction. Clinical trials have demonstrated the tissue-
protective role of EPO in various conditions, but the positive effects were
accompanied by significant adverse side effects. The beneficial effects of EPO
are thought to be mediated by a ‘tissue-protective receptor’ that is distinct
from the ‘classical’ erythropoiesis-associated receptor, EpoR. It has been
proposed that the tissue-protective receptor is a heteromer of EpoR together
with the β-common receptor (βcR). There is an urgent need to fully
understand the mechanisms underlying the tissue-protective role of EPO, to
facilitate the development of an effective and safe treatment for sepsis-
associated myocardial dysfunction.
Results
In this study, the effects of EPO on cardiac function were assessed in vivo and
ex vivo (using Langerdorff-perfused hearts) in mouse models of endotoxemia
and polymicrobial sepsis. EPO treatment improved systolic contractility in
young as well as aged mice with either condition. The observed beneficial
effects of EPO were shown to be associated with activation of well-known
survival pathways (Akt and endothelial nitric oxide synthase) and inhibition of
pro-inflammatory pathways (glycogen synthase kinase-3β, nuclear factor-κB
and interleukin-1β). Using βcR knockout mice, the authors demonstrated that
the effects of EPO are dependent on the presence of βcR.
Implications and future directions
This study demonstrates for the first time that activation of βcR by EPO is
essential for the observed improvement in systolic contractility afforded by
EPO treatment in endotoxemia or sepsis. Recently, it has been demonstrated
that chemically modified versions of EPO (e.g. carbamylated EPO) and peptides
that mimic the structure of EPO [e.g. pyroglutamate surface B helix peptide
(pHBSP)] show tissue-protective effects, but do not mediate erythropoiesis,
suggesting that these agonists are specific for the tissue-protective receptor.
These agonists potentially do not give rise to the complications associated
with EPO treatment, such as thrombosis or hypertension. In light of the data
presented here, targeting the βcR-EpoR heterocomplex with agonists such as
pHBSP might represent a novel, specific approach for the treatment of sepsis-
associated cardiac dysfunction. The clinical evaluation of the effects of EPO-like
agonists in conditions associated with tissue injury and inflammation is
eagerly awaited.
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mice, endotoxemia in βcR KO mice resulted in a significant reduction
in percentage EF, FS and FAC (P<0.05) (Fig.  2B-D), indicating
impairment in systolic contractility. Administration of EPO to
endotoxemic βcR KO mice did not alter this impairment in systolic
contractility (P>0.05) (Fig. 2B-D).
We sought to confirm these effects in the isolated Langendorff-
perfused heart. When compared with sham mice, βcR KO mice
subjected to LPS exhibited impaired systolic contractility, measured
as a significant reduction in LVDP in response to 30 μl (maximum
response) volume loading (P<0.05) (Fig. 2E,F). Administration of
EPO to endotoxemic βcR KO mice caused no significant change
in the impairment in systolic contractility associated with
endotoxemia (P>0.05) (Fig. 2E,F).
Effect of EPO on the phosphorylation of Akt, GSK-3β and eNOS in
the hearts of endotoxemic WT and βcR KO mice
In order to gain a better insight into the potential mechanism(s)
underlying the observed cardioprotective effects of EPO, we
investigated the effects of EPO on cell signalling pathways known
to confer tissue protection or to inhibit inflammation, by semi-
quantitative western blot analysis of the heart. When compared
with sham mice, WT and βcR KO mice subjected to LPS
demonstrated no change in the phosphorylation of Akt on Ser473
(P>0.05) (Fig. 3A), GSK-3β on Ser9 (P>0.05) (Fig. 3B) or eNOS on
Ser1177 (P>0.05) (Fig. 3C). Administration of EPO to endotoxemic
WT mice, however, resulted in a significant increase in the
phosphorylation of Akt on Ser473 (P<0.05) (Fig. 3A), GSK-3β on
Ser9 (P<0.05) (Fig. 3B) and eNOS on Ser1177 (P<0.05) (Fig. 3C).
In contrast, administration of EPO to endotoxemic βcR KO mice
caused no change in the phosphorylation of Akt on Ser473 (P>0.05)
(Fig. 3A), GSK-3β on Ser9 (P>0.05) (Fig. 3B) or eNOS on Ser1177
(P>0.05) (Fig. 3C).
Effect of EPO on the nuclear translocation of the p65 NFκB subunit
in the hearts of endotoxemic WT and βcR KO mice
When compared with hearts from sham mice, the hearts of
endotoxemic WT and βcR KO mice exhibited significant increases
in the nuclear translocation of the p65 subunit (P<0.05) (Fig. 3D),
indicating activation of NFκB. Administration of EPO to
endotoxemic WT mice significantly attenuated the increase in
nuclear translocation of p65 and, hence, inhibition of activation of
NFκB in the heart (P<0.05) (Fig. 3D). In contrast, administration
of EPO to endotoxemic βcR KO mice did not attenuate the nuclear
translocation of p65 caused by LPS (P>0.05) (Fig. 3D).
Effect of EPO on the expression of IL-1β in the hearts of
endotoxemic WT and βcR KO mice
When compared with hearts from sham mice, the hearts of
endotoxemic WT and βcR KO mice demonstrated a significant
increase in IL-1β expression (P<0.05) (Fig. 3E). Administration of
EPO to endotoxemic WT mice significantly attenuated IL-1β
expression (P<0.05) (Fig. 3E). In contrast, administration of EPO
to endotoxemic βcR KO mice caused no alteration in IL-1β
expression (P>0.05) (Fig. 3E).
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Table 1. Effect of EPO on echocardiographic parameters (diastolic function) in WT or βcR KO mice subjected to endotoxemia for 16-18 
hours or CLP for 24 hours 
Group Genotype LVID(D) (mm) LVEDV (μl) n 
Endotoxemia in 2-month-old mice 
Sham + vehicle WT 3.4±0.06 47±2.13 10 
Sham + EPO WT 3.1±0.14 39±4.34 6 
LPS + vehicle WT 3.6±0.07 54±2.60 15 
LPS + EPO WT 3.6±0.08 53±2.61 15 
Sham + vehicle KO 3.1±0.09* 39±2.91 9 
Sham + EPO KO 3.5±0.15 52±5.36 3 
LPS + vehicle KO 3.5±0.08 53±2.96 14 
LPS + EPO KO 3.5±0.07 53±2.65 25 
Polymicrobial sepsis in aged mice 
Sham + vehicle (8 months) WT 3.5±0.30 51±9.44 3 
Sham + EPO (8 months) WT 3.5±0.12 51±3.98 3 
CLP + vehicle (2 months) WT 3.5±0.08 51±2.61 5 
CLP + vehicle (5 months) WT 4.1±0.15 73±6.29 5 
CLP + vehicle (8 months) WT 3.9±0.09 68±3.55 9 
CLP + EPO (8 months) WT 3.8±0.13 62±5.03 10 
Sham + vehicle (8 months) KO 4.2±0.11 80±4.83 5 
Sham + EPO (8 months) KO 3.5±0.00 52±0.76 2 
CLP + vehicle (8 months) KO 3.8±0.12 64±4.24 7 
CLP + EPO (8 months) KO 4.1±0.14 74±6.05 7 
WT or βcR KO mice received either LPS (9 mg/kg i.p.) or vehicle (5 ml/kg 0.9% saline i.p.) or underwent CLP surgery. At 1 hour after induction of endotoxemia or CLP surgery, mice 
were treated either with EPO (1000 IU/kg s.c.) or vehicle (10 ml/kg 0.9% saline s.c.). All echocardiographic images were assessed for changes in LVID(D) and LVEDV. Data are 
expressed as means ± s.e.m. for n number of observations. *P<0.05 versus LPS + vehicle (KO). 
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Effect of EPO on cardiac dysfunction in WT and βcR KO mice that
underwent CLP
The murine model of CLP with fluid resuscitation and antibiotics
used in this study is regarded as a clinically relevant model of
abdominal polymicrobial human sepsis. We established an aged
model of polymicrobial sepsis-induced cardiac dysfunction, using
2-, 5- and 8-month-old mice, which demonstrated an age-
dependent decrease in systolic contractility (see supplementary
material Fig. S1). Therefore, 8-month-old mice were used in all the
subsequent experiments.
We saw no differences in LV dimensions (Table 1) between the
WT groups. Fig. 4A shows representative M-mode
echocardiograms of sham + vehicle, sham + EPO, CLP + vehicle,
and CLP + EPO in WT mice. When compared with sham + vehicle
mice, sham mice treated with EPO demonstrated no significant
alterations in EF, FS or FAC (P>0.05) (Fig. 4B-D). When compared
with sham mice, WT mice subjected to CLP demonstrated a
significant reduction in percentage EF, FS and FAC (P<0.05)
(Fig.  4B-D), indicating the development of impaired systolic
contractility in vivo. Administration of EPO to WT mice
significantly attenuated the impaired systolic contractility
associated with CLP (P<0.05) (Fig. 4B-D).
We saw no differences in LV dimensions between the KO groups
(Table 1). Fig. 5A shows representative M-mode echocardiograms
of sham + vehicle, sham + EPO, CLP + vehicle, and CLP + EPO in
βcR KO mice. When compared with sham + vehicle mice, sham
mice treated with EPO demonstrated no significant alterations in
EF, FS or FAC (P>0.05) (Fig. 5B-D). When compared with sham
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Fig. 1. Effect of erythropoietin (EPO) on the cardiac dysfunction in
endotoxemic wild-type mice. (A-D)Representative M-mode
echocardiograms (A), and percentage ejection fraction (B), fractional
shortening (C) and fractional area of change (D) 18 hours subsequent to sham-
operation or lipopolysaccharide (LPS) administration. (E,F)Volume-pressure
curves were generated from isolated Langendorff-perfused hearts to assess
alterations in isovolumic left ventricular developed pressure (LVDP) in
response to 5 μl incremental increases in balloon volume (E) and in response
to 30 μl (maximum response) volume loading (F), 16-18 hours subsequent to
sham operation or LPS administration. Mice received either LPS (9 mg/kg i.p.)
or vehicle (5 ml/kg 0.9% saline i.p.). At 1 hour after induction of endotoxemia,
mice were treated either with EPO (1000 IU/kg s.c.) or vehicle (10 ml/kg 0.9%
saline s.c.). (B-D)Sham + vehicle (n=10); sham + EPO (n=6); LPS + vehicle
(n=15); LPS + EPO (n=15). (E,F)Sham + vehicle (n=11); LPS + vehicle (n=11);
LPS + EPO (n=10). Data are expressed as means ± s.e.m. for n number of
observations. P<0.05 versus LPS + vehicle; •P<0.05 sham + vehicle versus LPS
+ vehicle; ≠P<0.05 LPS + vehicle versus LPS + EPO.
Fig. 2. Effect of erythropoietin (EPO) on the cardiac dysfunction in
endotoxemic β-common receptor knockout (βcR KO) mice.
(A-D)Representative M-mode echocardiograms (A), and percentage ejection
fraction (B), fractional shortening (C) and fractional area of change (D) 18
hours subsequent to sham-operation or lipopolysaccharide (LPS)
administration. (E,F)Volume-pressure curves were generated from isolated
Langendorff-perfused hearts to assess alterations in isovolumic left ventricular
developed pressure (LVDP) in response to 5 μl incremental increases in
balloon volume (E) and in response to 30 μl (maximum response) volume
loading (F), 16-18 hours subsequent to sham operation or LPS administration.
Mice received either LPS (9 mg/kg i.p.) or vehicle (5 ml/kg 0.9% saline i.p.). At 1
hour after induction of endotoxemia, mice were treated either with EPO (1000
IU/kg s.c.) or vehicle (10 ml/kg 0.9% saline s.c.). (B-D)Sham + vehicle (n=9);
sham + EPO (n=3); LPS + vehicle 
(n=14); LPS + EPO (n=25). (E,F)Sham + vehicle (n=11); LPS + vehicle (n=9); LPS
+ EPO (n=9). Data are expressed as means ± s.e.m. for n number of
observations. P<0.05 versus LPS + vehicle; •P<0.05 sham + vehicle versus LPS
+ vehicle.
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mice, βcR KO mice subjected to CLP demonstrated a significant
reduction in percentage EF, FS and FAC (P<0.05) (Fig.  5B-D),
indicating the development of impaired systolic contractility in vivo.
Treatment of βcR KO mice with EPO did not alter this cardiac
dysfunction (P>0.05) (Fig. 5B-D).
DISCUSSION
We report here, for the first time, that activation of βcR by EPO
attenuates the impaired systolic contractility caused by endotoxemia
in young mice or by polymicrobial sepsis in aged mice. Sepsis most
frequently occurs in older patients (Girard et al., 2005), yet most
of the animal studies carried out to date use young and healthy
animals (Aoshiba et al., 2009). We developed a model of CLP-
induced cardiac dysfunction and discovered that the degree of
impaired systolic contractility increased with age. We were unable
to document a significant degree of impaired systolic contractility
(at 24 hours) in young (2- and 5-month-old) mice, whereas 8-
month-old mice exhibited severe impairment in systolic
contractility. Although we have not investigated the effect of age
on the cardiac dysfunction caused by LPS, there is very good
evidence from a multitude of studies documenting that the
mortality caused by endotoxins in rodents increases significantly
with age (Chang et al., 1996; Chorinchath et al., 1996; Tateda et al.,
1996). It should be noted that an investigation into the effects of
age on the pathophysiology of sepsis was not the main focus of our
study, but rather a by-product of the development of a reproducible
model of CLP-induced cardiac dysfunction. Most notably, EPO
attenuated the severe impairment in systolic contractility caused
by polymicrobial sepsis in aged mice. This effect of EPO was lost
in age-matched βcR KO mice. Our finding that the beneficial effects
of EPO were of a similar magnitude when cardiac dysfunction was
measured either in vivo or ex vivo (in an isolated heart) also
indicates that the effects of EPO are secondary to a specific
improvement in cardiac contractility, independent of preload or
afterload. Most notably, whether determined in vivo or ex vivo, the
observed beneficial effect of EPO was lost in βcR KO mice.
Having discovered that βcR is essential for the cardioprotective
effects of EPO in sepsis, we then investigated the molecular
pathways that are activated by EPO in a βcR-dependent fashion.
In summary, EPO activated Akt and eNOS and inhibited the
(endotoxemia-induced) activation of GSK-3β and NFκB and
expression of IL-1β. Most notably, all of these beneficial effects of
EPO were lost in βcR KO mice.
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Fig. 3. Effect of erythropoietin (EPO) on signalling pathways and IL-1β
expression in the hearts of wild-type and β-common receptor knockout
(βcR KO) mice with endotoxemia. Mice received either lipopolysaccharide
(LPS; 9 mg/kg i.p.) or vehicle (5 ml/kg 0.9% saline i.p.). At 1 hour after induction
of endotoxemia, mice were treated either with EPO (1000 IU/kg s.c.) or vehicle
(10 ml/kg 0.9% saline s.c.). Densitometric analysis of the bands is expressed as
relative optical density (O.D.) of (A) Akt phosphorylation at Ser473 (pSer473),
corrected for the corresponding total Akt (ΣAkt) content and normalized using
the related sham band, (B) glycogen synthase kinase (GSK)-3β
phosphorylation at Ser9 (pSer9), corrected for the corresponding total GSK-3β
(ΣGSK-3β) content and normalized using the related sham band, (C)
endothelial nitric oxide synthase (eNOS) phosphorylation at Ser1177
(pSer1177), corrected for the corresponding total eNOS (ΣeNOS) content and
normalized using the related sham band, (D) nuclear factor (NF)-κB p65
subunit levels in both cytosolic and nuclear fractions and expressed as a
nucleus:cytosol ratio, and (E) IL-1β expression in heart tissue of endotoxemic
mice. Each immunoblot is from a single experiment and is representative of
four separate experiments. Data are expressed as means ± s.e.m. for n number
of observations. P<0.05 versus LPS + vehicle.
Fig. 4. Effect of erythropoietin (EPO) on the cardiac dysfunction in wild-
type mice that underwent cecal ligation and puncture (CLP).
Representative M-mode echocardiograms (A), and percentage ejection
fraction (B), fractional shortening (C) and fractional area of change(D) in wild-
type mice 24 hours subsequent to CLP surgery. At 1 hour after induction of
CLP, mice were treated either with EPO (1000 IU/kg s.c.) or vehicle (10 ml/kg
0.9% saline s.c.). (B-D)Sham + vehicle (n=3); sham + EPO (n=3); CLP + vehicle
(n=9); CLP + EPO (n=10). Data are expressed as means ± s.e.m. for n number of
observations. P<0.05 versus CLP + vehicle.
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Akt is a member of the phosphoinositide 3-kinase (PI3K) signal
transduction enzyme family and regulates cellular activation,
inflammatory responses, chemotaxis and apoptosis (Cantley, 2002).
When phosphorylated by its upstream regulator, phosphoinositide-
dependent kinase, Akt modulates cell survival and growth (Cantley,
2002). In our study, EPO caused a significant increase in
phosphorylation of Akt on Ser473 (resulting in activation of this
kinase), an effect that was lost in βcR KO mice. Our hypothesis that
activation of Akt importantly contributes to the improvement in
cardiac contractility afforded by EPO is supported by the following
findings: (1) transgenic mice with cardiac-specific expression of Akt
exhibit a significant increase in cardiac contractility compared with
WT mice (Condorelli et al., 2002); (2) protection by EPO against
doxorubicin-induced cardiotoxicity is mediated by PI3K activation
(Kim et al., 2008); (3) the reduction of infarct size afforded by EPO
in a murine model of myocardial infarction is associated with
activation of Akt (Calvillo et al., 2003); and (4) both the activation
of Akt and the cardioprotective effects of EPO are lost when animals
are pre-treated with an inhibitor of the PI3K-Akt pathway (Cai and
Semenza, 2004). Interestingly, Recknagel et al. demonstrated that
PI3K signalling also plays a crucial role in the development of liver
dysfunction in septic rats (Recknagel et al., 2012). We report here
that the increase in Ser473 phosphorylation on Akt afforded by EPO
was lost in βcR KO mice. Similarly, a neutralizing antibody to the
βcR subunit in endothelial cells also abolished the phosphorylation
of Akt caused by EPO in these cells (Su et al., 2011). It is likely that
Akt is a key molecule for the prevention of apoptosis in the heart
and that activation of Akt by EPO elicits cytoprotection through an
Akt-dependent pathway, in part by antagonizing the effects of TNFα
(Ueba et al., 2010). Taken together, all of the above results support
the view that activation of Akt, secondary to activation of the βcR
subunit, by EPO importantly contributes to the improvement in
cardiac function afforded by EPO in sepsis.
Activation of Akt is associated with a pronounced increase in
the phosphorylation of GSK-3β at Ser9. GSK-3β is a serine-
threonine kinase that was originally recognized as a kinase that
phosphorylates glycogen synthase. In contrast to most other
kinases, GSK-3β is active in a resting cell state; however, it is
inactivated by phosphorylation of Ser9. Activation of Akt inactivates
GSK-3β by causing Ser9 phosphorylation (Cross et al., 1995). We
report here that EPO caused a significant increase in
phosphorylation of GSK-3β on Ser9 (resulting in inhibition of this
kinase), an effect that was lost in βcR KO mice. Our hypothesis
that inhibition of GSK-3β importantly contributes to the
improvement in cardiac contractility afforded by EPO is supported
by the following findings: (1) inhibition of GSK-3β attenuates the
multiple organ dysfunction caused by co-administration of LPS and
peptidoglycan in the rat (Dugo et al., 2005) and improves survival
in murine endotoxemia (Martin et al., 2005); (2) the
cardioprotective effects of EPO are secondary to inhibition of GSK-
3β (measured as Ser9 phosphorylation) (Nishihara et al., 2006); (3)
prevention by EPO of vascular integrity in animals with diabetes
is dependent on activation of Akt and inhibition of GSK-3β (Chong
et al., 2011); and (4) prevention of the inhibition of GSK-3β in the
heart of diabetic mice results in the loss of the cardioprotective
effects of EPO (Ghaboura et al., 2011). Taken together, all of the
above results support the view that inhibition of GSK-3β secondary
to activation of βcR by EPO importantly contributes to the
improvement in systolic contractility afforded by EPO in sepsis.
In addition to inhibiting the activation of GSK-3β, activation of
Akt is known to phosphorylate eNOS at Ser1177 in endothelial
cells (Dimmeler et al., 1999; Fulton et al., 1999) and cardiomyocytes
(Burger et al., 2006). There is evidence that EPO induces nitric oxide
(NO) production and eNOS phosphorylation (Su et al., 2011; Souza
et al., 2012; Kao et al., 2011), and that its cardioprotective effects
are, in part, mediated by the upregulation of eNOS, demonstrated
in vitro (Burger et al., 2006; Rui et al., 2005) and in vivo (Rui et al.,
2005). Inhibition of the βcR subunit also abolishes the EPO-induced
increase and phosphorylation of eNOS, Akt, Src and Janus kinase
2 in endothelial cells (Su et al., 2011). Indeed Sautina et al.
demonstrated the requirement of the βcR subunit in the induction
of NO by EPO (Sautina et al., 2010). This supports the view that
the βcR subunit plays a key role in the activation of eNOS by EPO
in endothelial cells. We report here that the increase in Ser1177
phosphorylation of eNOS by EPO in the heart is lost in βcR KO
mice. In conditions associated with sepsis, activation of eNOS is
beneficial because enhanced formation of NO causes local
vasodilation, inhibition of platelets and neutrophils, and regulates
angiogenesis (Tyml, 2011; Khan et al., 2010). Thus, it can be said
that the activation of eNOS contributes to the beneficial effects of
EPO reported here.
Downstream of GSK-3β, several studies have now reported an
association between GSK-3β and NFκB activity in vitro (Hoeflich
et al., 2000; Schwabe and Brenner, 2002) and in vivo (Dugo et al.,
2005; Dugo et al., 2006). NFκB is a transcriptional factor that plays
an important role in regulating the transcription of a number of
genes, especially those involved in producing mediators involved
in local and systemic inflammation, such as cytokines, chemokines,
cell adhesion molecules, apoptotic factors and other mediators
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Fig. 5. Effect of erythropoietin (EPO) on the cardiac dysfunction in β-
common receptor knockout (βcR KO) mice that underwent cecal ligation
and puncture (CLP). Representative M-mode echocardiograms (A), and
percentage ejection fraction (B), fractional shortening (C) and fractional area
of change (D) 24 hours subsequent to CLP surgery. At 1 hour after induction of
CLP, mice were treated either with EPO (1000 IU/kg s.c.) or vehicle (10 ml/kg
0.9% saline s.c.). (B-D)Sham + vehicle (n=5); sham + EPO (n=2); CLP + vehicle
(n=7); CLP + EPO (n=7). Data are expressed as means ± s.e.m. for n number of
observations. P<0.05 versus CLP + vehicle.
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
(Senftleben and Karin, 2002). Treatment of TNFα-stimulated
hepatocytes with a specific GSK-3β inhibitor results in decreased
NFκB-dependent gene transcription (Schwabe and Brenner, 2002).
This study also indicated four potential phosphorylation sites for
GSK-3β on the NFκB subunit p65. Most notably, pre-treatment with
a number of chemically distinct inhibitors of GSK-3β attenuates
organ injury and dysfunction caused by endotoxemia (Dugo et al.,
2005; Martin et al., 2005). This protective effect was associated with
inhibition of the activation of NFκB and NFκB-dependent
proinflammatory genes, along with a reduced phosphorylation of
Ser536 on the NFκB p65 subunit. In addition, GSK-3β might also
inhibit the activation of NFκB by phosphorylating and degrading
IκBα, which is required to prevent NFκB translocation (Takada et
al., 2004). In our study, EPO attenuated the activation of NFκB
caused by endotoxemia in the heart, an effect that was lost in βcR
KO mice. NFκB is involved in the regulation of IL-1β transcription
(Cogswell et al., 1994). EPO attenuates neuroimmune activation in
neuropathic pain by inhibiting the production of TNFα, IL-1β and
IL-6 (Jia et al., 2009). We report here that mice subjected to LPS
show an increase in IL-1β production, which is significantly
attenuated following the administration of EPO. This effect was
lost in endotoxemic βcR KO mice.
Clinical relevance
Myocardial function is depressed in sepsis and has a significant
impact on patient outcome (Rudiger et al., 2013). Using a long-
term rat model of fecal peritonitis, Rudiger et al. demonstrated most
recently that significant differences in stroke volume and heart rate
assessed 6 hours after insult could predict a 3-day mortality with
positive and negative predictive values of 93% and 80%, respectively.
Based on these findings the authors suggest a crucial role for early
cardiovascular performance as a prognosticator with clear
therapeutic implications (Rudiger et al., 2013).
It could be argued that the clinical relevance of the EPO-related
improvement in systolic contractility is limited. It is well established
that survivors of septic shock present with a reversible ventricular
dilatation, which is referred to as an adaptation to impaired systolic
contraction (Parker et al., 1984; Parrillo et al., 1990). These authors
showed that the initial ejection fraction determined by radionuclide
cineangiography is significantly lower in the survivors. Improved
outcome of ‘dilators’ versus ‘non-dilators’ is also shown in
resuscitated murine CLP-induced septic shock (Zanotti Cavazzoni
et al., 2010). However, other authors demonstrated that mortality
is higher (47% versus 16%) in patients with a subnormal fractional
area contraction upon initial echocardiography (Charpentier et al.,
2004). Moreover, Kumar et al. did not find a significant difference
in baseline LVEF as determined by radionuclide cineangiography,
but a lacking increase of LVEF during dobutamine infusion allowed
distinguishing between survivors and non-survivors (Kumar et al.,
2008). Finally, it is noteworthy that, in the present experiment, any
EPO-induced increase in LVEF coincided with unchanged end-
diastolic diameter and volume. Hence, diastolic relaxation was not
affected by the treatment. This observation is in contrast to our
previous investigation in murine CLP-induced septic shock (Barth
et al., 2006); genetic deletion and pharmacological blockade of
inducible nitric oxide synthase increased systolic contractility and
improved myocardial catecholamine responsiveness at the expense
of impaired diastolic relaxation, i.e. ‘stiffening of the ventricle’.
Conclusions
Our results show for the first time that the administration of EPO
reduces the impaired systolic contractility associated with sepsis.
In endotoxemia the observed beneficial effects of EPO are
associated with: (a) activation of Akt, (b) inhibition of GSK-3β, (c)
activation of eNOS, (d) inhibition of NFκB, and (e) inhibition of
the expression of IL-1β (Fig. 6). Most notably, attenuation of the
impairment of systolic contractility as well as all of the above
signalling events afforded by EPO were dependent on the presence
of a functional βcR. Thus, targeting the tissue-protective receptor
with EPO or specific agonists, which selectively activate the tissue-
protective βcR-EpoR heterocomplex (Brines et al., 2008), could
represent a therapeutic approach for the treatment of sepsis-
induced cardiac dysfunction.
MATERIALS AND METHODS
The animal protocols followed in this study were approved by the
local Animal Use and Care Committee in accordance with the
derivatives of both the Home Office guidance on the Operation of
Animals (Scientific Procedures Act 1986) published by Her
Majesty’s Stationery Office and the Guide for the Care and Use of
Laboratory Animals of the National Research Council.
Animals and quantification of organ dysfunction
This study was performed on 113 wild-type (WT) C57BL/6 mice
(Harlan Laboratories, Wyton, UK) and 101 βcR KO mice
(B6.129S1-Csf2rbtm1Cgb/J) on a C57BL/6J genetic background
(bred and maintained at Queen Mary University of London,
Biological Services Unit) weighing 20-30 g (2 months old) or 30-
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Fig. 6. Schematic overview of the signalling events modulated by
erythropoietin (EPO) in the hearts of endotoxemic wild-type mice.
Activation of βcR-EpoR by EPO is associated with (a) activation of the
phosphoinositide 3-kinase (PI3K)-Akt signalling pathway, which results in the
inhibition of the activation of glycogen synthase kinase-3β (GSK-3β), which is
known to suppress the activation of nuclear factor-κB (NFκB), resulting in a
blunted expression of the NFκB-driven gene transcription of pro-inflammatory
mediators such as interleukin-1β (IL-1β), and (b) activation of the PI3K-Akt
signalling pathway, which results in the increased activation of endothelial
nitric oxide synthase (eNOS) and thus the enhanced formation of nitric oxide
(NO). The signalling steps that were analyzed in our study are highlighted in
light grey.
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50 g (8 months old), receiving a standard diet and water ad
libitum. Mice were anesthetized with a ketamine (100 mg/ml) and
xylazine (20  mg/ml) mixture (2:1; 1.5  ml/kg body weight i.p.)
before being sacrificed.
Experimental design
Cardiac function was assessed in mice subjected to endotoxemia
for 16-18 hours (2 months old) or CLP for 24 hours (8 months old).
The following, specific groups were studied for endotoxemic and
CLP experiments: (1) sham (5 ml/kg body weight 0.9% saline i.p.)
+ vehicle (10 ml/kg 0.9% saline s.c.); (2) sham (5 ml/kg 0.9% saline
i.p.) + EPO (1000 IU/kg s.c.); (3) LPS (9  mg/kg i.p.) + vehicle
(10 ml/kg 0.9% saline s.c.); (4) LPS (9 mg/kg i.p.) + EPO (1000 IU/kg
s.c.); (5) sham (no CLP) + vehicle (10 ml/kg 0.9% saline s.c.); (6)
sham (no CLP) + EPO (1000 IU/kg s.c.); (7) CLP + vehicle (10 ml/kg
0.9% saline s.c.); and (8) CLP + EPO (1000 IU/kg s.c.).
Cecal ligation and puncture
We followed the original CLP protocol introduced by Wichterman
et al. (Wichterman et al., 1980) with slight modifications, including
analgesia (buprenorphine; 0.05  mg/kg) and antibiotic therapy
(Imipenem/Cilastin; 20  mg/kg). Based on previous evidence and
preliminary data, an 18-G needle was used with the double puncture
technique in order to generate cardiac dysfunction during the early
phase of sepsis (24 hours). Briefly, mice were anesthetized i.p. with
1.5 ml/kg of a ketamine (100 mg/ml)/xylazine (20 mg/ml) solution
in a 2:1 ratio. Buprenorphine was injected additionally to provide
adequate analgesia. The rectal temperature of the animals was
maintained at 37°C with a homeothermic blanket. The abdomen was
opened via a 1.5 cm midline incision, and the cecum exposed. The
cecum was ligated just below the ileocecal valve and punctured at
both opposite ends. After a small amount of fecal matter was
extruded from both ends, the cecum was placed back in its
anatomical position. The abdomen was sutured; 1  ml of Ringer’s
solution was given for resuscitation s.c. and the mice were placed
back in their cages. Antibiotic therapy and analgesia was administered
6 hours after surgery and every 12 hours after that. We evaluated
the susceptibility of mice of increasing ages (2, 5 and 8 months old)
to develop cardiac dysfunction 24 hours after CLP. Finally, we
established a model of severe polymicrobial sepsis in 8-month-old
male WT mice, which developed reliable cardiac dysfunction 24
hours after CLP.
Assessment of cardiac function in vivo (echocardiography)
Cardiac function was assessed in mice by echocardiography in vivo
as reported previously (Kapoor et al., 2010). At 18 hours after
administration of LPS or 24 hours after CLP surgery, anesthesia was
induced with 3% isoflurane and maintained at 1% for the duration
of the procedure. Two-dimensional and M-mode echocardiography
images were recorded using a Vevo-770 imaging system
(VisualSonics, Toronto, Ontario, Canada) by two blinded operator.
Percent FAC was assessed with a two-dimensional trace at papillary
muscle level. We measured LVID(D) in M-mode in the parasternal
short axis view at the level of the papillary muscles. FS, EF and LVEDV
were calculated from the M-mode. During echocardiography the
heart rate was obtained from ECG tracing and the temperature was
monitored with a rectal thermometer. Additionally, heart samples
were taken and stored at −80°C for further analysis.
Assessment of cardiac function ex vivo (isolated Langendorff-
perfused heart)
Cardiac function was assessed in mice by the isolated Langendorff-
perfused heart ex vivo as reported previously (Kapoor et al., 2010).
At 16-18 hours after the administration of LPS, mice were
anesthetized and heparinized (heparin sodium, 1000 IU/100 g, i.p.).
Following thoracotomy, the heart was excised and rapidly
transferred to ice-cold Krebs-Henseleit buffer (KHB), containing
(in mmol/l) NaCl 118, KCl 3.8, MgSO4 1.19, NaHCO3 25, CaCl2
1.25, KH2PO4 1.18, sodium pyruvate 5, and glucose 10; equilibrated
with 95% O2/5% CO2 (pH 7.4). Aortic cannulation was performed
and hearts were perfused immediately with filtered KHB, gassed
continuously with 95% O2/5% CO2 and maintained at 37°C. Hearts
were retrogradely perfused in a non-recirculating Langendorff
mode. The flow was measured and could be adjusted using a flow
meter to achieve a coronary perfusion pressure of 75±5 mmHg. A
small water-filled polyethylene balloon was carefully inserted into
the LV via a small incision in the left atrium made near the opening
for the pulmonary vein. The hearts were electrically paced at ~590
beats per minute via a silver electrode attached to the wall of the
right atrium and then allowed to stabilise for at least 10 minute
before any experimental protocols were carried out. Alterations in
isovolumic LVDP in response to 5 μl incremental intraventricular
loading of the balloon up to 40 μl were assessed. Pressure volume
curves were generated to assess LVDP.
Western blot analysis
Briefly, mouse heart samples were homogenized in 10%
homogenization buffer and centrifuged at 1500 g for 5 minutes at
4°C. Supernatants were removed and centrifuged at 18,600 g at 4°C
for 40 minutes to obtain the cytosolic fraction. The pelleted nuclei
were resuspended in extraction buffer and centrifuged at 18,600 g
for 20 minutes at 4°C. The resulting supernatants containing
nuclear proteins were carefully removed, and protein content was
determined on both nuclear and cytosolic extracts using a
bicinchoninic acid (BCA) protein assay following the
manufacturer’s directions (Therma Fisher Scientific, Rockford, IL).
Proteins were separated by 8% sodium dodecyl sulphate-PAGE
(SDS-PAGE) and transferred to a polyvinyldenedifluoride (PVDF)
membrane, which was then incubated with a primary antibody
(rabbit anti-total GSK-3β, dilution 1:200; goat anti-pGSK-3β Ser9,
dilution 1:200; rabbit anti-total-Akt, dilution 1:1000; mouse anti-
pAkt Ser473, dilution 1:1000; rabbit anti-total-eNOS, dilution
1:200; goat anti-peNOS Ser1177, dilution 1:200; rabbit anti-NFκβ
p65, dilution 1:1000). Blots were then incubated with a secondary
antibody conjugated with horseradish peroxidase (dilution 1:10,000)
for 30 minutes at room temperature and developed with the ECL
detection system. The immunoreactive bands were visualized by
autoradiography. Densitometric analysis of the bands was
performed using the Gel Pro Analyzer 4.5, 2000 software (Media
Cybernetics, Silver Spring, MD). Each group was then adjusted
against corresponding sham data to establish relative protein
expression when compared with sham animals.
Quantitative determination of tissue IL-1β by ELISA
The expression of IL-1β in mouse heart samples was determined
using a mouse IL-1β/IL-1F2 immunoassay kit (R&D Systems,
Minneapolis, MN) and has been normalized to the protein content.
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Materials
Unless otherwise stated, all compounds in this study were
purchased from Sigma-Aldrich Company Ltd (Poole, Dorset, UK).
All solutions were prepared using non-pyrogenic saline [0.9% (w/v)
NaCl; Baxter Healthcare Ltd, Thetford, Norfolk, UK]. Recombinant
human EPO (epoetin beta) was manufactured by Roche Diagnostics
(Sussex, UK).
Statistical analyses
All values described in the text and figures are presented as mean
± standard error of the mean (s.e.m.) of n observations, where n
represents the number of animals studied. Statistical analysis was
performed using GraphPad Prism 5.0d (GraphPad Software, San
Diego, CA). Data without repeated measurements were assessed
by a one-way ANOVA followed by Bonferroni post-hoc test. Data
with repeated measurements were assessed by a two-way ANOVA
followed by a Bonferroni post-hoc test. A P-value of less than 0.05
was considered to be significant.
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Figure S1: The development of cardiac dysfunction in aging wild-type mice 
following cecal ligation and puncture (CLP). (A) Representative M-mode 
echocardiograms, percentage (B) ejection fraction, (C) fractional shortening and (D) 
fractional area of change 24 h subsequent to CLP surgery. Sham + vehicle, (n = 3), 
CLP 2 months (n = 5); CLP 5 months (n = 5); CLP 8 months (n = 9). Red circles 
indicate animals used for representative M-mode images seen in (A). Data are 
expressed as means ± SEM. for n number of observations.  P < 0.05. 
 	  
 	  
